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Chapter 1
Abstract
Transcription factors control expression of genes essential for the normal functioning of 
the hematopoietic system and regulate development of distinct blood cell types. During 
leukemogenesis, aberrant regulation of transcription factors such as RUNX1, CBF-√ü MLL, C/EBP?, 
SPI1, GATA and TAL1 is central to the disease. Here, we will discuss the mechanisms of transcription 
factor deregulation in leukemia and how in recent years next generation sequencing approaches 
have helped to elucidate the molecular role of many of these aberrantly expressed transcription 
factors. We will focus on the complexes in which these factors reside, the role of post translational 
modification of these factors, their involvement in setting up higher order chromatin structures as 
well as their influence on the local epigenetic environment. We suggest that only comprehensive 
knowledge on all these aspects will increase our understanding of aberrant gene expression in 
leukemia as well as open new entry points for therapeutic intervention. 
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Transcription factor regulation of gene expression
In eukaryotes, chromatin structure and interaction between transcription factors (TFs) modulates 
transcription of genes. TFs initiate transcription and/or control transcriptional elongation and thereby 
influence gene expression programs and consequently cell state (1-5). Through their DNA binding 
domain all TFs expressed in a given cell type interact with specific regulatory elements. In this way, 
they exert control over spatial and temporal expression of genes through a variety of regulatory 
domains, consequently modulating all complex biological processes such as cell differentiation, 
proliferation and apoptosis (6). Approximately 10% of genes in the human genome are presumed 
to code for TFs (7), with different sets of TFs expressed during different developmental stages. In 
the same cell type, different TFs can co-localize (8,9), and in different cell types and developmental 
stages these factors and complexes can bind in a different pattern (10-12). For example, in mouse 
macrophages and splenic B-cells Pu.1 (SPI1) binds to a distinct set of cis regulatory elements, which 
in both cell-types are also enriched for the motifs of a distinct group of lineage specific TFs. Co-
localization of different TFs -C/EBPα for macrophages and Oct2 for B-cells- at cell-type specific Pu.1 
sites was subsequently confirmed with chromatin immuno-precipitation followed by massively 
parallel sequencing (ChIP-seq) (13). 
Given the wide-variety of TFs expressed in a given cell type, one main question is what the 
role of each individual TF is and how it functions in the context of the other DNA binding proteins 
that are present. Studies in embryonic stem cells (ESCs) and in differentiated cells have suggested 
that the integrity of cell-type specific gene expression programs is set up and maintained by only 
a few TFs (master regulators) (14-17). For example, it is believed that master TFs in ESCs, such 
as NANOG, OCT4 and SOX2 are expressed at high levels and exert auto regulation, properties 
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Figure 1: TF binding aberrations at promoters and enhancers. TFs can cease to bind the correct or bind to the 
wrong target region because of mutations in the underlying DNA motif (A1). The accessibility of the target 
can have changed due to aberrant histone-variants or DNA-methylation (A2). Aberrantly placed activating or 
repressing histone marks can interfere with the binding of TFs (A3). Or, on the protein level, lead to aberrant 
binding of TFs or co-factors and aberrant (un)- pausing of Pol II (B1-3) All this can cause an aberrant loop 
formation, which activates or silences the wrong targets (B4). Lastly, aberrant posttranslational modification 
of TFs or co-factors can perturb the recruitment and/or activity of TF complexes at promoters and enhancers 
(B5).
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shared with master TFs of other cell types (17,18). Also hematopoiesis is classically thought to be 
governed by a small fraction of crucial TFs that are lineage specific and interact among themselves 
to control cell state (19), such as RUNX1, C/EBPα and SPI1 in myeloid (20-22) and IKZF1, E2A and 
EBF1 in B lymphocyte development (23). However, it has also been suggested that a large number 
of TFs constitute a complex multi-tier gene regulatory network to control hematopoiesis (24-
27). These two theories have reopened the debate on the coordinated mechanistic role of TFs in 
regulating hematopoiesis. Is hematopoiesis indeed modulated by a small set of master regulators 
or dependent on interactions between several different sets of TFs? Also, how is transcription 
regulated by differential usage of TF modules and how are other molecular constituents involved? 
It has become clear that although TFs are key proteins in regulating gene expression, it is further 
governed through synergistic contributions from several entities, including interaction between the 
TFs, post-transcriptional modifications, as well as the structure of the chromatin template (Figure 
1) (18). For example, chromatin regulators such as complexes of the SWI/SNF family and histone-
modifying enzymes, assist in mobilizing and modifying nucleosomes during gene transcription 
and silencing (18,28,29). Indeed in several diseases and syndromes, including distinct classes of 
leukemias, regulatory elements, chromatin regulators and noncoding RNAs can be mutated (18), 
suggesting that knowledge of the context in which TFs operate is imperative in understanding the 
molecular mechanisms governing gene expression in physiological and diseased states. 
The last few decades have witnessed enormous advancements in DNA-sequencing technology, 
from Sanger sequencing to its automation and finally the advent of next-generation sequencing 
(NGS) methods. Especially NGS has led to the identification of many new regulatory sequences, 
insight into transcriptional machinery and chromatin regulators, and has provided novel insights 
into gene regulatory mechanisms in normal but also diseased cells. Application of different NGS 
methods has made great contributions to the field of hematology. For example whole-genome 
sequencing (WGS) for detection of single nucleotide variants (SNV), insertions, deletions, and copy 
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Figure 2: Promoters and enhancers can interact in various ways. A) Chromatin looping within topological 
domains can occur in numerous ways. An enhancer can directly loop with one or more promoters or other 
enhancers, in some cases simultaneously. It is also possible for promoters to loop directly with other 
promoters. B) The open chromatin will often be in a ‘hairball’ conformation, where numerous enhancers 
and promoters are interacting with each other through various TF complexes. C) When an aberrant TF or 
co-factor binds, changes in gene transcription may happen due to loss or gain of interactions.
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number variations has facilitated the sequencing of the first cancer genome (30) and identification 
of mutations in several types of leukemia (31). Mate-pair sequencing has allowed to simultaneously 
detect mutations, copy number variations, and structural rearrangements and contributed to the 
unfolding of molecular mechanisms in leukemia (32). Whole-exome sequencing (WES) for studying 
exons and UTRs has assisted with the identification of mutations -including potential driver 
mutations- in several leukemias (33,34), including Hairy Cell Leukemia (HCL) patients (35) and 
multiple myeloma (36). RNA sequencing for the detection of transcripts, quantification of expressed 
transcripts, and detection of mutations has contributed to the identification of functionally 
relevant leukemic fusion genes (37) and ChIP-sequencing to detect genomic sites occupied by 
proteins/histone modifications, has led to genome-wide identification of binding sites of mutated 
transcription factors (38-41). Together with whole genome bisulphite sequencing (WGBS), this 
allowed for the first time a comprehensive analysis of full leukemia epigenomes (42).
These NGS technologies facilitate characterization of the molecular pathology of different 
diseases, while they have also been used to differentiate related diseases on the basis of mutations 
in genes of driver pathways (43), gene expression profiles (34), and epigenetic patterns (44). Below 
we will further discuss what has been learned from these genome-wide analyses, with a specific 
focus on leukemia-associated TFs and the context in which they operate.
TF mutations in hematopoiesis
TFs control expression of genes essential for the normal functioning of the hematopoietic system 
and regulate development of distinct blood cell types. In an event of genetic perturbations, including 
deletions, insertions and translocations, the molecular roles of these TFs can be altered, resulting in 
uncontrolled proliferation of immature blood cell lineages and sometimes depletion of one or more 
blood cell lineage. Throughout the years many TFs important for various stages of hematopoietic 
development have been discovered and molecularly characterized. Many of these were initially 
identified as being mutated in hematological disorders. Given their importance to disease, genome-
wide profiles were generated for many of these TFs in recent years aiming to further elucidate their 
role in normal and aberrant hematopoiesis. These genome-wide datasets were mostly submitted 
to the Gene Expression Omnibus (GEO) online repository (www.ncbi.nlm.nih.gov/geo/) and can be 
identified through GSE accession numbers. Examples include the core binding factors, MLL, C/EBPα, 
SPI1, GATA and TAL1 (Figure 2). 
Core-binding factors (CBF)
(GSE: 24674, 29181, 29225, 23730, 46044, 43834, 42075, 45144, 22178, 40235, 29514, 45377 & 
45372)
The CBF family consists of two types of proteins: CBFα, which represents a variable DNA-binding 
subunit, and CBFβ, a non-DNA-binding subunit thought to stabilize the DNA binding of the alpha 
subunit. The CBFα subunit can in distinct cell lineages be represented by one of three proteins: 
RUNX1 (AML1, CBFα2), RUNX2 (CBFα1) or RUNX3 (CBFα3) (45). RUNX1 and CBFβ are needed 
at several stages of hematopoiesis, such as megakaryocytic differentiation, platelet formation, 
erythropoiesis, B-cell development and T-cell development (46). In addition, RUNX1 and CBFβ are 
frequent targets of chromosomal translocations. For example, in acute myeloid leukemia (AML) 
the translocation t(8;21) involves a fusion of the AML1 (RUNX1) and ETO (RUNX1T1) genes and its 
expression results in the chimeric protein AML1-ETO (47), while inversion of a part of chromosome 
16
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16 results in the fusion of the CBFβ and MYH11 genes, coding the chimeric protein CBFβ-MYH11 
(48). The two CBFs are reported to be mutated in 5-10% of AMLs and function by interfering with 
the normal CBF gene program (40). 
MLL/KMT2A
(GSE38403)
MLL fusions are reported in approximately 10% of acute leukemias (AL). In ALs, the MLL protein is 
reported to fuse with one of >50 identified partner genes and generates a chimeric protein (49-51). 
Often, a super elongation complex (SEC) component (like ENL or AF4) is a partner in MLL fusions 
(52) and it is speculated that the SEC part of the fusion anomalously stabilizes itself at MLL target 
genes, consequently modifying the normal MLL transcriptional program (52-55) and inducing 
leukemogenesis. Moreover, MLL fusion proteins are believed to cause changes in chromatin 
structure through altering histone 3 lysine 4 trimethylation (H3K4me3) and H3K27me2 deposition 
(56,57). 
C/EBPα
(GSE: 29196, 50565, 47003 & 43007)
C/EBPα controls differentiation and proliferation of myeloid cells (21) and mutations have been 
associated with AML (58,59). N-terminal mutations in CEBPα inhibit the expression of the p42 isoform 
of the C/EBPα protein resulting in loss of apoptosis and failed myeloid differentiation (59,60), while 
C-terminal mutations disrupt the DNA-binding domain (58,61) and increase premalignant HSCs 
(62). Both N- and C-terminal mutations contribute to aggressive leukemia and are reported to be 
mutated in 10% of AMLs (58,59,63). Moreover, a decreased expression of C/EBPα is observed in 
both t(8;21) (59) and inv(16) (64,65), suggesting that chromosomal translocations as well as the 
level of CEBPα expression are critical for leukemogenesis. 
SPI1/Pu.1
(GSE: 46044, 22178, 33611 & 50406)
SPI1, which is mutated in 5-7% of AMLs (66), regulates the proliferation and differentiation of 
myeloid progenitors (67) and is crucial for cell cycle regulation. In murine myeloid cells, for example, 
Pu.1 expression leads to an exit from the cell cycle, thereby blocking proliferation and inducing 
differentiation (68). Sustained expression of Pu.1 is necessary to modulate the transcription of cell 
cycle regulators, and maintain the HSC population (69). Increased and reduced expression of SPI1 
directs commitment to the myeloid lineage and formation of immature eosinophils, respectively 
(70). The expression of SPI1 is deregulated in AML by action of onco-fusion proteins. For example, 
SPI1 is hyper-activated in the presence of MOZ-TIF2 and hypo-activated in the presence of PML-
RARα (71,72).
GATA
(GSE: 18868, 24674, 29196, 42843, 50406, 29181, 46044, 45144, 22178)
The members of the GATA zinc finger TF family, such as GATA1, GATA2 and GATA3 are involved in the 
regulation of hematopoiesis (73). The expression of GATA1 is crucial for differentiation of erythroid 
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cells and megakaryocytes (74,75). Somatic mutations in GATA1 have been observed in patients with 
Down syndrome acute megakaryoblastic leukemia (DS-AMKL) (76,77), while mutations in GATA2 
are linked with AML, chronic neutropenia and myelodysplasia (78-80). GATA3 is important for the 
self-renewal program of Long-Term HSCs (LT-HSCs) (81), and mutations in GATA3 are associated with 
Philadelphia chromosome like childhood acute lymphoblastic leukemia (82). 
SCL/TAL1
(GSE: 24674, 29181, 45144, 22178, 46044, 15806, 40235 & 42843)
SCL/TAL1 is a master regulator of early hematopoiesis and is frequently reported to be mutated 
in leukemia (83). SCL/TAL1 is reported to be over-expressed in T-cell acute lymphoblastic leukemia 
(T-ALL) patients. It forms an auto-regulatory loop with other master regulator TFs, such as AML1 
and GATA3, and activates the MYB oncogene, thereby activating the TAL1 mediated oncogenic 
program in T-ALL patients (84). 
Interestingly, single mutations of the above-described TFs are often not sufficient to cause a 
hematological disorder in mouse models and many studies have indicated that in line with other 
cancers, hematological disorders need several mutations to accumulate. Still, comparative analysis 
of different cancer types suggested that generally fewer mutations accumulate in leukemia than in 
other cancers (85).
The mutations in hematopoietic disorders were discovered using many different techniques, 
varying from the early karyotyping analysis pioneered by Janet Rowley (86,87) to comparative 
genome hybridization (CGH) (88), single-nucleotide polymorphism (SNP) arrays and the introduction 
of exome sequencing. This allowed the identification of many gene rearrangements but also 
‘smaller’ mutations associated with hematological disorders, including TET2 in MDS (89), DNMT3A 
(90,91), FLT3 (92), BCOR and IDH1 in AML (93), MLL2 (KMT2B) in diffuse large B-cell lymphoma (DLBCL) 
(94) and NOTCH1 in mantle cell lymphoma (MCL) (95). Different international consortia have been 
initiated to comprehensively characterize the mutational landscape of different cancers. Most 
notable, The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) set out to identify and 
catalogue genetic lesions associated with cancer by exome as well as whole genome sequencing 
and reported already many new potential driver mutations, for example in different AML subtypes 
(34). From these analyses it has become clear that apart from TF mutations, various other mutations 
in proteins that define the chromatin context (histones, signaling pathways, epigenetic enzymes) in 
which TFs operate are associated with leukemogenesis. 
Upon identification of mutations in hematological disorders the main question remains to 
identify which mutations are driving the leukemia and which ones are passengers, acquired 
during leukemogenesis. Since the analyses described above were mostly based on patients with 
advanced stages of leukemia, experimental analysis to identify mutations that occur early during 
leukemogenesis in the clinically silent and transient phase have been mostly limited to model 
organisms. However, Shlush et al. observed the presence of a mutation in the DNA-methyltransferase 
enzyme DNMT3A not only in an AML cell population, but also in cells of the lymphoid system, 
suggesting that the DNMT3A mutation already occurred in HSCs, and gave rise to a clonal pool of 
pre-leukemic HSCs that ultimately led to the development of AML (96). Similar analysis in other 
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hematological disorders, together with single cell technologies can be expected to further increase 
our knowledge on these driving mutations. 
TF binding during hematopoiesis
As discussed above, numerous TFs can be aberrantly expressed in hematological diseases and hence 
have been among the prime targets of investigation. Table 1 provides a selection of ChIP-seq studies 
from recent years that have been carried out to gain insights into the molecular mechanisms that 
drive normal blood development as well as leukemogenesis. Many of these studies focused on 
leukemias harboring chromosomal translocations, as these are central to the disease and of clinical 
importance. MLL-AF4 was the first translocation product for which the genome-wide binding profile 
was elucidated in acute lymphoblastic leukemia (57), which was followed by PML-RARα in acute 
promyelocytic leukemias (APLs) (72,97), AML1-ETO in 
AMLs (39,41,98,99) and recently CBFβ-MYH11 in AMLs 
(38). 
Analysis of these genome-wide binding profiles 
revealed that many aberrant TFs bind at non-promoter 
regulatory elements, corroborating results on normal 
TFs in other cell types (100-104). Indeed, in recent years 
it has become clear that TFs not only predominantly 
bind putative enhancer regions (105), but that dynamic 
regulation of transcription by TFs is to a large extend 
correlated with differential enhancer occupancy, and 
linked to various biological processes including lineage 
commitment (13). For example, differential enhancer 
binding of TFs such as SPI1, and the C/EBPα and AP-1 
families play an important role in differentiation during 
hematopoietic development (13,106-108). Also, TFs 
responding to an external signal as for example NF-κB or 
the estrogen receptor family, have been shown to bind 
predominately to enhancer elements, and disruption of 
these binding patterns has been implicated as a major 
cause in leukemic development (105,109,110). 
TF regulation of gene expression 
Classically, TFs are described as being either an activator 
or a repressor of transcription. Subsequent mutations in 
these TFs would then result in a reversal of their effect 
on transcription. For example, RUNX1/AML1 is generally 
described as a transcriptional activator, while the fusion 
protein AML1-ETO acts as a dominant repressor on 
RUNX1 target genes. These mechanistic conclusions 
were however mostly based on in vitro and single 
loci in vivo analysis. Genome-wide binding analysis in 
combination with transcriptional analysis revealed that 
many AML1-ETO target genes are actually expressed at 
Looping Scenarios
1. Enhancer - Promoter
2. Enhancer - Enhancer
3. Enhancer - Promoter - Promoter
1
3
2
Gene A E 1
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Figure 3: Promoters and enhancers can 
interact in various ways. A) Chromatin 
looping within topological domains can 
occur in numerous ways. An enhancer 
can directly loop with one or more 
promoters or other enhancers, in some 
cases simultaneously. It is also possible 
for promoters to loop directly with other 
promoters. B) The open chromatin will 
often be in a ‘hairball’ conformation, where 
numerous enhancers and promoters are 
interacting with each other through various 
TF complexes. C) When an aberrant TF or co-
factor binds, changes in gene transcription 
may happen due to loss or gain of 
interactions.
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substantial levels (39,41,98). Knockdown of AML1-ETO in these cells results in increased as well 
as in decreased target gene expression, suggesting that dependent on the context AML1-ETO is 
involved in gene activation or repression. Another example is the CBFβ-MYH11 fusion, for which it 
was commonly believed the normally AML1 (RUNX1) co-activating CBFβ turns into a repressor by 
means of its fusion partner (40). Again using genome-wide approaches revealed that also here the 
majority of target genes are actually expressed and that upon knockdown expression is decreased, 
suggesting CBFβ-MYH11 functions as a transcriptional activator (38). Together, these examples 
show the importance of genome-wide analysis as compared to single locus studies in elucidating 
the molecular mechanisms involved in leukemogenesis.
Activating TFs can broadly be categorized into those that initiate transcription, and those that 
elongate transcription by facilitating the release of RNA polymerase II (RNAPII) from its poised state. 
Both can occur via promoter-only binding or via looping through an enhancer element (18). As a 
Table 1: A selection of genome-wide binding profiles for TFs in different cell lineages.
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Organism	 Factor(s)	 Cell(s)	 Year	 GEO	ID	&	Reference	
Hs	 AF4	&	MLL	 SEM	&	REH	 2008	 Guenther	et	al	(57)		
Hs	 GATA1	&	GATA2	 K562	 2009	 GSE18868	Fujiwara	et	al	(165)	
Hs	 PML,	RXR,	RAR	&	RNAPII	 NB4,	MR4,	UPR9	&	patients		 2010	 GSE18886	Martens	et	al	(97)	
Hs	 EGR1	 K562	 2010	 GSE21665	Tang	et	al	(166)		
Hs	
CBP,	CBPR742m,	CBPR768m,	CBPR2151m,	ERα,	RNAPII,	RAC3	&	
CARM1	
H3396	 2011	 GSE32349	Ceschin	et	al	(167)		
Hs	
CBX2,	CBX8,	CHD1,	CHD7,	ESET,	EZH2,	HDAC1,	HDAC2,	HDAC6,	
HP1g,	JARID1A,	JARID1B,	JARID1C,	HP1g,	KAT3A-CBP,	LSD1,	
MI2,	NCOR,	NSD2,	EP300,	PCAF,	PHF8,	PLU1,	RBBP5,	REST,	
RNAPII,	RNF2,	SIRT6,	SAP30	&	SUZ12	
K562	&	H1	 2011	 GSE32509	Ram	et	al	(168)		
Hs	 GATA1,	GATA2,	RUNX1,	FLI1	&	SCL/TAL1	 	Megakaryocytes	 2011	 GSE24674	(169)		
Hs	 MLL	&	AF4	 RS4;11	 2012	 GSE38403	Geng	et	al	(170)	
Hs	 EP300	 NB4	&	SKNO-1	 2012	 GSE30254	Saeed	et	al	(124)	
Hs	 SCL/TAL1,	HEB,	E2A,	GATA3,	RUNX1,	LMO1	&	LMO2	
Jurkat,	CCRF-CEM	&	primary	T-
ALL		
2012	 GSE29181	Sanda	et	al	(84)		
Hs	
RUNX1,	RUNX1-ETO,	RUNX1-ETO	siMM,	RUNX1-ETO	siRE,	
RUNX1	siMM,	RUNX1	siRE,	RNAPII	siMM	&	RNAPII	siRE	
Kasumi-1	&	patient		 2012	 GSE29225	Ptasinska	et	al	(41)	
Hs	 AML1-ETO,	RUNX1,	CBFβ,	HEB,	ETO,	FLI1,	ERG	&	RNAPII	
Kasumi-1,	SKNO-1,	K562,	
MCF7,	UAE,	NB4	,	CD34+	&	
patients		
2012	 GSE23730	Martens	et	al	(39)		
Hs	
CBFβ,	MYH11,	RUNX1,	RNAPII,	TBP,	HEB,	GATA2,	SCL/TAL1,	
FLI1,	ELF1,	ERG,	PU.1/SPI1,	EP300	&	HDAC1	
ME-1,	U937	&	patient	 2013	 GSE46044	Mandoli	et	al	(38)		
Hs	 AML1-ETO,	HEB,	E2A	&	LMO2	 Kasumi-1	 2013	 GSE43834	Sun	et	al	(98)		
Hs	 RUNX1	 SEM	 2013	 GSE42075	Wilkinson	et	al	(171)	
Hs	 ERG,	FLI1,	SCL/TAL1,	LYL1,	GATA2,	RUNX1	&	LMO2	 CD34+	 2013	 GSE45144	Beck	et	al	(125)	
Hs	 SUZ12	&	REST	 APL	patient	 2013	 GSE42044	Schoofs	et	al	(172)		
Hs	 BACH2	&	BCL6	 OCI-Ly7	 2013	 GSE44420	Swaminathan	et	al	(173)	
Hs	&	Mm	 Notch1,	ZNF143	&	RBPJ	 CUTLL1,	T6E	&	G4A2	 2011	 GSE29600	Wang	et	al	(174)		
Hs	&	Mm	 GATA1,	GATA2,	SMAD1,	WNT/TCF7L2	&	C/EBPα	
K562,	U937,	G1E,	G1ER	&	
CD34+	
2011	 GSE29196	Trompouki	et	al	(175)		
Hs	&	Mm	 ZNF143,	ZNF76	&	ICN1	
HeLa,	K562,	T-REx	HEK293,	
HPB-ALL,	mESC,	FLP143-HA	&	
FLP76	
2013	
GSE39263	Ngondo-Mbongo	et	al	
(176)		
Mm	 Scl/Tal1	 HPC-7	 2009	 GSE15806	Wilson	et	al	(177)		
Mm	
Fli1,	Gata2,	Gfi1b,	Lmo2,	Lyl1,	Meis1,	Pu.1/Spi1,	Runx1	&	
Scl/Tal1	
HPC-7	 2010	 GSE22178	Wilson	et	al	(126)	
Mm	 Cbp	 HPC-BM	 2011	 GSE25274	Chan	et	al	(178)		
Mm	 Pu.1/Spi1	&	RNAPII	
Spleen-derived	
erythroleukemic	
2012	 GSE33611	Ridinger-Saison	et	al	(179)		
Mm	 Gfi1	
MLL-ENL–immortalized	bone	
marrow	progenitors	
2012	 GSE31657	Khandanpour	et	al	(180)		
Mm	 Runx1,	Fli1,	Scl/Tal1,	C/ebpβ	&	RNAPII	 Blood	cells	 2012	 GSE40235	Lichtinger	et	al	(181)		
Mm	 Runx1	 CD41+	&	CD41-	 2012	 GSE29514	Tanaka	et	al	(182)		
Mm	 Gata1,	Gata2	&	Pu.1/Spi1	 HSC	 2013	 GSE50406	May	et	al	(183)	
Mm	 C/ebpα	 Macrophages	 2013	 GSE50565	Zhang	et	al	(184)	
Mm	 Runx1	 Bone	Marrow	 2013	 GSE45377	Niebuhr	et	al	(185)		
Mm	 Ldb1,	Gata1	&	Scl/Tal1	 Bone	Marrow	 2013	 GSE42843	Li	et	al	(186)		
Mm	 Runx1	&	Ep300	 Megakaryocytes	 2013	 GSE45372	Pencovich	et	al	(187)	
Mm	 Erg	 Primary	cells	 2013	 GSE46554	Goldberg	et	al	(188)	
Mm	 C/ebpα	 GMP	 2014	 GSE47003	Ohlsson	et	al	(189)	
Mm	 C/ebpα	 LSK	&	GMP	 2014	 GSE43007	Hasemann	et	al	(190)	
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significant fraction of TFs bind at enhancer elements (105) it is of importance to investigate which 
genes are actually regulated by a given TF occupied genomic region through interaction mapping 
(Figure 3). 
The development of NGS has enhanced the identification of interacting genomic regions. 
Classically the interactions between promoters, enhancers, and TFs are mapped using 3C (111). 
For example 3C analysis was used to show that SWI/SNF aids leukemogenesis through cis elements 
interacting with the Myc promoter in mouse models of MLL-AF9 induced AML and BCR-ABL induced 
ALL, as well as several human cell lines carrying various types of AML and ALL (112). Another study 
showed that Pu.1 expression in murine HSCs is auto-regulated by the binding of Pu.1 itself to an 
upstream regulatory element, which was shown to loop with the promoter by 3C. In addition, 
removal of the regulatory element in this mouse model greatly reduced Pu.1 expression (69), 
indicating that also for future studies on gene regulation it is of importance to investigate the 
contribution of these regulatory elements. An entry point for this in human AMLs could be the 
mutations recently described in non-coding genomic regions (113). 
In recent years the 3C technology has been extended towards different chromosome 
conformation capture methods including 4C (114), Hi-C (115), ChIA-PET (116), and Capture-C (117) 
allowing a more comprehensive identification of interacting genomic regions. Interestingly, it was 
recently shown that combining motif finding with ChIP-seq could also give information about long-
range interactions, by looking for ‘indirect’ ChIP-seq peaks; peaks lacking the consensus motif for 
the ChIPed TF (118). In this case, insulator-binding proteins were shown to interact with RNAPII 
pausing sites and distal regulatory sites in Drosophila. However, whether this technique will be 
generally applicable for all TFs remains to be seen. 
It can be expected that applying the technologies described above to leukemia will further 
contribute to our understanding on how aberrant TFs regulate transcription.
As mentioned above, recent genome-wide sequencing efforts have revealed several mutations 
in non-genic regions. It can be expected that these mutations lie in regulatory elements and can 
disrupt TF binding, affect DNA-DNA interactions, and transcription of target genes. In concordance 
with the identification of mutations in non-genic regions it has been estimated that 40% of all 
GWAS (Genome-wide association studies) SNPs can be found in non-coding regions (119). Indeed, 
GWAS in leukemia have for instance identified several SNPs important for chronic lymphocytic 
leukemia/small lymphocytic lymphoma (CLL/SLL) development. These SNPs were subsequently 
used in expression quantitative trait loci (eQTL) analysis to assess their functional relevance to the 
disease. This revealed that most of them lie in putative regulatory elements, of which several have 
previously been implicated with CLL/SLL and other hematological malignancies (120).
The complexity of TF complexes
Generally, mutations in TFs affect either the DNA binding properties or the transcription regulatory 
function of the protein. For example, leukemia associated RUNX1 mutations have been described 
that affect its ability to bind DNA, while when its involved in the translocation t(8;21) the normal 
DNA binding domain is retained and the resulting onco-fusion protein binds to the motif(s) 
corresponding to the DNA-binding part of RUNX1. Interestingly, in the case of PML-RARα both 
properties are affected. Through its oligomerization properties the binding capacity of wt RARα 
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to DR2 and DR5 repeats (the classic DNA consensus targeted by the RARα/RXR heterodimer) is 
extended towards other DR configurations, while also its ability to retain binding of co-repressor 
proteins is enforced (97). 
Clearly, analysis of the motif directly bound by aberrant TFs can provide insights into the 
molecular function. However, these analyses can also be extended to identify enrichments of 
additional DNA motifs to potentially identify other co-binding TFs that contribute to regulate the 
TF’s gene program. For example, analysis of Pu.1 binding sites in macrophages as well as B-cells 
revealed enrichment for ETS and CTCF motifs (13), suggesting a potential co-regulating role of CTCF. 
In a leukemic setting, i.e. AML1-ETO induced AML, the ETS motif was also enriched at the onco-
fusion protein binding sites, which could subsequently be validated by ChIP-seq using ERG and FLI1 
antibodies (39,41). Defining novel motifs not yet associated with a TF at accessible sites by ways 
of genome-wide DNAseI foot printing has opened the possibility to further refine the definition 
of TF binding sites (121). Indeed, given that a significant fraction of leukemic sub-types is caused 
by aberrant TFs, an important next step would be to extend these efforts and generate genome-
wide accessibility profiles for all leukemic -and normal- hematopoietic cell types in order to identify 
motifs and predict TF binding. 
Multiple factors will usually bind to a given TF binding site, either directly or indirectly. In the case 
of poised promoters, for instance, the chromatin will be opened and bound by general transcription 
factors (GTFs) such as the TFII family, TBP, TAFs, and RNAPII in addition to any gene-program specific 
TF such as SPI1 or RUNX1 which are the actual catalyst for the whole machinery to bind (122). Next 
to this, active promoters will also bind complexes such as the super elongation complex, which is 
aberrantly recruited and regulated in MLL-fusion leukemias (123). Moreover, co-factors such as CBP 
and EP300 are often required to initiate transcription and have also been suggested to play a role in 
leukemogenesis. For example, EP300 was shown to co-localize with both the PML-RARα and AML-
ETO fusion proteins in human cell-lines (124).
As a further example of the relevance of co-binding TFs for leukemia, combinatorial binding of a 
heptad of TFs (FLI1, ERG, GATA2, RUNX1, SCL, LYL1, and LMO2) (125,126) was shown to contribute 
to a stem-cell like signature and adverse prognosis in AML. FLT3-ITD based AML patients with high 
expression of the heptad factors had a significantly lower overall survival rate than other patients 
(127). Clearly the identification of the genome-wide binding pattern of TFs, co-factors, and GTFs 
has already provided new insights into the activation of specific gene-programs in leukemia and 
with more data sets becoming available will even further elucidate our understanding of aberrant 
hematopoiesis.
Although the focus has mainly been on the role of aberrant TFs, recent studies have revealed 
the importance of the presence and co-binding of wt copies of TFs. It was shown that WT RUNX1 
(AML1) is needed for both AML1-ETO and CBFβ-MYH disease progression (128), while it is down 
regulated or silenced in a host of other AMLs (129). As both RUNX1 and the fusion proteins bind 
the same motif, albeit with slight variations, it became apparent that the WT RUNX1 and the AML1-
ETO fusion compete over a subset of binding regions (130). Moreover, RUNX1 has been shown to 
co-bind with partners from the AML1-ETO-containing transcription factor complex (AETFC), which 
includes AML1-ETO, CBFβ and the E-proteins HEB and E2A (98).
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In addition to co-binding of factors, post-translational modification (PTM) of TFs plays an 
important role in regulating their activity. These PTMs may act as a ‘molecular switchboard’, coupling 
the upstream signaling events to downstream transcriptional events. A classic example of this is the 
phosphorylation of different serine residues on RNAPII flagging the paused and active states of the 
complex (131). In leukemia, PTMs can be required for disease progression, although the underlying 
mechanisms are not yet fully understood. PML-RARα induced APL transformation for instance, is 
on the one hand dependent on sumoylation of lysine residues in the PML moiety (132), while on 
the other hand treating PML-RARα with arsenic has been shown to induce a different, specific 
poly-sumoylation on lysine residues 65 and 160 of the PML moiety, which leads to degradation 
of the protein and differentiation of the APL cells (133). As another example, RUNX1 function was 
shown to be dependent on phosphorylation of specific serine and threonine residues (134), and 
methylation of specific arginine residues (135). Moreover, the AML1-ETO onco-fusion protein is 
acetylated on specific lysine residues by EP300 and inhibition of this acetylation was shown to 
impair leukemic transformation (99). Clearly, our understanding of regulation of TFs by PTMs in 
leukemia is still limited and additional efforts are needed to fully comprehend the effects of these 
modifications, certainly in light of the possibilities to develop therapies that might target these 
modifications. 
Epigenetics and TFs
Differential cistromes emerge during hematopoietic development, resulting in specialization of cells 
into different lineages. A sub-set of ‘master regulators’ such as SPI1 mediate this process by opening 
the chromatin at key loci, thus paving the way for epigenetic enhancer marks such as H3K4me1 to 
be deposited, and more lineage specific TFs to bind (13,136). Interestingly, the reverse also seems 
to happen as Ostuni et al. describe cryptic enhancers where the histone marks are placed before 
SPI1 binding (137), which emphasizes the dynamic nature of the chromatin state. This epigenetic 
chromatin state is an important aspect of regulation by TFs (138). Histone marks flagging open 
and closed chromatin, or active and inactive promoters and enhancers can affect the binding 
of TFs, thereby regulating their ability to modulate gene expression (139). Through mutation or 
translocation of histone tail reading, writing, or erasing factors, like MLL, EZH2, or JARID1A, the 
chromatin state can be adversely altered in a leukemic setting (140). A mutation in an epigenetic 
enzyme can in this way lead to the deposition of an erroneous signal on a genome-wide scale and 
all putative binding loci of a TF can be affected (141). In many cases, the aberrant TFs themselves 
are involved in altering the epigenetic environment. In some of the MLL-fusion induced leukemias, 
for instance, the deposition of H3K79me2 is disturbed because of the co-binding of the MLL-AF9 
fusion protein with the DOT1L complex which deposits this histone mark (142). Furthermore, an 
imbalance of histone deacetylases (HDACs) and histone acetyltransferases ( HATs) in AML can lead 
to aberrant acetylation patterns contributing to leukemic progression (143). For example, a HDAC 
complex co-binding at PML-RARα target sites alters the acetylation state of its target genes (144), 
while inhibition of HDACs is shown to be effective against PML-RARα induced APL (145,146).
In order to understand the full impact of a cell’s epigenetic state on TF binding we need genome 
wide maps of epigenetic modifications, including histone marks (144) and DNA methylation, in 
different cell types, and in wild type and diseased states. Increasingly, this effort is being made, 
as more and more profiles become available. In particular, the work done by consortia that work 
under the umbrella of IHEC (ihec-epigenomes.org), such as Roadmap (www.roadmapepigenomics.
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org), BLUEPRINT (www.blueprint-epigenome.eu) and DEEP (www.deutsches-epigenom-programm.
de), which strive to define the epigenetic landscape of different (hematopoietic) cell types may 
help to couple events on the epigenetic level to (aberrant) TF binding and subsequent activation or 
repression of target genes (147,148). 
Next to the post-translational modification of histone-tails, the actual histone variants themselves 
are also involved in gene-regulation. Histone H2A.Z is generally associated with accessible chromatin 
(149) and is aberrantly regulated on a genome-wide level in certain forms of acute myeloid leukemia 
(124). It has also been shown that the abundance of replication-dependent H2A variants, which 
normally get up-regulated right before S-phase, is altered in chronic lymphocytic leukemia (150). 
Genome-wide mapping of histone-variants, therefore, will be another entry point in deciphering 
the complex factors that define the leukemic process. 
In tandem with histone tail modifications, DNA methylation is another important epigenetic 
mechanism that can be deregulated during the leukemic process (151), as is evident from the 
frequent mutations of DNMT3a in AMLs(91). In AML, distinct and aberrant methylation profiles can 
be distinguished for the various AML French-American-British (FAB) subtypes, while concurrently 
a more global AML specific set of genes was shown to be deregulated in all subtypes (152,153). 
Furthermore, it was shown that mutations in IDH1/IDH2 or TET2 lead to a distinct and overlapping 
pattern of hyper methylation in AML (154). Moreover, DNA methyltransferase (DNMT) inhibitors 
such as the 5-aza family of nucleoside analogs have been shown to be effective against various 
cancers including AML by inducing hypomethylation on aberrantly methylated leukemic targets 
(155). 
The discovery of new (epi) drugs is therefore a promising utilization of genome-wide analysis 
of leukemic cells. Genome-wide maps can be used to unravel mechanisms that can be used for 
targeted therapy with novel drugs, or to investigate and re-evaluate the global mechanism of action 
of established drugs. PML-RARα induced AML, for instance, can be treated with all trans retinoic acid 
(ATRA) and arsenic trioxide (156), while MLL-AF9 induced leukemia was found to be responsive to 
DOT1L inhibitors (142,157). Moreover, aberrant gene silencing in leukemia can be combatted with 
HDAC inhibitors (158,159). A major drawback of this, however, is the indiscriminate effect of such 
inhibitors, which can lead to severe side effects. Combining part of an HDAC inhibitor with ATRA into 
a novel drug designated MC2392 has been shown to selectively affect HDAC complexes recruited 
to PML-RARα binding sites in NB4 cells (146). MC2392 was shown to selectively kill leukemic cells 
harboring the PML-RARα translocation. Initiatives like this showcase the potential for future studies 
to combine and design specifically targeted drugs by applying genome wide maps during the design 
and validation phase to elucidate putative mechanisms of action. 
Outlook
Throughout recent years more and more data became available revealing which DNA sequences are 
altered in hematopoietic disorders. It has become clear that not only genic alterations are associated 
with disease development, but that also mutations in regulatory non-coding DNA elements can be 
linked to aberrant phenotypes. The next challenge is to understand how these DNA alterations are 
mechanistically involved in altering gene expression and driving disease. The arrival of NGS has not 
only helped to identify the alterations in DNA sequences, but also led to the development of many 
techniques allowing for a better understanding of the function of the mutations. For TFs the focus 
24
Chapter 1
was initially on translocation products that are classically associated with leukemias, but with the 
discovery of additional smaller mutations in other TFs the aim will be to also analyze their molecular 
role. It has become clear that these analyses should be extended to the genome-wide level to truly 
understand the role of these TFs. Given the variety of the regulatory repertoire at different genomic 
positions, single loci and in vitro experiments might lead to a wrong interpretation. 
Apart from analyzing the binding of the TF itself, it is of importance to also know the context 
in which the TF acts to fully comprehend its gene program. Knowledge on the TF complexes, 
epigenetic environment, interaction with regulatory elements and post-translational modifications 
is imperative to provide these mechanistic insights. In addition, it will be of importance to extend 
the analysis to primary patient material. As is clear from Table 1, most studies have thus far been 
conducted using cell lines, mainly because of the relatively high cell numbers required for these 
comprehensive analyses. With the further development of technologies it can be expected that 
in the coming years the cell requirements will decrease, opening the possibility to further include 
primary normal and aberrant cell types in these types of analysis. With primary material, an 
associated question will be connected to the inter- and intra-tumor heterogeneity in malignancies. 
Although single cell transcriptome analysis can already elucidate several questions, the further 
development of other single-cell methods is needed (160,161) to gain further mechanistic insights. 
Another challenge lies in the computational analysis of the genomic profiles. Although analysis 
of single or limited numbers of genome-wide profiles has become routine, the comprehensive 
and integrative analysis of multiple datasets from different techniques still poses a major difficulty. 
Several initiatives, such as the Leukemia Gene Atlas (LGA) (162) set out to enable these integrative 
analysis of diverse genomic data linked to leukemia. Similarly, the application of bio-informatic tools 
like Gene Set Control Analysis (GSCA) (163) assists with the identification of potential upstream 
regulators from genome-wide TF binding data. Still, key challenges remain to be resolved, including 
the management of the vast data sets arising from sequencing experiments, appropriate choice of 
genome aligners based on experimental set up, variability between profiles created on different 
platforms, application of various peak callers generating non-identical DNA binding profiles and 
difference in normalization methods (43,164). Defining new roads to perform these analyses will 
be crucial to take the next step in understanding disease development and ultimately open up new 
avenues for improved therapy. 
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In this thesis
Genomic translocations involving various transcription factors and chromatin modifying enzymes 
can lead to deregulation of the epigenetic programming, which in turn can lead to the leukemic 
transformation of myeloid (precursor) cells. Here, we aim to investigate the genome wide binding, 
the associated epigenetic landscape, and the transcriptional output of a number of different 
onco-fusion proteins, in order to further elucidate the molecular mechanisms behind, and the 
commonalities and differences between, the etiology of various subtypes of acute myeloid leukemia.
 In chapter 1 we introduce the role of transcription factors in AML and review the current 
understanding of its various subtypes. In chapter 2 we investigate the mechanisms behind FUS-ERG 
induced AML, followed by an assessment of the role of RUNX1 and ERG in AML-ETO induced AML 
in chapter 3. In chapter 4 we investigate the genome wide binding of MLL-fusion induced AMLs and 
their interplay with RUNX1. Hereafter, we zoom in on two sub-groups of MLL-AF9 patients based on 
BRE expression in chapter 5, where we also identify the novel CHORDC1-BRE fusion protein. Finally, 
in chapter 6 we discuss the results presented in this thesis.
For chapter 1, I co-wrote the manuscript. For chapters 2 and 3, I performed bio-informatic 
analyses, and proofed the manuscript. For chapter 4, I performed most wet-lab experiments and 
bio-informatic analyses, and wrote the manuscript. Finally, for chapter 5, I performed experiments, 
carried out the bio-informatics analyses, and co-wrote the manuscript. For all experimental chapters 
I was involved in data-interpretation and experimental design.
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Abstract
The ETS transcription factor ERG has been implicated as a major regulator of both normal 
and aberrant hematopoiesis. In acute myeloid leukemias harboring t(16;21), ERG function is 
deregulated due to a fusion with FUS/TLS resulting in the expression of a FUS-ERG oncofusion 
protein. How this oncofusion protein deregulates the normal ERG transcription program is unclear. 
Here, we show that FUS-ERG acts in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, 
LMO2, RUNX1 and TAL1) central to proper expression of genes involved in maintaining a stem cell 
hematopoietic phenotype. Moreover, in t(16;21) FUS-ERG co-occupies genomic regions bound by 
the nuclear receptor heterodimer RXR-RARα inhibiting target gene expression and interfering with 
hematopoietic differentiation. All-Trans Retinoic Acid treatment of t(16;21) cells as well as FUS-ERG 
knock down alleviate the myeloid differentiation block. Together, the results suggest that FUS-ERG 
acts as a transcriptional repressor of the retinoic acid signaling pathway.
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Introduction 
Members of the large E-Twenty-Six specific (ETS) protein family are winged helix-turn-helix DNA 
binding domain transcription factors that have diverse functions and activities in physiology and 
oncogenesis, amongst which normal and aberrant hematopoiesis1. ERG (V-ets avian erythroblastosis 
virus E26 oncogene homolog), a hallmark ETS factor protein, is known to have a critical role in 
establishing definitive hematopoiesis and is required for normal megakaryopoiesis. Truncated 
forms of ERG due to oncogenic fusion translocations have been associated with multiple cancers 
such as Ewing’s sarcoma (EWS-ERG), prostate cancer (TMPRSS2-ERG) and acute myeloid leukemia 
(FUS-ERG; ELF3-ERG)2,3,4.
The FUS-ERG chimeric oncogene has been associated with acute myeloid leukemia’s (AMLs) 
carrying the non-random t(16;21)(p11;q22) chromosomal aberration. The resulting fusion protein 
retains the N-terminal domain of FUS/TLS (FUsed in Sarcoma or Translocated in LipoSarcoma) 
protein, and the C-terminal domain is replaced by the ETS motif-DNA-binding domain of ERG5. 
In vitro experiments suggest that the FUS/TLS fusion domain (TFD) regulates the DNA binding 
activity of the FUS-ERG chimeric protein which as a result shows weaker transcriptional activation 
properties compared to normal ERG proteins6. However, whether this mechanism also works in vivo 
is still unclear.
The normal FUS gene encodes an RNA-binding protein that serves in transcription regulation 
and RNA metabolism7. Both the amino- and the carboxy- terminal regions of FUS/TLS containing 
the conserved RNA binding motifs are needed for poly G specific RNA binding activity. In addition, 
analysis of TLS-ERG mutants showed that the first 173 amino acids of the FUS/TLS N-terminal 
comprise a subdomain that mediates interaction with RNAPII8,9, suggesting a direct role in 
transcriptional regulation and/or transcription coupled RNA processing. A role in transcription 
regulation was further suggested by the finding that the N-terminal part of FUS binds retinoid-x 
receptor (RXR)10,11,12. Finally, it has been shown that the C-terminal of FUS inhibits the DNA binding 
and transcription activation of SPI1 (PU.1)13,14.
FUS expression is downregulated in the early stages of ATRA-induced granulocytic differentiation 
of HL60 leukemic cells15,16. Furthermore, a knock-out study showed that Fus null mice have an 
increased number of granulocytes17. Another study with Fus deficient mice showed that Fus-/- 
fetal livers developed normally, except for a mild reduction in numbers of hematopoietic stem 
and progenitor cells compared to wild-type18. These findings suggest a role for FUS in regulating 
hematopoietic stem cell (HSC) self-renewal and terminal differentiation along the myeloid lineage19.
ERG has also been associated with aberrant hematopoiesis. High expression of ERG is linked with 
poor prognosis in a subgroup of leukemia patients with AML and acute T-lymphoblastic leukemia 
(T-ALL)2,20,21. In addition, correct Erg gene dosage is critical for the maintenance of HSC function. 
Mice homozygous for the loss-of-function ErgMld2 mutation die at mid gestation, with a profound 
defect in definitive hematopoiesis suggesting an essential role in HSC self-renewal22,23,24,25.
Still, how FUS-ERG fusion protein may lead to cellular abnormalities by deregulating normal 
ERG gene transcription in vivo is not understood. Therefore, in the present study we used massive 
parallel sequencing of chromatin immunoprecipitates (ChIP-seq) and quantitative sequence of 
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transcripts (RNA-seq) for identification of FUS-ERG binding sites in t(16;21) AML cells. We found 
that FUS-ERG mainly binds non-promoter regions in a complex consisting of other ETS factors, 
GATA2, LMO2, LYL1, RUNX1, TAL1 and RNAPII. Interestingly, we noticed that apart from interacting 
with RXR, FUS-ERG also colocalizes to similar regions as the nuclear receptor RARα. Treatment with 
ATRA resulted in reduced FUS-ERG binding and higher expression of target genes, suggesting that 
the role of FUS-ERG in leukemogenesis relates to repressing the ATRA signaling pathway.
Results
FUS-ERG expression in leukemic cells. 
The reciprocal translocation t(16;21)(p11;q22) is a rare abnormality associated with AML and 
present in the TSU-1621-MT and YHN-1 cells, an M4 and M1 AML type respectively according 
to the FAB classification. To validate gene expression arising from the translocation we examined 
expression of FUS-ERG mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR). Using 
primers that recognize exon 6 from FUS and exon 10 from ERG30 (Figure 1A), we were able to 
confirm the expression of the oncofusion gene in the TSU-1621-MT and YNH-1 cells (Figure 1B), 
while it is not expressed in KG-1 and U937 cells that do not harbor this translocation.
To assess whether the fusion of ERG to FUS would affect wt ERG or FUS we extended the qPCR 
and analyzed the relative expression levels of the fusion gene as compared to the wild type. This 
analysis revealed that wt FUS (FUS4-5) levels are comparable in all 4 cell types, while ERG levels are 
comparable in TSU, YNH-1 and KG-1 cells, but not detectable in U937. Western blot analysis using 
a C-terminal ERG antibody and a N-terminal FUS antibody confirmed the presence of high levels of 
FUS, and expression of FUS-ERG and ERG proteins in the nucleus of TSU-1621-MT cells (Figure 1C), 
while both FUS-ERG as well as wt ERG are not present in the U937 cells, corroborating the RT-qPCR 
results. 
ERG-fusion specific binding in cancer. 
The t(16;21) fusion results in aberrant expression of ERG in AML. ERG is also involved in translocations 
underlying prostate cancer (TMPSSR2-ERG) and Ewing’s sarcoma (EWS-ERG)31. To examine whether 
a common ERG cancer signature could be observed we used an ERG antibody (recognizing the 
C-terminal region) in ChIP-seq experiments in the TSU-1621-MT leukemic cells and compared the 
profile with the ERG binding profiles resulting from expression of TMPRSS-ERG in VCaP (prostate 
cancer) and EWS-ERG in CADO-ES1 cells32,33 (Figure 1D). We used MACS234 at a p-value cut off of 
10-6 to identify all ERG binding regions in TSU-1621-MT, EWS-ERG in CADO-ES1 (Ewing’s sarcoma) 
cells and identified 31,596, 32,406 and 17,469 ERG binding regions from TSU-1621-MT, VCaP and 
CADO-ES1 cells respectively. Between TSU-1621-MT and VCaP cells we identified 35% overlap 
(11,216 binding sites), while only an overlap of 1% (404 binding sites) was found between EWS-ERG 
and FUS-ERG expressing cells. Intersection of the three datasets revealed an overlap of 148 peaks 
representing mainly promoter regions associated with genes belonging to the Jak-STAT signaling 
and Wnt signaling pathways (p-values 5E-04 and 6E-04 respectively; data not shown).
The low overlap between the different ERG profiles suggests that ERG binds to different genomic 
loci depending on cell type. To examine whether the aberrant ERG expression in t(16;21) AML would 
reflect ERG binding in other AML subtypes we compared ERG binding in TSU-1621-MT cells with 
those in SKNO-1 and ME-1 cells, two cell lines representative of the t(8;21) and inv(16) translocation 
respectively. Overlapping the binding regions of the three leukemic cell lines revealed a large 
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Figure 1. Aberrant ERG expression in cancer. (A) Schematic diagram of the organization of FUS (blue) and 
ERG (black) genes. Genomic organization of the FUS-ERG fusion gene at the chromosome translocation 
breakpoint. Boxes indicate exons; lines indicate introns. (B) Gene expression levels of FUS (exon 4-5), ERG 
(exon 1-2) and FUS-ERG (FUS exon 6 – ERG exon 10) determined by quantitative real-time PCR (qPCR). The 
relative expression levels of the genes indicated (x-axis) were assessed in the t(16;21) AML cells TSU-1621-
MT and YNH-1 and in two control cell lines KG-1 and U937. (C) Western analysis of the cytoplasmic and 
nuclear fraction of U937 and TSU-1621-MT cells using antibodies recognizing FUS, ERG and a control β-ACTIN 
antibody. (D) Venn diagram representing the overlap of ERG binding sites in CADO-ERG, VCaP and TSU-1621-
MT cells (left). ChIP-seq using ERG antibody. Overview of the RSBN1 and PTPN2 EWS-ERG, TMPRRSS2-ERG 
and FUS-ERG binding sites (right). Brown represents the EWS-ERG ChIP-seq data; pink, the TMPRRSS2-ERG 
data and green the FUS-ERG data. (E) Venn diagram representing the overlap of ERG binding sites in the 
AML cell lines TSU-1621-MT, ME-1 and SKNO-1 (left). ChIP-seq using ERG antibody. Overview of the SPI1 
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ERG binding sites in TSU-1621-MT, ME-1 and SKNO-1 cells (right). Green represents the TSU-1621-MT ChIP-
seq data; purple, the ME-1 data and blue SKNO-1 data. (F) Bar chart showing the enrichment of biological 
process of FUS-ERG binding sites in TSU-1621-MT cells (based on a single ontology-specific table from 
GREAT). The metric plotted is Binomial p-value.
common set of 17,750 regions (Figure 1E). As these AML common regions potentially represent 
key binding sites for ERG induced leukemic transformation we performed functional analysis of the 
associated genes. This revealed high enrichment scores (>10) for genes involved in regulation of 
the cell cycle (Figure 1F), suggesting the involvement of ERG target genes in deregulation of normal 
cell proliferation.
FUS-ERG targets ETS factor sites in promoter and enhancer regions. 
To identify potential FUS-ERG binding sites we extended our ChIP-seq analyses and included an 
antibody recognizing the N-terminal of the FUS protein. Using the same peak calling settings as 
above allowed the identification of 16,533 FUS occupied regions in TSU-1621-MT cells. A total of 
10,364 binding regions were found that overlapped between FUS and ERG, for example at ITGAM 
and CSF3R promoter and enhancer regions, potentially representing FUS-ERG binding sites (Figure 
2A-B). 
A subset of these binding sites was validated through re-ChIP experiments on targeted loci, 
confirming that the two parts of the fusion protein occupy the same genomic region (Supplementary 
Figure 1). Moreover, transfecting a flag tagged FUS-ERG followed by ChIP-qPCR in U937 cells 
which do not express the fusion showed binding at target sites identified in TSU-1621-MT cells 
(Supplementary Figure 2), confirming that the fusion protein can bind to these DNA regions.
To investigate whether wt FUS colocalizes with ERG we extended our ChIP-seq analysis and 
examined binding of FUS at ERG occupied regions in SKNO-1 and ME-1 cells (Supplementary 
Figure 3). This analysis revealed enrichments of FUS signal at ERG binding sites in these two cell 
types, suggesting that wt FUS can also colocalize with ERG. Together these results suggest that 
FUS stabilization at ERG binding sites might represent a common event in oncofusion protein 
leukemogenesis.    
The putative FUS-ERG occupied regions in TSU-1621-MT cells are predominantly located in non-
promoter, mostly intergenic regions (Figure 2C) whereas ERG peaks not overlapping with FUS (and 
likely representing wt ERG binding) show a higher percentage localized to promoter regions. Motif 
analysis of the FUS-ERG binding sites revealed that the ETS factor core motif GGAAG was enriched 
in nearly all of the binding sites (Figure 2D). In addition to the ETS motif the RUNX1 motif was 
also found to be enriched in FUS-ERG binding sites, suggesting FUS-ERG is involved in aberrant 
regulation of RUNX1 target genes. Motif analysis of the 6,169 FUS only peaks surprisingly also 
revealed enrichment/presence of the ETS transcription factor motif. It was previously suggested 
that wt FUS binding to DNA could be mediated by interaction with SPI113,14. Indeed, including a 
SPI1 ChIP-seq in our analysis revealed SPI1 enrichment at all FUS only binding sites (Supplementary 
Figure 4), suggesting that non-fused FUS recruitment to DNA might in part be ETS factor dependent.
FUS has been suggested to multimerize through its N-terminal domain35, suggesting that this 
property might also be present in the FUS-ERG fusion protein. Such oligomerization could be 
strengthened by the presence of multiple binding motifs for ERG. To inspect whether multiple ETS 
motifs are present in FUS-ERG binding sites we examined the number of motifs present within 
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one peak (Figure 2E). In addition, we examined the number of RUNX1 motifs. This revealed that 
within one FUS-ERG occupied region generally one RUNX1 but multiple ETS motifs can be detected, 
suggesting that FUS-ERG may act in an oligomeric complex as has previously been suggested for 
other oncofusion proteins36 and/or that FUS-ERG collaborates with other ETS factors. 
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Figure 2. Genome-wide binding of FUS-ERG. (A) Venn diagram representing the overlap of FUS and ERG 
binding sites in TSU-1621-MT cells. (B) ChIP-seq using FUS and ERG antibodies. Overview of the ITGAM and 
CSF3R FUS and ERG binding sites in TSU-1621-MT cells. Green represents the FUS binding sites data; red, 
the ERG ChIP-seq data and black the FUS-ERG peaks in TSU-1621-MT cells. (C) Distribution of the FUS-ERG 
and ERG binding site locations relative to RefSeq genes. Locations of binding sites are divided in promoter 
(− 500 bp to the transcription start site), non-promoter CpG island, exon, intron, and intergenic (everything 
else). (D) Motif analysis of the FUS-ERG binding sites. Overview of the resulted scores of ETS and RUNX1 
core binding motifs. (E) Number of FUS-ERG peaks that harbor a given number (indicated on the x-axis) of 
ETS or RUNX1 motifs. (F) Western analysis of a DNA pull-down in TSU-1621-MT cells using an ERG, FLI1 and 
FUS antibody. ERG, FLI1 and FUS are more enriched in the pull-down with the ETS motif in comparison to 
the control. Specific binding to the oligo is further confirmed by ERG and FLI1 depletion in the supernatant 
that is left after incubation with the ETS oligo, but not with the Control oligo. (G) Scatter plot showing the 
result of a pull-down mass spectrometry experiment. Proteins are plotted by their dimethyl-ratios in the 
forward (x axis) and reverse (y axis) SILAC experiment. ETS proteins and specific interactors of the ETS pull-
down lie in the lower right quadrant. (H) Heat map displaying ERG and FLI1 tag densities at high-confidence 
FUS-ERG-binding sites.
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To examine which other ETS factors might be involved in regulating ETS motif containing binding 
sites we performed a DNA pull-down experiment using a specific nucleotide sequence that contains 
the ETS consensus motif CCGGAAG (ETS bait) and a control sequence (Control bait) with a scrambled 
ETS motif (Supplementary Table 3). The ETS bait motif used represent the consensus site for class 
I, IIa, IIb, and IV ETS family members33 like ERG, ELF1 and FLI1 (Figure 2F), while class III family 
members such as SPI1, bind a distinctive consensus motif G(A/G)GGAAG. Western blot experiments 
confirmed that the ETS motif containing oligo efficiently pulls down ERG, as well as FUS-ERG from 
TSU-1621-MT cell lysates (Figure 2F). Specific binding to the oligo was further confirmed by ERG Figure	3
A
B
Figure 3. FUS-ERG binds genomic regions occupied by a heptad of transcription factors. (A) ChIP-seq using 
heptad (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) antibodies. Overview of the CBFA2T3 heptad 
binding sites in TSU-1621-MT cells. ‘FUS-ERG peaks’ represents regions occupied by FUS and ERG, ‘CD34+ 
peaks’ represents heptad binding sites in CD34+ cells and ‘TSU peaks’ represents heptad peaks in TSU-1621-
MT cells. (B) Heat map displaying ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1 tag densities at high-
confidence FUS-ERG-binding sites.
41
The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans 
retinoic acid signaling pathway in t(16;21) acute myeloid leukemia
depletion in the supernatant that is left after incubation with the ETS oligo, but not with the Control 
oligo. 
 Subsequently, the protein extracts derived from TSU-1621-MT cells incubated with 
oligonucleotides containing the ERG or a scrambled ERG motif were subjected to specific labeling 
methods with ‘heavy’ or ‘medium’ dimethyl labels and analyzed by mass spectrometry37 (see 
supplemental Materials and Methods). As expected, specifically ETS family members of the I, IIa, IIb, 
and IV classes, but not SPI1, were enriched in the ETS motif pull down (Figure 2G). Unfortunately, 
peptides recognizing the N-terminal of FUS (present in wt FUS and in FUS-ERG) were not found, 
likely due to the inability of trypsin to digest the FUS glycine-rich regions. Interestingly, the ratio 
Control vs ETS pull down peptides was higher for FUS C-terminal peptides, representing the wt FUS, 
suggesting wt FUS is underrepresented at genomic regions harboring ETS consensus sequences. 
As our ChIP-seq results using an N-terminal antibody indicate enrichment of FUS at ETS containing 
binding sites this signal is likely due to the fusion of FUS and ERG. Figure	4
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Figure 4. FUS-ERG targets RXR:RARα binding sites. (A) ChIP-seq using RARα, RXR, FUS and ERG antibodies. 
Overview of the SPI1 binding sites in TSU-1621-MT cells. Pink represents RARα data; blue represents the 
RXR data; green represents the FUS data; red, the ERG ChIP-seq data and black the FUS-ERG peaks identified 
in TSU-1621-MT cells. (B) Heat map displaying ERG, RXR, FUS and RARα tag densities at high-confidence 
FUS-ERG-binding sites. (C) Barplot showing the expression levels (RPKMs) of nuclear receptors in the RNA-
seq data. 
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To confirm the interactions of FLI1 with the ETS motif containing DNA fragment we used an 
antibody recognizing FLI1 in western analysis after pull down as well as in ChIP-seq. This revealed 
specific FLI1 binding to the ETS containing DNA fragment (Figure 2F) as well as increased occupancy 
of FLI1 at FUS-ERG binding sites (Figure 2H), corroborating the pull down results.
FUS-ERG does not interfere with assembly of a hematopoietic transcription factor complex
Both ERG and FLI1 have been suggested to function in a heptad of proteins38,39,40 which is central to 
proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. RNA-seq 
analysis using TSU 1621 MT cells revealed that all these 7 heptad transcription factors (GATA2/FLI1/
RUNX1/TAL1/LYL1/LMO2/ERG) are expressed in this cell type, suggesting that also in the context 
of FUS-ERG the heptad can potentially assemble. To examine whether the heptad is present or 
whether assembly of the heptad is interfered due to the FUS-ERG fusion we performed ChIP-seq 
for all the heptad factors in TSU-1621-MT cells (Figure 3A). Analyzing the binding data revealed 
that in TSU-1621-MT cells heptad complexes were present and that the majority of the heptad 
binding sites were occupied by FUS-ERG, suggesting that the FUS moiety does not interfere with TF 
complex assembly (Figure 3B). We further characterized the distribution of binding events across 
FUS-ERG/heptad occupied genomic features and identified 4 clusters that could be distinguished on 
different levels of FLI1, GATA2, and LYL1. Cluster 2 and 3 represent intergenic regions with relatively 
low FLI1 levels, and are functionally enriched for abnormal hematopoiesis, apoptosis signaling 
and myeloid cell differentiation. Cluster 4 represents promoter regions with higher levels of FLI1 
and LYL1 and is functionally enriched for cell proliferation, myeloid differentiation and immune 
response. In contrast, cluster 1, which is linked to promoter regions, is enriched for transcriptional 
coupled events and represents regions strongly bound by ERG, FLI1, RUNX1 and TAL1. Together, 
these results suggest that FUS-ERG does not interfere with heptad formation, but that depending 
on the genomic context occupancy strength of heptad components can vary.
Next we compared the heptad occupancy in the TSU-1621-MT cells with available data from 
non-leukemic CD34+ 40 cells which represent a normal hematopoietic cell population. We found 
enrichment of heptad components in CD34+ cells at many of our FUS-ERG binding sites, for example 
HHEX, LAPTM5 and CBFA2T3 genes were bound by all seven TFs in both cell types (Supplementary 
Figure 5A, B). Together these results suggest that the heptad distribution in TSU cells resembles at 
least part of the heptad signature in CD34+ cells.
FUS/TLS has been reported to interact with RXR10 and also our mass spectrometry analysis 
revealed ~2-fold enrichment of RXR (RXRβ) in the ETS motif containing DNA pull down (Figure 2G). 
To examine whether FUS-ERG binds similar genomic regions as RXR we performed ChIP-seq using 
an RXR antibody (recognizing RXRα, RXRβ and RXRγ). This analysis revealed enrichment of RXR at 
high confidence FUS-ERG binding sites (Figure 4A-B), although at varying strength. As RXR is acting 
in heterodimeric complexes we wondered whether another nuclear receptor could be present 
interacting with RXR. We found a variety of other nuclear partners expressed in normal TSU-1621-
MT cells, of which RARα was one of the highest NR expressed known to form a heterodimer with 
RXR (Figure 4C). Moreover, as RARα is a common fusion partner in APLs41, another subset of AMLs, 
we wondered whether RARα could be present in the FUS-ERG/RXR complex. 
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To answer this question, we performed ChIP-seq using a RARα antibody. Quantitation of RARα 
tag densities at FUS-ERG peaks revealed enrichment of RARα at FUS-ERG binding sites (Figure 4A-B) 
suggesting that FUS-ERG might be involved in regulating retinoic acid signaling in t(16;21) AMLs. 
A variety of AML cells have been shown to be responsive to ATRA treatment, in particular AMLs 
harboring a translocation involving RARα. No studies so far have considered patients with t(16;21) 
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Figure 5. ATRA treatment of t(16;21) AML cells reduces viability and increases expression of FUS-ERG target 
genes. (A) Viability curves in TSU-1621-MT cells (n=3) exposed to increasing concentrations of ATRA over 
time. (B) Cell pictures of TSU-1621-MT cells before and after ATRA treatment. The inset zooms in on one of 
the cells. (C) Heat map (left) and box plot (right) displaying H3K9K14ac densities at high-confidence FUS-ERG-
binding sites before and after treatment of TSU-1621-MT cells with ATRA. (D) Overview of RNA-seq data in 
TSU-1621-MT cells treated or untreated with ATRA at the CD38 genomic region. RNA tracks are represented 
in red for untreated cells and in blue for cells after 24 hours of ATRA treatment. (E) Boxplot showing RPKM 
values of FUS-ERG occupied regions before (red) and after (blue) ATRA treatment. FUS-ERG occupied regions 
are divided in three groups, high (>10 RPKMs), medium (1<RPKMs<10)and low (RPKMs<1). (F) Box plot 
displaying SPI1 and H3K9K14ac densities at ATRA increased SPI1 binding sites before and after treatment of 
TSU-1621-MT cells with ATRA. (G) Venn diagram representing the overlap of FUS-ERG and ATRA increased 
SPI1 binding sites. (H) Functional annotation of genes associated with increased SPI1 binding sites. 
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(p11;q22) translocations as possible candidates for retinoic acid treatment. As our findings show 
that RARα-RXR might function as a partner of FUS-ERG we wondered whether these AML cells 
would be responsive to ATRA treatment. Therefore, TSU-1621-MT cells were exposed to different 
concentrations of ATRA during 4 days. The rate of cell growth for the TSU-1621-MT cells was 
calculated as 0.7 times/day. After 4 days, the number of viable cells had increased 2.5 fold (Figure 
5A). This slow increase of cell number was halted by the presence of ATRA as evidenced by reduced 
viability (Figure 5A) and differentiation of the cells (5-8 % of the total living cells per day attached to 
the plate) into granulocytes (Figure 5B). 
In APL, ATRA treatment was shown to 
increase histone acetylation levels at PML-
RARα binding sites. To examine whether 
histone acetylation is changed at FUS-ERG 
binding sites we performed ChIP-seq analysis 
using antibodies recognizing histone H3K9K14 
acetylation. After ATRA treatment increased 
levels of H3 acetylation were observed at 
nearly all binding sites (Figure 5C), suggesting 
a role for the fusion protein in maintaining a 
less active chromatin structure. 
To examine which genes are differentially 
expressed upon ATRA treatment we exposed 
TSU-1621-MT cells for 24 h to 1 µM ATRA 
and performed RNA-seq analysis. Gene 
expression levels from control and treated 
cells were estimated by counting the number 
of reads mapping to constitutive exons for 
each gene and determining RPKM values 
(reads per kilobase of exon model per million 
uniquely mapped reads). 
Initial analysis of CD markers revealed 
significant increased RPKM values for the 
differentiation marker CD38 compared with 
untreated cells (Figure 5D; Supplementary 
Table 6). Other CD markers shown to be lower 
expressed after ATRA treatment (log ratio <-1) 
were the progenitor marks HLA-DR, CD34 and 
CD44, while granulocytic markers like CD13, 
CD15, CD11b, CD18 and MPO were higher 
expressed. As also increased expression of 
other granulocytic markers including HIC1, 
ASB2 and NCF1 was observed after treatment, these results suggest differentiation of ATRA treated 
TSU-1621-MT cells towards the granulocyte-macrophage lineage(s). 
Figure	6
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Figure 6. ERG and RNAPII changes at FUS-ERG binding 
sites. (A) Heat map displaying ERG, FUS, RNAPII and 
RARα tag densities in untreated or ATRA treated TSU-
1621-MT cells at high-confidence FUS-ERG-binding 
sites. (B) Density plots of K-means clustered ERG, FUS, 
RNAPII and RARα tag densities in untreated or ATRA 
treated TSU-1621-MT cells at high-confidence FUS-
ERG-binding sites. N represent the number of binding 
sites per cluster.
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To examine the effect of ATRA treatment 
on FUS-ERG target genes we assigned FUS-ERG 
binding sites to the closest gene and analyzed 
gene expression. This revealed that FUS-ERG 
target genes are expressed at different level with 
11% of genes expressed at a high level (RPKM 
>10), 59% moderately expressed (1< RPKM <10) 
and 30% low expressed (RPKM <1) (Figure 5E, 
red boxes). RT-qPCR of a selection of genes from 
each of these 3 groups confirmed their relative 
expression results in both TSU1621-MT as well as 
YNH-1 cells (Supplementary Figure 6).
Upon ATRA treatment we observed increased 
expression for a majority of FUS-ERG target genes 
(68%; Figure 5E, blue boxes), suggesting FUS-ERG 
functions as a transcriptional repressor of genes 
part of the ATRA signaling pathway. 
Our results identified FUS-ERG binding at the 
third intron of SPI1 (Figure 4A), a key regulator of 
hematopoietic differentiation. It is characterized 
by the presence of direct repeat (DR) motifs, 
which represent canonical RARα-RXR binding 
sites (Supplementary Figure 7A), as well as the 
consensus binding sequence for ETS factors 
(such as ERG). This region has previously been 
associated with repression of SPI1 transcription 
(Ebralidze et al., 2008), which can in APLs be 
relieved after treatment with ATRA (Martens et 
al., 2010). In line with the suggestion that FUS-
ERG functions as a repressor of transcription, also 
in ATRA treated TSU-1621-MT cells SPI1 expression 
is increased (Supplementary Table 6). SPI1 and 
ERG are both members of the ETS family of 
transcription factors. We wondered whether SPI1 
could alter the FUS-ERG repressed gene program 
Figure	7
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Figure 7. FUS-ERG knock down alters the t(16;21) AML gene expression program. (A) Viability curves in TSU-
1621-MT cells in samples with 23% knock down (KD1) or 40% knockdown (KD2) of FUS-ERG over a period of 
3 days. (B) Scatterplot of RPKM values (log2) for FUS-ERG regulated genes. The Y axis represents expression 
of ATRA treated genes versus control, the X-axis expression of genes when induced with shRNA versus not 
induced. Each quadrant shows the gene enrichment for biological processes (BP) and pathways (P). (C) 
Schematic model for the suggested actions of FUS-ERG in t(16;21) cells before and after ATRA treatment. 
Before treatment FUS-ERG binds as an oligomer to promoter and intergenic regions together with a heptad 
of transcription factors as well as RARα:RXR and RNAPII. After ATRA treatment, FUS-ERG is lost from the 
complex allowing RNAPII to transcribe genes involved in myeloid differentiation.
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through increased binding activity at FUS-ERG target genes after ATRA treatment. However, ChIP-
seq results of SPI1 binding before and after ATRA treatment of TSU-1621-MT cells revealed no 
differences in binding site occupancy at FUS-ERG binding sites (Supplementary Figure 7B). Using 
a 3-fold cut off we identified 1,377 genomic regions were SPI1 binding is increased (Figure 5F, 
left). As expected, these regions do not overlap with FUS-ERG binding sites and represent sites of 
no/low histone acetylation, which is increased upon binding of SPI1 (Figure 5F, right; Figure 5G). 
Interestingly, these regions are associated with genes that upon knock out in mice are associated 
with granulocyte abnormalities, suggesting activation of these regions is required for normal 
granulopoiesis. 
Together these results suggest that FUS-ERG acts as a repressor of SPI1, preventing it to activate 
a granulocytic differentiation program.  
ATRA treatment induces a FUS-ERG/ERG switch at enhancer regions
To examine the effect of ATRA treatment on FUS-ERG binding we performed ChIP-seq using FUS 
and ERG antibodies in ATRA treated TSU cells. In addition, we included RNAPII occupancy after 
treatment allowing to validate alterations in transcriptional activity. K-means clustering distinguished 
5 groups of FUS-ERG binding sites (Figure 6A, B). While cluster 1, 3 and 4 were characterized by 
increases in ERG and lowered FUS occupancy, clusters 2 and 5 showed reduced FUS and ERG levels, 
suggesting that FUS-ERG binding is lost and that at a subset of regions (clusters 1, 3 and 4) ERG 
binding is gained. Interestingly, sites were ERG occupancy is increased are mostly non-promoter 
(~85%) (cluster 1, 3 and 4) and show increased levels of RNAPII suggesting these are enhancers 
activated upon ATRA treatment (Figure 6B, Supplementary Figure 8). Functional analysis of these 
three clusters revealed a clear enrichment of genes downregulated in AML1-ETO and PML-RARα 
leukemic translocations, suggesting that these represent a set of regions commonly targeted in 
different subtypes of AML. Additional comparison with AML1-ETO and PML-RARα binding regions, 
2,754 and 2,721 peaks respectively 20,41, pointed out that indeed, 50-60% of regions overlapped 
(Supplementary Table 7).
In contrast to clusters 1, 3 and 4, clusters 2 and 5, which represent mostly promoter regions 
(~83%) showed enrichment for mRNA metabolism, mRNA splicing, cell cycle check-points and 
gene expression. These two clusters show loss of RNAPII occupancy upon ATRA treatment, likely 
representing a switch from a poised RNAPII to a transcriptional active molecule. 
FUS-ERG silencing results in cell death
To examine the molecular targeting of the FUS-ERG oncofusion protein in TSU-1621-MT cells we 
generated a shRNA construct targeting the fusion point sequence of FUS-ERG under the control of a 
tetracycline-regulated promoter (FH1t-UTG). FUS-ERG silenced TSU-1621-MT cells (Supplementary 
Figure 9) resulted in cell death and decreased proliferation (Figure 7A) suggesting FUS-ERG is 
needed to maintain the full leukemogenic potential of these cells. 
To examine the effect of FUS-ERG knock down on target gene expression we performed RNA-
seq analysis. We identified 1,833 FUS-ERG target genes, such as CTNNB1 and IL1B (Supplementary 
Figure 7) that were differentially expressed. Among these genes, 1,149 were up-regulated and 684 
were down-regulated by at least two-fold (Supplementary Table 8) suggesting FUS-ERG is involved 
in gene repression, but can also activate particular gene sets. In agreement with the knock down 
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induced cell death we found increased expression of genes inducing apoptosis like CASP10, ATM, 
SAMD3, BMF, FAF1 while anti-apoptotic genes like BCL-2, GADD45B, IL1B, IL2RA were downregulated.
Finally, we integrated the knock down analysis with the ATRA induced differentiation results to 
identify the key ATRA responsive genes regulated by FUS-ERG. A scatter plot (Figure 7B) showing the 
log2 ratios of both the shRNA knock down experiment (x-axis; induced/non-induced) and the ATRA 
differentiation experiment (y-axis; ATRA treated/non-treated) revealed 138 FUS-ERG target genes 
higher expressed after FUS-ERG knock down or after ATRA treatment. This set is enriched for genes 
involved in myeloid differentiation (Figure 7B), suggesting FUS-ERG has a role in repressing this 
particular gene set from becoming activated by ATRA. In contrast, amongst the common 76 down 
regulated genes enrichment for immune response, anti-apoptosis and cytokine-cytokine receptor 
interaction pathways were found.
Together our results suggest that FUS-ERG acts in part as a transcriptional repressor of the 
retinoic acid signaling pathway for a subset of target genes. It acts in the context of other master 
hematopoietic transcription factors, as well as RARα:RXR to inhibit genes that can drive myeloid 
differentiation. Both ATRA treatment and FUS-ERG knock down can alleviate this repression and 
induce expression of this set of target genes (Fig 7C).     
Discussion
Acute myeloid leukemias harboring t(16;21)(p11;q22) express the oncofusion protein FUS-ERG. 
Expression of this fusion protein in normal human myeloid progenitors has been shown to result in a 
block in development at the promyelocytic stage42, an arrest in erythroid and myeloid differentiation 
and an increase in proliferation and self-renewal capacity of human myeloid progenitors42. 
However, these transduction experiments can only partially recapitulate the disease state43. In 
this study, we describe for the first time the molecular mechanisms underlying the actions of the 
FUS-ERG oncofusion in AML at a genome-wide level in patient derived cell line models. We found 
that this oncofusion is expressed at similar levels as wt ERG, and might interfere with normal ETS 
factor regulation. To identify FUS-ERG binding we used two antibodies specifically recognizing the 
N-terminal of FUS and the C-terminal of ERG. We identified a set of 10,364 genomic regions, mainly 
intergenic and thus representing putative enhancer regions, to which FUS-ERG binds with high 
confidence. We discovered that the oncofusion protein occupies genomic regions bound by ERG, 
RUNX1, FLI1, GATA2, LMO2, LYL1, TAL1/SCL, which together form a heptad of transcription factors 
associated with stem cell programs and clinical outcome in acute myeloid leukemia, suggesting the 
expression of FUS-ERG might interfere with the activity but not the assembly of this heptad.
In addition, we identified binding of the nuclear receptor heterodimer RARα-RXR to FUS-ERG 
occupied genomic regions, suggesting the oncofusion protein might be involved in modulating 
the retinoic acid response. Treatment of t(16;21) cells with All-Trans Retinoic Acid resulted in cell 
differentiation as exemplified by increased expression of the myeloid differentiation markers CD11b 
and CD3844,45. Prolonged treatment with ATRA resulted in apoptosis consistent with the onset of 
post-differentiation cell death. Together these results suggest that ATRA triggers differentiation and 
thereby stops self-renewal in t(16;21) AML cells. Thus far only APLs are unique among leukemias 
due to their sensitivity to ATRA46. However, our results would suggest that also for t(16;21) AMLs 
ATRA treatment might provide an entry point for eradicating the leukemic cells.    
48
Chapter 2
Our genome-wide profiling revealed that upon ATRA treatment FUS-ERG binding is lost at 
enhancers and promoters, correlating with increased ERG binding at enhancers and loss of RNAPII 
binding at promoters. RNAPII loss at promoters likely reflects transcriptional initiation corroborating 
the RNA-seq analysis that revealed increased transcription of a majority of FUS-ERG target genes. 
Together, these results suggest FUS-ERG might act as a transcriptional repressor. 
To further test this we performed knock down of FUS-ERG in t(16;21) cells and could show that 
loss of the oncofusion protein results in higher expression of a subset of 138 genes that are also 
higher expressed after ATRA treatment. Interestingly, functional analysis of this gene set revealed 
enrichment for myeloid differentiation programs, corroborating at the gene level the FUS-ERG 
imposed block of retinoic acid induced differentiation. 
The repressive activities of FUS-ERG towards myeloid differentiation genes, including master 
regulators of hematopoieisis such as SPI1, GATA2, GFI1, JUNB or JUNC mimics the molecular effects 
previously reported for other oncofusion proteins such as AML1-ETO20 and PML-RARα41,47, which 
target many of the same genes as FUS-ERG. Both AML1-ETO and PML-RARα have been shown 
to multimerize and recruit histone deacetylase (HDAC) activities in order to repress target gene 
transcription48,49,50,51,52. As FUS-ERG binding sites harbor multiple ETS consensus sequences and 
the oncofusion protein through its FUS domain might also have oligomerization capacity53, it is 
tempting to speculate FUS-ERG might use a similar mechanism to inhibit transcription. 
Together our results reveal that FUS-ERG has a key role in t(16;21) AMLs through aberrant 
regulation of the ATRA response and inhibiting differentiation along the myeloid lineage.
Experimental procedures
Cell culture
TSU-1621-MT cells were cultured in RPMI 1640 supplemented with 10% FCS, 10 ng/ml of G-CSF and 
incubated at 37˚ C and 5% CO2
26. YNH-1 cells were cultured in RPMI 1640 supplemented with 10% 
FCS, 10 ng/ml of IL-3 or 10 ng/ml of G-CSF and incubated at 37˚ C and 5% CO2
5,8.
Chromatin immunoprecipitation (ChIP) 
Chromatin was harvested as described27. ChIPs were performed using specific antibodies to ERG, 
FLI1, RXRα, SPI1, TAL1, LYL1, GATA2, LMO2 (Santa Cruz), RARα, H3K9K14ac, RNAPII (Diagenode), 
FLI1, RUNX1 (Abcam), FUS (lot. A300-302A-1 that detects the N-terminal domain, Bethyl) and 
analyzed by quantitative PCR (qPCR) or ChIP-seq (see also supplementary information). Primers 
for qPCR are described in Supplementary Table 1. Relative occupancy was calculated as fold over 
background, for which the second exon of the Myoglobin gene or the promoter of the H2B gene 
was used. 
Illumina high throughput sequencing
End repair was performed using the precipitated DNA of ~6 million cells (3-4 pooled biological 
replicas) using Klenow and T4 PNK. A 3’ protruding A base was generated using Taq polymerase 
and adapters were ligated. The DNA was loaded on gel and a band corresponding to ~300 bp (ChIP 
fragment + adapters) was excised. The DNA was isolated, amplified by PCR and used for cluster 
generation on the Genome analyzer (Illumina) and HiSeq 2000 (Illumina). The 50 bp tags were 
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mapped to the human genome HG18 using the eland program allowing 1 mismatch or BWA28. For 
each base pair in the genome the number of overlapping sequence reads was determined and 
averaged over a 10 bp window and visualized in the UCSC genome browser (http://genome.ucsc.
edu). A list of the ChIP-seq profiles analyzed in this study can be found in Supplementary Table 2. 
For processing and manipulation of SAM/BAM files SAM tools29 was used. All ChIP-seq data can be 
downloaded from Gene Expression Omnibus accession number GSE60477.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
This work was supported by the EU (BLUEPRINT-282510), the Dutch Cancer Foundation (KWF KUN 
2009-4527 and KUN 2011-4937) and the Netherlands Organization for Scientific Research (NWO-
VIDI to JM). 
Supplemental Material
The supplemental material pertaining to this publication can be found online at: nature.com/onc/
journal/v35/n15/full/onc2015261a.html
References 
1 Sharrocks, A. D., Brown, A. L., Ling, Y. & Yates, P. R. The ETS-domain transcription  factor family. The International 
Journal of Biochemistry & Cell Biology 29, 1371-1387,  doi:http://dx.doi.org/10.1016/S1357-2725(97)00086-1 
(1997).
2 Salek-Ardakani, S. et al. ERG Is a Megakaryocytic Oncogene. Cancer Research 69, 4665-4673, doi:10.1158/0008-5472.can-
09-0075 (2009).
3 Tomlins, S. A. et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 310, 644-
648, doi:10.1126/science.1117679 (2005).
4 Sorensen, P. H. B. et al. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS?family 
transcription factor, ERG-EWS gene to another ETS?family transcription factor, ERG. Nature Genetics 6, 146-151 (1994).
5 Yamamoto, K. et al. Establishment of a novel human acute myeloblastic leukemia cell line (YNH-1) with t(16;21), t(1;16) and 
12q13 translocations. Leukemia 11, 599-608 (1997).
6 Prasad, D. D., Ouchida, M., Lee, L., Rao, V. N. & Reddy, E. S. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting 
from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. 
Oncogene 9, 3717-3729 (1994).
7 Crozat, A., Aman, P., Mandahl, N. & Ron, D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. 
Nature 363, 640-644 (1993).
8 Zou, J. et al. The Oncogenic TLS-ERG Fusion Protein Exerts Different Effects in Hematopoietic Cells and Fibroblasts. 
Molecular and Cellular Biology 25, 6235-6246, doi:10.1128/mcb.25.14.6235-6246.2005 (2005).
9 Yang, L., Embree, L. J. & Hickstein, D. D. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine 
proteins. Molecular and Cellular Biology 20, 3345-3354 (2000).
10 Powers, C. A., Mathur, M., Raaka, B. M., Ron, D. & Samuels, H. H. TLS (Translocated-in-Liposarcoma) Is a High-Affinity 
Interactor for Steroid, Thyroid Hormone, and Retinoid Receptors. Molecular Endocrinology 12, 4-18, doi:10.1210/
me.12.1.4 (1998).
11 Zinszner, H., Immanuel, D., Yin, Y., Liang, F.-X. & Ron, D. A topogenic role for the oncogenic N-terminus of TLS: nucleolar 
localization when transcription is inhibited. Oncogene 14, 451-461 (1997).
12 Zinszner, H., Sok, J., Immanuel, D., Yin, Y. & Ron, D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. 
Journal of Cell Science 110, 1741-1750 (1997).
13 Delva, L. et al. Multiple functional domains of the oncoproteins Spi-1//PU.1 and TLS are involved in their opposite splicing 
effects in erythroleukemic cells. Oncogene 23, 4389-4399 (2004).
14 Hallier, M., Lerga, A., Barnache, S., Tavitian, A. & Moreau-Gachelin, F. The Transcription Factor Spi-1/PU.1 Interacts with the 
Potential Splicing Factor TLS. Journal of Biological Chemistry 273, 4838-4842, doi:10.1074/jbc.273.9.4838 (1998).
15 Mills et al. High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology 108, 316-321, 
doi:10.1046/j.1365-2141.2000.01883.x (2000).
16 Walsby, E. J., Gilkes, A. F., Tonks, A., Darley, R. L. & Mills, K. I. FUS expression alters the differentiation response to all-trans 
retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139, 94-97, doi:10.1111/j.1365-2141.2007.06756.x 
(2007).
17 Hicks, G. G. et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of 
chromosomal instability and perinatal death. Nat Genet 24, 175-179 (2000).
18 Sugawara, T. et al. FET family proto-oncogene Fus contributes to self-renewal of  hematopoietic stem cells. 
Experimental Hematology 38, 696-706,  doi:http://dx.doi.org/10.1016/j.exphem.2010.04.006 (2010).
50
Chapter 2
19 Lian, Z. et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood 98, 513-524, doi:10.1182/
blood.V98.3.513 (2001).
20 Martens, J. H. A. et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in 
acute myeloid leukemia. Blood 120, 4038-4048, doi:10.1182/blood-2012-05-429050 (2012).
21 Bock, J. et al. ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase 
Signaling. PLoS ONE 8, e52872 (2013).
22 Ng, A. P. et al. Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood 118, 
2454-2461, doi:10.1182/blood-2011-03-344739 (2011).
23 Lacadie, S. A. & Zon, L. I. The ERGonomics of hematopoietic stem cell self-renewal. Genes & Development 25, 289-293, 
doi:10.1101/gad.2031511 (2011).
24 Loughran, S. J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult 
hematopoietic stem cells. Nat Immunol 9, 810-819 (2008).
25 Goldberg, L. et al. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic 
ERG myeloid leukemia. Blood 122, 2694-2703, doi:10.1182/blood-2013-01-477133 (2013).
26 Shikami, M. et al. Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells 
with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor ? chain. British Journal of Haematology 
105, 711-719, doi:10.1046/j.1365-2141.1999.01384.x (1999).
27 Denissov, S. et al. Identification of novel functional TBP-binding sites and general factor repertoires. EMBO J 26, 944-954 
(2007).
28 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760, 
doi:10.1093/bioinformatics/btp324 (2009).
29 Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079, doi:10.1093/bioinformatics/
btp352 (2009).
30 Kong, X.-T. et al. Consistent Detection of TLS/FUS-ERG Chimeric Transcripts in Acute Myeloid Leukemia With t(16; 21)(p11; 
q22) and Identification of a Novel Transcript. Blood 90, 1192-1199 (1997).
31 Winnes, M., Lissbrant, E., Damber, J. & Stenman, G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 
gene fusions in 50 cases of prostate cancer. Oncology Reports 17, 1033-1036 (2007).
32 Wei, G.-H. et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29, 2147-2160 (2010).
33 Yu, J. et al. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2- ERG Gene Fusions in Prostate Cancer 
Progression. Cancer Cell 17, 443-454,  doi:http://dx.doi.org/10.1016/j.ccr.2010.03.018 (2010).
34 Zhang, Y. et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biology 9, R137 (2008).
35 Kryndushkin, D., Wickner, R. & Shewmaker, F. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with 
TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell 2, 223-236, doi:10.1007/s13238-011-1525-0 (2011).
36 Minucci, S. et al. Oligomerization of RAR and AML1 Transcription Factors as a Novel  Mechanism of Oncogenic Activation. 
Molecular Cell 5, 811-820,  doi:http://dx.doi.org/10.1016/S1097-2765(00)80321-4 (2000).
37 Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A. J. R. Multiplex peptide stable isotope dimethyl 
labeling for quantitative proteomics. Nat. Protocols 4, 484-494 (2009).
38 Wilson, N. K. et al. Combinatorial Transcriptional Control In Blood Stem/Progenitor Cells: Genome-wide Analysis of Ten 
Major Transcriptional Regulators. Cell stem cell 7, 532-544 (2010).
39 Diffner, E. et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in 
acute myeloid leukemia. Blood 121, 2289-2300, doi:10.1182/blood-2012-07-446120 (2013).
40 Beck, D. et al. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected 
network of coding and noncoding genes. Blood 122, e12-e22, doi:10.1182/blood-2013-03-490425 (2013).
41 Martens, J. H. A. et al. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 
17, 173-185 (2010).
42 Pereira, D. S. et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic 
cells. Proceedings of the National Academy of Sciences 95, 8239-8244 (1998).
43 Rapin N, Porse BT (2014). Oncogenic fusion proteins expressed in immature  hematopoietic cells fail to 
recapitulate the transcriptional changes observed in human  AML. Oncogenesis 3: e106.
44 Drach, J. et al. Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells Is Mediated through Retinoic Acid 
Receptor-alpha. Cancer Res 54, 1746-1752 (1994).
45 Drach, J., Zhao, S., Malavasi, F. & Mehta, K. Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic 
acid. Biochemical and Biophysical Research Communications 195, 545-550 (1993).
46 Dubois, C. et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 83, 
3264-3270 (1994).
47 Saeed, S., Logie, C., Stunnenberg, H. G. & Martens, J. H. A. Genome-wide functions of PML-RAR[alpha] in acute 
promyelocytic leukaemia. Br J Cancer 104, 554-558 (2011).
48 Grignani, F. et al. Fusion proteins of the retinoic acid receptor-[alpha] recruit histone deacetylase in promyelocytic 
leukaemia. Nature 391, 815-818 (1998).
49 Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814 (1998).
50 De Bellis, F. et al. Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC 
Inhibitor MC2392. Cancer Research 74, 2328-2339, doi:10.1158/0008-5472.can-13-2568 (2014).
51 Liu, S. et al. Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated 
Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells. Journal of Pharmacology 
and Experimental Therapeutics 321, 953-960, doi:10.1124/jpet.106.118406 (2007).
52 Saeed, S. et al. Chromatin accessibility, p300, and histone acetylation define PML-RARa and AML1-ETO binding sites in 
acute myeloid leukemia. Blood 120, 3058-3068, doi:10.1182/blood-2011-10-386086 (2012).
53 Sun, Z. et al. Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/
TLS. PLoS Biol 9, e1000614, doi:10.1371/journal.pbio.1000614 (2011).
51
The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans 
retinoic acid signaling pathway in t(16;21) acute myeloid leukemia
Supplementary Information
Methods
Cellular fractionation and western blotting
Nuclear and cytosolic fractions were harvested as described1. Briefly, cells were washed with cold 
PBS, resuspended in cold hypotonic lysis buffer and incubated on ice for 10 minutes. Cytoplasmic 
fraction was yielded after centrifugation for 10 seconds. The pellet was suspended in hypertonic 
buffer, incubated on ice for 20 min, centrifuged for 2 min at 4˚ C and supernatant was collected. 
Cytoplasmic and nuclear fractions were mixed with sample buffer and separated on 8% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane (Bio-
Rad), blocked in 5% nonfat dry milk in Tris (tris(hydroxymethyl)aminomethane)-buffered saline 
with 0.1% Tween 20 (TBS-T) for 1 hour at room temperature, and then incubated with primary 
antibodies in TBS-T (with 5 % nonfat dry milk) overnight at 4° C. FUS, ERG were detected with rabbit 
polyclonal antibody against FUS (1:1000), and rabbit polyclonal antibody against ERG (1:1000), 
respectively, followed by an IgG-HRP-conjugated secondary antibody against rabbit (Dako). Proteins 
were visualized using ECL (GE healthcare). 
Antibodies
RNAPII Diagenode 8WG16
RAR Diagenode A704
FLI1 Santa Cruz sc-356
RXR Santa Cruz sc-774x
FUS Bethyl A300-302A-1 
RUNX1 Abcam ab23980
LMO2 Santa Cruz sc-65736
GATA2 Santa Cruz sc-9008
LYL1 Santa Cruz sc-374164x
TAL1 Santa Cruz sc-12984x
SPI1 Santa Cruz sc-22805
H3K9K14ac Diagenode pAb-ACHBHS-044_DA-0010
ERG Santa Cruz sc-353x
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Re-ChIP
Re-Chip was performed as described (Martens et al., 2012). Briefly chromatin was first incubated 
overnight at 4° C with first antibodies as for regular ChIPs. After standard washing, elution was 
performed with 1% SDS (30 min, 37° C). Eluates from at least three ChIPs were combined, diluted 
with incubation buffer with protease inhibitors and incubated overnight with secondary antibodies 
and protein-A beads at 4° C. The subsequent steps were performed as for regular ChIPs followed 
by qPCR.
DNA pull down
DNA pull down was performed as described previously2 with some modifications. Bait (containing 
the ETS motif) and control (containing a scrambled ETS motif) oligonucleotides were generated 
by annealing sense and antisense strands (supplementary table 3). Sense strand of both bait and 
control oligos were biotinylated at the 5’ end for coupling to streptavidin beads. 60 ul of Dynabeads 
(Invitrogen) streptavidin magnetic beads were washed with DB buffer (20 mM Tris-HCl, pH 8.0, 2 
M NaCl, 0.5 mM EDTA, 0.03% NP-40) and incubated with 10 µg of bait and control DNA separately 
in a total volume of 0.35 ml DB buffer for 1h at RT on rotation wheel. After coupling, the beads 
were washed two times with DB buffer and two times in PB buffer. 500 µg of nuclear extract from 
TSU-1621-MT was added to beads in a total volume of 600 ul PB buffer (150 mM NaCl, 50 mM Tris/
HCl pH 8.0, 10 mM MgCl2, 0.5% NP-40, Complete Protease Inhibitor-EDTA [Roche]) supplemented 
with 10 µg of poly dIdC and incubated for 120 minutes at 4° C on rotation wheel. Beads were 
washed three times with PB buffer, resuspended in 2X NuPage loading buffer containing 20 mM 
DTT and analyzed by western blot and mass spectrometry. For mass spectrometry analysis pull 
down proteins were subjected to trypsin digestion as described3 and subject of modified dimethyl-
labelling protocol according to Paul J Boersema et al4. Light and medium dimethyl-labels were used 
for forward and reverse DNA pull-down samples. Labeling scheme was swapped for reverse and 
forward replicate experiments. The differentially labelled sample pairs were mixed, and collected 
peptides were desalted using StageTips5 and measured on a Q Exactive mass analyzer essentially as 
described 3. Raw mass spectrometric data were analyzed using the MaxQuant pipeline6.
Data acquisition
Sample was loaded onto a 30 cm column packed in house with 1.8 μm Reprosil-Pur C18-AQ (Dr. 
Maisch, 9852). The sample was separated during a gradient from 7% to 32% solvent B (80% 
acentonitrile / 20% water / 0.1% formic acid) in solvent A (0.1% formic acid in water) over 240 min 
using an Easy-nLC 1000 (Thermo Fisher Scientific). The column was heated to 40° C using a column 
oven (Sonation). Eluting peptides were sprayed directly into a QExactive mass spectrometer (Thermo 
Fisher Scientific). The mass spectrometer was operated in TOP10 data dependent acquisition. Target 
values for full MS were set to 3,000,000 ions and maximum injection time to 20 ms. Full MS were 
recorded at a resolution of 70,000 at m/z = 400 and a scan range of 300-1,650 m/z. Target values 
for MS/MS were set to 10,000 ions with a maximum injection time of 120 ms. MS/MS spectra were 
recorded at a resolution of 17,500. The isolation width was set to 3.0 m/z and the collision energy to 
NCE = 25. Dynamic exclusion was enabled for 20 seconds, peptides with single or unknown charge 
state were excluded for sequencing and the underfill ratio was set to 0.1%.
53
The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans 
retinoic acid signaling pathway in t(16;21) acute myeloid leukemia
FUS-ERG knock-down
The inducible RNAi system was obtained from TaconicArtemis. Oligos (see supplementary table 
4) were designed as follows: BbsI-shRNA-XhoI and cloned BbsI/XhoI into the pH1tet-flex transfer 
vector. The H1tetO-shRNA cassette was amplified by means of PCR using Phusion DNA polymerase 
(Thermo Scientific) and primers with PacI sites. The resulting product was digested with PacI 
and cloned into FH1tUTG7. Cell transfections were carried via Amaxa Nucleofector technology as 
described by the manufacture (Lonza). TSU-1621-MT cells were transduced. Dox-inducible cells 
were treated for 3 days with 0.1 μg/ml dox. After validating FUS-ERG knockdown by qPCR, strand 
specific RNA-seq was performed. Two pooled replicates for each RNA-seq experiment were used.
Strand specific RNA sequencing
Total RNA from TSU-1621-MT cells (control, ATRA treated (1 µM for 24 h), induced and uninduced 
shRNA) was extracted with the RNeasy kit and on-column DNase treatment (Qiagen) and the 
concentration was measured with a Qubit fluorometer (Invitrogen). 250 ng of total RNA was treated 
by Ribo-Zero rRNA Removal Kit (epicentre) to remove ribosomal RNAs according to manufacturer 
instructions. 16 µl of purified RNA were fragmented by addition of 4 µl  5x fragmentation buffer 
(200 mM Tris acetate pH 8.2, 500 mM potassium acetate and 150 mM magnesium acetate) and 
incubated at 94° C for exactly 90 s. After ethanol precipitation, fragmented RNA was mixed with 5 
μg random hexamers, followed by incubation at 70° C for 10 min and chilling on ice. We synthesized 
first-strand cDNA with this RNA primer mix by adding 4 μl 5× first-strand buffer, 2 μl 100 mM DTT, 
1 μl 10 mM dNTPs, 132 ng of actinomycin D, 200 U SuperScript III, followed by 2 h at 48° C. First 
strand cDNA was purified by Qiagen mini elute column to remove dNTPs and eluted in 34 μl elution 
buffer. Second-strand cDNA was synthesized by adding 91.8 μl, 5 μg random hexamers, 4 μl of 5× 
first-strand buffer, 2 μl of 100 mM DTT, 4 μl of 10 mM dNTPs with dTTP replaced by dUTP, 30 μl of 
5× second-strand buffer, 40 U of Escherichia coli DNA polymerase, 10 U of E. coli DNA ligase and 2 
U of E. coli RNase H, and incubated at 16° C for 2 h followed by incubation with 10 U T4 polymerase 
at 16° C for 10 minutes. Double stranded cDNA was purified by Qiagen mini elute column and used 
for Illumina sample prepping and sequencing according to the Illumina protocol. We incubated 1 U 
USER (NEB) with 250 bp size-selected, adaptor-ligated cDNA at 37° C for 15 min followed by 5 min 
at 95° C before PCR. Validation experiments were performed by RT-qPCR with primers as shown in 
supplementary information.
Bioinformatic analysis
Identification of FUS-ERG binding sites in TSU-1621-MT cells
Two antibodies (one for each factor ERG and FUS) were used to identify the binding sites of FUS-
ERG protein in TSU-1621-MT cells. Peak calling algorithm MACS8 was used to detect the binding 
sites for all ChIPs at a p-value cut off for peak detection of 1-6. To identify high confidence FUS-ERG 
binding sites, an overlap was taken of the binding sites detected by MACS for the two antibodies. 
Tag counting
Tags within a given region were counted and adjusted to represent the number of tags within a 1 kb 
region. Subsequently the percentage of these tags as a measure of the total number of sequenced 
tags of the sample was calculated.
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Peak distribution analysis
To determine genomic locations of binding sites, the peak file was analyzed using an in house script, 
genomic_distribution.py, that annotates binding sites according to all RefSeq genes. With this script 
every binding site is annotated either as promoter (-500 bp to the Transcription Start Site), exon, 
intron or intergenic (everything else). 
Generation of profiles and heatmaps
All heatmaps and bandplot profiles were generated using fluff (http://simonvh.github.com/fluff)9. 
For all heatmaps clustering the Euclidian distance metric was used. For hierarchical clustering we 
used the pairwise complete-linkage function. 
Motif analysis
To count motifs in FUS-ERG binding sites we used GimmeMotifs, a pipeline that incorporates an 
ensemble of computational tools to predict motifs de novo from ChIP-sequencing (ChIP-seq) data. 
Similar redundant motifs are compared using the weighted information content (WIC) similarity 
score and clustered using an iterative procedure10.
Expression analysis
RNA-seq reads were uniquely mapped to the human reference genome and subsequently used 
for bioinformatic analysis. RPKM (reads per kilobase of gene length per million reads)11 values for 
RefSeq genes were computed using tag counting scripts and used to analyze the expression level of 
genes in TSU-1621-MT cells. CD markers were extracts from the HCDM website (www.hcdm.org).
Protein identification and quantitation
The raw proteomics data thus acquired were processed with MaxQuant software (version 1.3.7.1) 
according to the standard workflow12. Database search was performed in MaxQuant with the 
Andromeda search engine13 against the human international protein index (IPI, version 3.68 with 
87,061 entries) database as well as a contaminants database. The search was performed with a final 
mass tolerance of 4.5 ppm mass accuracy for the precursor ion. Peptides and proteins were both 
accepted at an FDR of 0.01. For quantification, at least two ratio counts were required. For positive 
protein identification, at least two peptides were required, among which at least one peptide had 
to be unique in the database for the protein group given. For peptide and protein identifications, 
the 1% false discovery rate (FDR) was determined by accumulating 1% of reverse database hits 
as described before14,15. Moreover, protein quantification was based on both unique and razor 
peptides. Further analyses were performed using Perseus (http://www.perseus-framework.org) 
and R graphic environments.
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Supplementary Tables
Table 1: qPCR primers
CSF3Rf CTGTGAGGGAAGCTGGTGAG
CSf3Rr GACATCGTTGCCACATTCC
KDM1f GCAAGCTACACGTTCTTTGCT
KDM1r GACAAAAAGGGTCGGAGACA
RUNX1f AGAGTGCCTGGAAATGAACG
RUNX1r ATACCGGAAAGGCCTGTGAT
DDX5f AGGAAGGACACCGATGACAC
DDX5r GTAGGAGGCGGTCCAGACTA
POMPf CTGCGGAAGATGGTGAGTG
POMPr GAGGCGACTGCCTGTTTCT
DRG2f GCTGCTACCATGGGGATCTT
DRG2r GCCCTCACCCTTGTTCTTCT
DUSP6f TGTGCGACGACTCGTATAGC
DUSP6r CGACCCCCATGATAGATACG
CTSCf GATAGGTGCAGTTGGCAGGT
CTSCr CGGCTTCCTGGTAATTCTTC
SPI1f GGTATCGAGGACGTGCATCT
SPI1r CACAGCGAGTTCGAGAGCTT
CLTCf AAAGTAGTCCCTCCGGTTCC
CLTCr CGCCTTATGTACCCCTCCAC
OCT1f AGAGCGAGGGAGGGTTTATC
OCT1r ATCTTGACTCGCTGCTCCTC
MYOGf AAGTTTGACAAGTTCAAGCACCTG
MYOGr TGGCACCATGCTTCTTTAAGTC
H2Bf TTGCATAAGCGATTCTATATAAAAGCG
H2Br ATAAAGCGCCAACGAAAAGG
mRNA_FUS/ERGf GGTGGCTATGAACCCAGAGG
mRNA_FUS/ERGr CCTCGTCGGGATCCGTCATC
mRNA_ERGf AGCACAATCTCATCCGCTCT
mRNA_ERGr CGTTCCGTAGGCACACTCAA
mRNA_FUS4f CAGTCAACTCCCCAGGGATA
mRNA_FUS4r AGCTAGGCTGCTGGCTGTAG
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High ATRA
 mRNA_MYBf CCGCAGCCATTCAGAGACAC
 mRNA_MYBr GGTAGCTGCATGTGTGGTTC
mRNA_CTSCr AACTGCTCGGTTATGGGACC
mRNA_CTSCf CCCACCTTCTTTCCGGTGAA
mRNA_SUMF2r GCGACAGTGAAACCCTTTGC
mRNA_SUMF2f GTACAGACTTCATTGGCTGGG
mRNA_ITM2Br AACATCAAGGCTGGAACCTATT
mRNA_ITM2Bf TGCGAAACAATTGCTGGCTT
mRNA_MDH2r ATGATATCGCGCACACACCC
mRNA_MDH2f GGGATGGTGGAATTAACCGGA
Medium ATRA
mRNA_POLG2r TTACATGGCCGAGATGGACG
mRNA_POLG2f AGCCCTTGACAAACCTGTCTT
mRNA_COPS4r GCTGATGGTTCCAGCATCTTG
mRNA_COPS4f TCCATTCATACGTCCTTCGGT
mRNA_MGAr GTCTGCCTTTTTATGCAGGGC
mRNA_MGAr GCAGCATTTTCAATTGGCCG
mRNA_NETO2r TTTGGAAGCTGCTCCACGTC
mRNA_NETO2f ACCTCCTAGGTAAGTAAAGTCTGG
Low ATRA
mRNA_LRRC1r AGAAACGATTCCGGATGGCA
mRNA_LRRC1f TGCTTTTAGGCAGGGTCAGG
mRNA_GK5r GCAGTCAAAGCTGCAGGAAT
mRNA_GK5f AAGTGAAGCACTCGGCAAGA
mRNA_EXTL3r ATCATGTTTGGGTTCCGGGTG
mRNA_EXTL3f GCTTCCGAGTGATGTGGGAG
mRNA_HOOK2r GATGCCATTTCCATTTTGCTGA
mRNA_HOOK2f CTGCTTGGGTTCCATGGTCT
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Table 2: List of the ChIP-seq and RNA-seq profiles analyzed in this study.
Cells ChIP antibody/technique Treatment reference
TSU ChIP ERG1/2/3 no
TSU ChIP RXR no
TSU ChIP CTD of RNA polymerase II no
TSU ChIP CTD of RNA polymerase II ATRA
TSU ChIP RAR alpha no
TSU ChIP SPI1 no
TSU ChIP FLI-1 no
TSU ChIP ERG1/2/3 ATRA
TSU ChIP N-terminal FUS/TLS no
TSU ChIP N-terminal FUS/TLS ATRA
TSU ChIP RUNX1 no
TSU ChIP LMO2 no
TSU ChIP GATA2 no
TSU ChIP LYL1 no
TSU ChIP TAL1/SCL no
TSU RNA-seq no
TSU RNA-seq ATRA
TSU RNA-seq shRNA
TSU RNA-seq shRNA/Dox
CD34 ChIP ERG no 16
CD34 ChIP FLI1 no 16
CD34 ChIP TAL1/SCL no 16
CD34 ChIP RUNX1 no 16
CD34 ChIP LMO2 no 16
CD34 ChIP GATA2 no 16
CD34 ChIP LYL1 no 16
VCaP ChIP ERG no 17
CADO-ES1 ChIP ERG no 18
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Table 3: ETS oligos for Pull-down
ETS-Fw ACGCTAACCGGAAGTAACGCTA biotinylated
ETS-Rev TAGCGTTACTTCCGGTTAGCGT --
Scram-Fw ACGCTAACCGTAAGTAACGCTA biotinylated
Scram-rev TAGCGTTACTTACGGTTAGCGT --
Table 4: shRNA oligos
Fw_shRNA_FUS/ERG TCCCTAAATTTGGTGGCAGTGGCCATTCAAGAGATGGCCACTGCCACCAAATTTATTTTTC
Rv_shRNA_FUS/ERG TCGAGAAAAATAAATTTGGTGGCAGTGGCCATCTCTTGAATGGCCACTGCCACCAAATTTA
Table 5: Tag count from RNA-seq (control and ATRA treated) of FUS and ERG genes at exon level.
FUS 
Exons chr Start End Exon length RPKM RPKM ATRA 
Exon 1 chr16 31098931 31099049 118 0.708108 0.787759 
Exon 2 chr16 31101219 31101244 25 26.73814 0 
Exon 3 chr16 31101334 31101486 152 31.33376 37.30451 
Exon 4 chr16 31102679 31102824 145 17.28759 30.13041 
Exon 5 chr16 31103030 31103218 188 24.44478 30.65554 
Exon 6 chr16 31103760 31104001 241 13.17491 28.15665 
Exon 7 chr16 31105623 31105658 35 31.03534 39.83807 
Exon 8 chr16 31107146 31107179 33 15.19213 16.901 
Exon 9 chr16 31107944 31108048 104 11.24802 10.72564 
Exon 10 chr16 31108486 31108616 130 8.355669 10.72564 
Exon 11 chr16 31108861 31108963 102 5.734283 8.201956 
Exon 12 chr16 31109096 31109220 124 2.021533 5.997129 
Exon 13 chr16 31109563 31109664 101 13.2367 13.80527 
Exon 14 chr16 31109784 31109932 148 6.774867 11.93348 
Exon 15 chr16 31110220 31113693 3473 2.189363 2.489163 
ERG 
Exon chr Start End Exon length RPKM RPKM ATRA 
Exon 10 chr21 38673819 38677715 3896 9.715396 14.26781
Exon 9 chr21 38684786 38684834 48 1.740764 1.936573
Exon 8 chr21 38685450 38685507 57 1.465907 0
Exon 7 chr21 38686167 38686236 69 3.6329 1.347181
Exon 6 chr21 38694365 38694437 72 4.642039 3.873146
Exon 5 chr21 38696348 38696429 81 4.126257 4.590395
Exon 4 chr21 38697297 38697501 204 4.095916 5.467971
Exon 3 chr21 38717201 38717353 152 3.298291 10.39634
Exon 2 chr21 38739196 38739414 218 9.965477 10.23363
Exon 1 chr21 38792156 38792298 142 0.588427 1.309232
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Table 6: RPKM control vs ATRA list
See online supplement.
Table 7: FUS-ERG binding sites that overlap with PML-RAR and AML1-ETO binding sites.
FUS-ERG PML-RAR AML-ETO
Cluster Peaks Peaks % Overlap Peaks % Overlap
1 619 306 11 304 11
2 1774 252 9 170 6
3 3667 202 8 450 16
4 3247 403 15 669 24
5 961 176 6 102 4
Total 10,268 1,339 49 % 1,695 61 %
Table 8: RPKM shRNA control vs shRNA induced list.
See online supplement.
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Supplementary Figures
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Supplementary Figure 1: Re-ChIP experiment 
validating ERG and FUS binding to the same 
locus. Four binding sites were selected and 
validated for FUS-ERG binding by re-chip using 
ERG antibodies in the first round of ChIP followed 
by a second round using FUS and no antibodies.
Supplementary Figure 2: ChIP 
experiment validating FUS-ERG binding 
sites. U937 cells that do not express 
endogenous FUS-ERG were transfected 
with a construct expressing FLAG-FUS-
ERG. Three binding sites were selected 
and validated for FUS-ERG binding by 
ChIP using a FLAG antibody. 
ERG
SKNO-1 ME-1
ERGFUS FUS
Supplementary Figure 3: Heatmap 
displaying tag densities of ERG and 
FUS at ERG binding sites in SKNO-1 
or ME-1 cells. 
Supplementary Figure 4: Heat map displaying 
FUS, FLI1, SPI1, RAR and RXR tag densities at 
high-confidence only FUS-binding sites.
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A B
Supplementary Figure 5: 
A. ChIP-seq using heptad 
(ERG, FLI1, GATA2, LYL1, 
LMO2, RUNX1 and TAL1) 
antibodies. Overview 
of the LAPTM5 heptad 
binding sites in TSU-
1621-MT cells (green) 
and CD34+ cells (blue). B. 
Venn diagram representing 
the heptad binding sites 
overlap in TSU-1621-MT 
and CD34+ cells.
	
Supplementary Figure 6: Boxplot showing log10 expression values of genes targeted 
by FUS-ERG in TSU-1621-MT and YNH-1 cells treated with ATRA.
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A
GGGTCATGAGGTCACTTGGGGGGTCAGGCGGCAGCCGTTGGAGCTCCAGCCGCCGTTGGCACTGTGGGGCAGGAAG
B
Supplementary Figure 7A. Central sequence 
of the FUS-ERG/RARA/RXR peak in the third 
intron of SPI1. In yellow DR half sites (binding 
of RARA-RXR) and in green an ETS consensus 
(binding site for ERG) are shown. B. SPI1 
occupancy at FUS-ERG binding sites before 
and after ATRA treatment. 
Supplementary Figure 8: ChIP-
seq using RNAPII, FUS and ERG 
antibodies. Overview of the CSF1 
binding site in TSU-1621-MT 
cells. Red represents not treated 
data; blue represents data after 
treatment . Black represent FUS-
ERG binding sites.
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Supplementary Figure 9: RT-qPCR analysis of FUS-
ERG expression in TSU-1621-MT cells expressing a 
FUS-ERG knockdown hairpin without (control) or 
after induction.
Supplementary Figure 10: 
ChIP-seq using FUS and 
ERG antibodies. Overview 
of the CTNNB1 and IL1B 
binding sites in TSU-1621-
MT cells. Green represents 
the FUS data; red, the ERG 
data. Black represent FUS-
ERG binding sites. RNA 
tracks are represented 
in blue for cells before 
and after inducing shRNA 
expression.
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Abstract
The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal 
hematopoetic differentiation. Here, we have investigated its effects on the transcriptome and 
epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes 
with high levels of histone acetylation but also at distal elements characterized by low acetylation 
levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, 
TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-
ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While 
expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces 
leukemic characteristics, over- expression increases cell death. We find that expression of wild-type 
transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. 
Together our results show that the interplay of the epigenome and transcription factors prevents 
apoptosis in t(8;21) AML cells. 
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Introduction
The AML1-ETO (RUNX1-RUNX1T1) oncofusion protein, present in 10% of all de novo acute myeloid 
leukemia (AML) cases, is the result of the translocation t(8;21)(q22;q22), which involves the AML1 
(RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8 (Miyoshi et al., 1991). 
Expression of the AML1-ETO oncofusion protein in hematopoietic cells results in a stage-specific 
arrest of maturation and increased cell survival, predisposing cells to develop leukemia (Nimer and 
Moore, 2004). At the molecular level RUNX1 (Runt-related transcription factor 1; AML1, CBFα2) 
represents a DNA-binding transcriptional activator factor (Cameron and Neil, 2004; de Bruijn and 
Speck, 2004), involved in regulation of hematopoiesis and myeloid differentiation, while ETO (eight-
twenty-one; MTG8, RUNX1T1) acts as a corepressor by recruiting NCoR/SMRT/HDAC complexes 
(Davis et al., 2003; Wang et al., 1998). Apart from these repressor interactions the AML1-ETO fusion 
protein also assembles into transcription factor complexes. One of these, consisting of AML1-ETO, 
CBFβ, E proteins HEB and E2A, LYL1, LDB1 and LMO2 has recently been suggested to be essential for 
leukemic maintenance and differentiation block, as the knockdowns of components of this complex 
delayed leukemogenesis in mice (Sun et al., 2013), stressing the importance of the interplay 
between the fusion oncogene and other transcription factors. 
Mechanistically, the t(8;21) translocation has long been thought to convert the RUNX1 
transcriptional activator to a strong repressor by replacing the transactivation domain of RUNX1/
AML1 with an almost complete ETO protein, thereby inducing a repressive chromatin environment 
and gene repression at otherwise activated RUNX1 target sites (Buchi et al., 2014; Meyers et al., 
1995; Okuda et al., 1998; Yergeau et al., 1997). Nevertheless, a wildtype copy of RUNX1 is still 
required to maintain the AML1-ETO leukemic phenotype (Ben-Ami et al., 2013) as knockdown of 
RUNX1 in t(8;21) leukemia cell lines results in cell death (Hyde et al., 2015). 
Over the last years, it has become clear that the repressive nature of AML1-ETO does not 
define its full biological activities as the fusion protein has also been reported as an activator of 
transcription (Klampfer et al., 1996; Peterson and Zhang, 2004; Wang et al., 2011). Recent genome-
wide studies propose that relative binding of RUNX1 and AML1-ETO at genes determines the final 
transcriptional outcome (Li et al., 2015), while epigenetically, a mechanism for transcriptional 
activation involving AML1-ETO and p300 interactions has been suggested (Wang et al., 2011). 
Alternatively, it has been suggested that wild type RUNX1 interacts with p300 whereas AML1-ETO 
recruits HDACs, and binding of RUNX1/p300 and AML1-ETO/HDACs is mutually exclusive (Ptasinska 
et al., 2014). Hence, the precise mechanisms by which AML1-ETO deregulates the RUNX1 program 
and the histone acetylation machinery remain unclear.
So far the majority of studies have been performed using cell lines with limited validation of 
findings in clinical samples. In the present study, we investigated AML1-ETO associated epigenetic 
modification and its relation to gene expression in patient t(8;21) blasts. We explored the AML1-
ETO complex and the role of the individual components of this complex in leukemogenesis. We 
performed genome-wide binding analysis in cell lines and primary blasts, identifying two modules 
of AML1-ETO action, one on promoter regions and one on enhancer/distal elements. ChIP-seq 
studies together with pull down and mass spectrometry identified differential as well as similar co-
binding of regulators of transcription and chromatin modifications in the context of these promoter 
and distal elements. Using knockdown assays, we show that a balance between AML1-ETO, RUNX1 
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and ERG expression is required for leukemic maintenance, and that RUNX1 or ERG perturbations 
result in AML1-ETO overdose and lethality to cells. Together, our results suggest that the balanced 
interplay of the epigenetic environment and transcription factors retains an anti-apoptotic 
phenotype in t(8;21) AML cells.
Results
AML1-ETO binds promoter and distal genomic elements
To investigate the epigenetic alterations associated with AML1-ETO binding, we used ChIP-seq 
together with MACS peak calling (Zhang et al., 2008) to identify 2897 common AML1-ETO peaks in 
cells of three AML patients with t(8;21) (#186, #12 and #229)(Figure 1A). Subsequently, we profiled 
6 histone modifications (H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3 and H3K9me3) and 
accessibility by DNaseI-seq in AML cells of 2 t(8;21) patients expressing the AML1-ETO gene (Figure 
S1A). Examining these profiles at the 2897 common AML1-ETO binding sites revealed two distinct 
profiles for AML1-ETO that are differentially marked by H3K4me3, H3K4me1 and H3K27ac (Figures 
1B-C, S1B and Table S1). H3K4me3 enriched AML1-ETO binding sites constitute promoters of active 
genes (Figure 1D, E), as is also apparent from the enrichment of H3K27ac. In contrast, H3K4me1 
enriched regions represent distal elements and open chromatin regions harbouring low H3K27ac 
that are associated (by nearest gene approach) with genes that are lower expressed. Despite 
low H3K27ac levels, these distal elements did not enrich for the repressive histone modifications 
H3K27me3 or H3K9me3 (Figure 1F), suggesting that lower gene activity might be related to reduced 
acetylation levels. 
To investigate whether the difference in chromatin composition was related to differential 
transcription factor binding we assessed motif enrichment using GimmeMotifs (van Heeringen 
and Veenstra, 2011). This analysis revealed enrichment for the RUNX1 motif in distal elements, 
while both are enriched for ETS factor motifs (Figure 1G), in line with previous results showing 
enrichment of ETS factor motifs and presence of the ETS factors ERG and FLI1 at AML1-ETO binding 
sites in model cell lines (Martens et al., 2012; Ptasinska et al., 2012).
To examine which functions are affected by the AML1-ETO fusion product, we assigned 
promoter and distal element associated genes to pathways and calculated enrichment (Figure 
1H). This revealed involvement in many signaling pathways, apoptosis, self-renewal and other 
functions related to fully differentiated myeloid cells. Interestingly, most pathways were associated 
with AML1-ETO binding at promoters as well as at distal elements, suggesting that each pathway 
receives multiple AML1-ETO hits.
Identification of the RUNX1/AML1-ETO protein complex 
To investigate which proteins might be associated with AML1-ETO binding we performed pull down 
experiments combined with mass spectrometry analysis. As this assay typically requires high cell 
numbers we used two cell lines, Kasumi-1 and SKNO-1, which harbor t(8;21) and express AML1-ETO. 
For pull down we used two oligos, one harboring a RUNX1 consensus motif TGTGGT and a control 
oligo that contains no RUNX1 or other common transcription factor motif (Figure 2A). The RUNX1 
containing oligos efficiently pulled down AML1-ETO in Kasumi-1 cells (Figure 2B), while the control 
shows background binding. Subsequently, we analyzed enrichment for proteins in the RUNX1 oligo 
pull down using quantitative mass spectrometry analysis. This revealed specific enrichments in 
both SKNO-1 and Kasumi-1 cells of proteins associated with the RUNX1 containing oligo, like AML1-
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ETO, RUNX1 and CBFB (Figures 2C and S2). To identify proteins that are recognized in both RUNX1 
pull downs we intersected the enriched proteins from both pull downs and identified 34 common 
proteins that might be involved in regulation at AML1-ETO sites (Figure 2D and Table S2). Within the 
common interactors we identified FUS, a fusion partner of ERG in AML (Sotoca et al., 2015), HDAC1 
and HDAC2, deacetylases previously suggested as an interactor of AML1-ETO (Wang et al., 1998), 
several splicing factors as well as LMO2 and LYL1, two transcription factors previously identified to 
interact with AML1-ETO (Sun et al., 2013). Interestingly, despite enrichment of the motif in AML1-
Figure 1. Binding pattern of AML1-ETO in t(8;21) AMLs. (A) Intensity plot showing the AML1-ETO tag 
densities in AML patient cells with t(8:21) (n=3) at high confidence AML1-ETO binding sites. (B) Intensity plot 
displaying DNaseI accessibility and histone marks at promoter and distal AML1-ETO binding sites in t(8:21) 
AML #12. (C) ChIP-seq overview of AML1-ETO binding at the SETD5 promoter and a distal region of PTCH1 in 
t(8;21) primary AMLs. (D) Genomic distribution of AML1-ETO binding site locations relative to RefSeq genes. 
Locations of binding sites are divided in promoter (-500bp to the transcription start site), exon, intron and 
intergenic (everything else). (E) Expression (RPKM) of genes associated with AML1-ETO promoter and distal 
binding sites. (F) Intensity plot showing active and repressive histone mark enrichment at AML1-ETO binding 
sites in t(8;21) AML blasts. (G) Overview of the consensus ETS and RUNX1 motifs found at AML1-ETO binding 
sites. (H) Pathway enrichment analysis of genes associated with AML1-ETO binding. Percentage represents 
the fraction of AML1-ETO associated genes present in this pathway. SRP: self-renewal pathway.
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ETO binding sites (Figure 1G), we did not identify ETS factors in the pull down, suggesting these 
might constitute an independent stabilizing factor of the AML1-ETO complex on DNA (Figure 2E).
Hematopoietic transcription factors bind AML1-ETO occupied genomic regions
The identification of LMO2 and LYL1 as interactors of AML1-ETO (Figure 2D) (Sun et al., 2013) 
together with the notion that ETS factor consensus binding sites are enriched at AML1-ETO binding 
sites suggested that AML1-ETO is present at sites occupied by a heptad of proteins previously 
identified to be crucial for normal hematopoiesis (Wilson et al., 2010). The genes encoding 
these transcription factors are commonly expressed in t(8;21) but also in other AMLs (Figure 3A) 
and not mutated in t(8;21) AMLs (Cancer Genome Atlas Research, 2013), suggesting wildtype 
expression is essential for leukemogenesis. To investigate whether AML1-ETO binding relates to 
co-occupancy of this heptad of transcription factors we performed ChIP-seq experiments using 
Figure 2. Identification of interactors of the AML1-ETO/RUNX1 complex. (A) DNA sequence of oligos used 
in the pull down experiment. (B) Western analysis of identified proteins in the DNA pull down using the 
Kasumi-1 cell lysate and AML1-ETO (AE), RUNX1, CBFB and HDAC1 antibodies. (C) Scatter plot showing the 
results of a pull-down mass spectrometry experiment from Kasumi-1 cells. Proteins are plotted by their 
di-methyl ratios in the forward (x axis) and reverse (y axis) di-methyl experiment. Specific interactors of 
the AML-ETO/RUNX1 pulldown are identified in the lower right quadrant. (D) Venn diagram showing the 
overlap of 34 proteins identified as RUNX1 motif interactor in pull down experiments using Kasumi-1 or 
SKNO-1 cells. (E) Schematic diagram showing a hypothetical model of ETS factor stabilization of the AML1-
ETO protein complex.
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antibodies recognizing these factors in Kasumi-1 t(8;21) cells. We then examined their presence 
at the previously identified AML1-ETO binding sites in patients AML cells. These results revealed 
that RUNX1, ERG, FLI1 and TAL1 occupied similar genomic regions as AML1-ETO (Figures 3B, C), 
while GATA2 occupancy was generally low. Co-occupancy of similar genomic regions by RUNX1 and 
AML1-ETO and ERG and AML1-ETO could be confirmed by re-ChIP experiments (Figures 3D and 
Martens et al., 2012), suggesting no exclusive allele specific binding of these factors. Interestingly, 
in contrast to the other heptad factors, LMO2 and LYL1 binding was enriched at distal elements 
(Figure 3B, C), suggesting that these might be involved in creating a specific chromatin environment 
(as observed in Figure 1B) at these sites. 
Indeed, examining gene responses upon LYL1 knockdown (Sun et al., 2013) revealed that genes 
associated with AML1-ETO distal element binding are increased in expression while promoter 
associated genes are less affected (Table S3).
Figure 3. AML1-ETO co-localizes with hematopoietic transcription factors. (A) Relative expression of 
hematopoietic transcription factor genes in t(8:21) and other AML subtypes. (B) Boxplot displaying the tag 
densities of hematopoietic transcription factors at AML1-ETO binding sites in Kasumi-1 cells. LMO2 and LYL1 
are enriched at distal binding sites. (C) ChIP-seq of AML1-ETO and other transcription factors in Kasumi-1 
cells. Overview of the VPS29 and RAD9B AML1-ETO binding sites showing less binding of LMO2 and LYL1 at 
the VPS29 promoter region whereas increased binding of LMO2 and LYL1 is observed at the HVCN1 distal 
region. (D) Re-ChIP experiment validating AML1-ETO and RUNX1 binding to the same locus. Five binding 
sites were selected and validated for AML1-ETO/RUNX1 binding by re-ChIP using AML1-ETO in the first 
round of ChIP followed by a second round using RUNX1 and no antibodies.
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p300 and HDACs collaborate with AML1-ETO to regulate local histone acetylation 
To examine whether promoter and distal element AML1-ETO occupied regions have a similar 
epigenetic pattern in Kasumi-1 cells as in patient AML cells, we examined H3 and H4 acetylation 
at its binding regions. This revealed increased acetylation at AML1-ETO promoter sites, while in 
contrast, lower acetylation at distal regions was observed (Figure 4A), in line with the patient cells 
(Figure 1B). We identified the deacetylases HDAC1 and HDAC2 as interacting partners of AML1-ETO 
(Figure 2D), while also the acetyltransferase p300 has been suggested to interact with AML1-ETO 
(Wang et al., 2011). To examine whether differential occupancy of these enzymes at promoter or 
distal element regions relates to acetylation levels we performed ChIP-seq using antibodies against 
these three proteins. Our results reveal increased occupancy of p300 and HDACs at promoter 
elements, but reduced at distal elements (Figure 4B). However, within one module the relative 
occupancy of p300/HDACs is similar (Figure 4B). Re-ChIP experiments revealed the presence of 
p300/AML1-ETO and HDACs/AML1-ETO at the same locus (Figure 4C, D), suggesting that AML1-ETO 
co-localizes with HDAC/p300 complexes, which counteracting activities (HAT/HDAC) might relate to 
histone acetylation output. 
To see whether this balanced output can be deregulated we used MS275 (Entinostat), an 
HDAC inhibitor that induces cell death in Kasumi-1 cells (Duque-Afonso et al., 2011; Nebbioso 
et al., 2005; Xu et al., 2011). HDACi treatment of Kasumi-1 cells increased H3K9K14 acetylation 
whereas H3K4me3 was unaffected (Figure 4E). Examining histone acetylation at AML1-ETO binding 
sites revealed increased acetylation at distal elements, while at promoter regions a decrease is 
observed. (Figures 4F, G) (Dudakovic et al., 2013; Ooi et al., 2015; Rafehi et al., 2014). The changes in 
acetylation level correlate with increased cell death (Figure S3), suggesting a possible involvement 
of AML1-ETO in regulating the apoptosis program, in line with previous results (Spirin et al., 2014). 
t(8;21) AML addiction to RUNX1 and ERG
Apart from treatment with HDACi, AML1-ETO as well as RUNX1 knockdown have been suggested 
to induce apoptosis (Ben-Ami et al., 2013; Spirin et al., 2014). To further explore AML1-ETO 
involvement in regulation of the apoptotic pathway, we examined AML1-ETO binding in patients’ 
AML cells at genes associated with apoptotic programming. Using gene names from KEGG and GO 
annotation, we identified 172 AML1-ETO binding regions associated with apoptotic genes (Table 
S4). In t(8;21) AML blast cells these regions were partially enriched for H3K4me3 and H3K27ac 
(Figure 5A), representing promoter regions, and partially for H3K4me1 representing distal elements. 
As indicated above, promoter regions were related to more active genes (Figure 5B), while distal 
regions associated genes generally had lower expression. In addition, both promoter and distal 
regions were enriched for RUNX1 and ETS motifs and bound by ERG, as could be corroborated by 
ChIP-seq in patient AML cells (Figure 5C). Given the previously reported dependency on a copy of 
Figure 4. AML1-ETO distal binding regions are hypoacetylated. (A) Heatmap displaying H3K9K14ac and 
H4ac tag densities at promoter and distal binding regions of AML1-ETO (AE). Promoter regions have more 
acetylation then distal regions. (B) Intensity plot showing the tag densities of H3ac, H4ac, p300, HDAC1 
and HDAC2 at AML1-ETO binding regions. HDACs and p300 are enriched at promoter regions occupied by 
AML1-ETO. (C-D) Re-ChIP experiment validating (C) AML1-ETO and p300 binding and (D) AML1-ETO and 
HDAC1 binding to the same locus. (E) Western analysis showing increased H3K9K14 acetylation after HDACi 
treatment in Kasumi-1 cells whereas H3K4me3 was unaffected. (F) Boxplot demonstrating decreased 
H3K9K14ac tag densities at AML1-ETO promoter and increased H3K9K14ac tag densities at distal binding 
sites after HDACi treatment in Kasumi-1 cells. (G) Overview of H3K9K14ac acetylation at AML1-ETO binding 
sites showing increased levels at distal regions and a decrease at the promoter region of SDF4. 
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Figure 5. RUNX1 and ERG are essential for Kasumi-1 cells survival. (A) Heatmap showing H3K4me3, 
H3K4me1 and H3K27ac tag densities at AML1-ETO binding sites related to genes involved in apoptosis in a 
t(8:21) AML blast. (B) Expression (RPKM) of apoptotic genes associated with AML1-ETO promoter or distal 
binding. (C) Intensity plot displaying ERG tag density at AML1-ETO (AE) binding sites related to apoptotic 
genes in t(8:21) patient blast cells (#12). (D) Schematic diagram showing the shRNA targeting regions for 
knockdown of either RUNX1 or both RUNX1 and AML1-ETO. * Marks show the approximate position of 
the shRNA. (E) RT-qPCR analysis of RUNX1 before and after induction of shRNA for 72h targeting RUNX1 in 
Kasumi-1 cells. Data normalized to GAPDH and ***p<0.001. (F) Cell cycle analysis by FACS using propidium 
iodide to measure cellular DNA content in 7 days RUNX1 shRNA control and knockdown cells. Left: Cell cycle 
analysis. A representative result is shown from one of the four replicate experiments. Right: Bar diagram 
displaying the distribution of the analyzed cells. Data represent the mean ± SD values of four independent 
experiments. (G) Annexin V staining showing increased apoptosis after KD of RUNX1. (H) RT-qPCR analysis 
of ERG before and after induction of ERG shRNA expression for 72h in Kasumi-1 cells. Data normalized 
to GAPDH ***p<0.001. (I) Analysis of cells in sub-G1 after 7 days of ERG shRNA or no induction (control). 
Data represent the mean ± SD values of four independent experiments. A marked increase was observed 
in sub-G1 cells in comparison to non-induced cells. (J) Heatmap showing expression changes of apoptosis 
associated genes after ERG knockdown. 
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wt RUNX1 for AML maintenance in t(8;21) and the lack of mutations for any of the other heptad 
factors in t(8;21) (Cancer Genome Atlas Research, 2013) suggests activity of these transcription 
factors is essential for AML1-ETO leukemogenesis. To investigate whether t(8;21) cells might also be 
dependent on other transcription factors for their survival, we choose to focus on ERG, as it was not 
identified in our RUNX1 proteomic approach (Figure 2D) but still occupied similar genomic regions 
as AML1-ETO (Figure 3B), suggesting it has a DNA binding dependent contribution to the complex. 
First, we confirmed t(8;21) dependency on RUNX1 by creating a stable inducible RUNX1 knockdown 
system in Kasumi-1 cells using a specific shRNA hairpin targeting the RUNX1 moiety not present in 
AMLl-ETO (shRUNX1.2)(Figure 5D). Although we only obtained a RUNX1 knockdown of 50% (Figure 
5E), cell cycle analysis using propidium iodide (PI) staining demonstrated a marked increase in the 
sub-G1 fraction, a hallmark of increased cell death, and a decrease in live cells (Figures 5F and S4A). 
This increased accumulation of dead cells in sub-G1 was due to apoptosis mediated cell death as 
confirmed by Annexin V staining (Figure 5G, S4B). Next, we created a stable knockdown system in 
Kasumi-1 cells using a shRNA targeting ERG. Similar as for RUNX1 knockdown, induction of shRNA 
expression (Figure 5H, S4C) resulted in increased apoptosis and decreased cell viability (Figures 5I, 
S4D-G), suggesting expression of ERG is required for leukemic maintenance and addiction to this 
transcription factor in t(8;21) AML. 
To investigate which genes are differentially regulated upon ERG knockdown we performed 
RNA-seq using the stable ERG knockdown system in Kasumi-1. This analysis revealed an increased 
expression of CASP8, CASP6 and CASP10 (Figure 5J and S4H) and decreased expression of BCL2, BIRC7 
and BCL2L1, suggesting that the expression alterations within the apoptosis pathway activate the 
program upon knockdown of ERG.
AML1-ETO overdose increases cell death
Increased AML1-ETO expression has been associated with induction of cell death (Burel et al., 
2001; Lu et al., 2006). Interestingly, our RNA-seq results revealed that upon down regulation of 
ERG, AML1-ETO expression is increased (Figure S5A). To confirm this observation, we performed RT-
qPCR using AML1-ETO specific primers and western analysis and could again show increased AML1-
ETO expression (Figure 6A and S5B). To further examine whether increased AML1-ETO expression 
correlates with the onset of the apoptosis program we also examined expression upon RUNX1 
knockdown (using shRNA RUNX-1.2). This again revealed increased expression of AML1-ETO by RT-
qPCR and western blotting (Figure 6B and C). 
To investigate whether this increase in AML1-ETO expression is modulated by altered binding 
of epigenetic modifiers, we performed ChIP using p300 and HDAC1 antibodies. ChIP-qPCR after 
knockdown of RUNX1 (Figure 6D) or ERG (Figure S5C) revealed increases in p300 occupancy and 
decreases in HDAC1 at two promoter regions (RUNX1.P1 and RUNX1.P2) of AML1-ETO, suggesting 
that alterations in transcription factor presence alter epigenetic protein recruitment to the AML1-
ETO promoter resulting in increased transcription. 
To confirm the effect of AML1-ETO overexpression on cell viability, we used a human induced 
pluripotent stem cell (iPSC) differentiation system that harbors a dox-inducible AML1-ETO construct, 
allowing to express the protein at different stages during in vitro hematopoietic differentiation. We 
first tested the differentiation of iPSCs toward the monocytic and granulocytic lineages (Figures 6E 
and S5D) and confirmed granulocytic differentiation by detecting segmented nuclei and intracellular 
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granules using May-Grunwald and Giemsa staining (Figure 6F, top) and confirmed enrichment 
of CD15 and/or CD16-positive cells by fluorescence-activated cell sorting (FACS) (Figure S5E). In 
contrast, we could not detect any segmented nuclei and granules after monocytic differentiation 
(Figure 6F, bottom) but could observe enrichment for CD14-positive cells (Figure S5F). Using these 
iPSC cells and expressing AML1-ETO during granulocytic differentiation at levels similar to patient 
blasts (14 ng/mL dox; Figures 6E and S5G) revealed increased numbers of progenitor (CD34+) cells 
in AML1-ETO-expressing conditions, while lower numbers of granulocytic (CD16-expressing) cells 
were detected (Figures 6G and 6H), suggesting a differentiation block along this lineage. To further 
assess the oncogenic potential of our differentiation system, we examined at the molecular level 
whether AML1-ETO has similar effects on gene expression as in leukemic cells. For this, we selected 
five genes that are upregulated and two that are downregulated upon AML1-ETO knockdown in 
AML1-ETO-expressing leukemic cells (Figure S5H, left). This revealed that in our iPSC system AML1-
ETO induction has similar effects on both gene sets. For example, genes that are increased in 
expression upon AML1-ETO knockdown in leukemic cells (such as CD82 and NFE2) show decreased 
expression upon AML1-ETO induction in the iPSC system (Figure S5H, right). In line with an AML1-
ETO oncogene overdose-inducing apoptosis in Kasumi-1 cells, overexpression (60 ng/mL dox) of 
AML1-ETO in this system resulted in decreased cell viability (Figures 6E and 6I). 
AML1-ETO, RUNX1, and ERG Regulate the Apoptosis Program in t(8;21) AML
Finally, to investigate the relation between an increase of AML1- ETO expression and apoptosis, we 
generated stable cell lines that allowed double knockdown of RUNX1/AML1-ETO, using an shRNA 
construct that targets the common RUNX1 part of both (shRUNX1.1) (Figure 5D), or ERG/AML1-
ETO, using two in- dependent shRNA constructs. Double knockdown of RUNX1/ AML1-ETO or ERG/
AML1-ETO resulted in lower expression of both targeted proteins (Figures 7A-7D). Interestingly, in 
both cases double knockdown rescued the cells from apoptosis (Figures 7E, 7F, and S6A-S6C), with 
marked decreases in the sub-G1 population. These results suggest that ERG and RUNX1 restrain 
AML1-ETO from becoming overexpressed and the subsequent activation of an apoptosis program. 
Figure 6. AML1-ETO oncogene expression levels determine the fate of leukemic cells. (A) RT-qPCR analysis 
of AML1-ETO and ERG in Kasumi-1 cells, before and after induction of a shRNA targeting ERG for 72h. 
AML1-ETO expression increased after ERG KD. Data normalized to GAPDH ***p<0.001. (B) RT-qPCR and (C) 
western analysis show increased AML1-ETO (AE) expression after RUNX1 KD for 72h in Kasumi-1. (D) p300 
and HDAC ChIP qPCR before and after induction of RUNX1 shRNA for 72h. Two primers were used targeting 
the promoter of RUNX1/AML1-ETO and data was normalized with H2B. (E) Effect of dox concentration on 
AML1-ETO expression during granulocytic differentiation of iPSCs. Top: Schematic representation of iPSC 
differentiation protocol towards granulocytes. Bottom: RT-qPCR analysis of AML1-ETO expression during 
granulocytic differentiation using different dox concentration; data is normalized to GAPDH. (F) Cytospin of 
iPS cells differentiated towards granulocytic and monocytic cells using May-Grunwald and giemsa staining. 
Top: Granulocyte differentiated cells. Bottom: Monocyte differentiated cells (G) Flow cytometry results of 
iPSC differentiation towards granulocytes with (14ng/ml dox) or without (no dox) AML1-ETO expression 
examining CD34/CD31 expressing cells after normal in vitro differentiation (left) or in the presence of 
AML1-ETO expression (right) (H) Bar diagram showing the percentage of CD34 and CD16 cells in AML1-ETO 
expressing (+dox 14ng/ml) and control cells (no dox). (I) Effect of increased AML1-ETO expression (using 
increased concentrations of dox) on viability of iPSCs differentiated along the granulocytic pathway. Cell 
viability was checked by trypan-blue cell counting.
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Discussion
Leukemic transformation is associated with the dysregulation of the normal cell machinery 
and characterized by alterations in the epigenome, transcriptome and proteome. To elucidate 
the molecular mechanism(s) of AML1-ETO in leukemogenesis we analysed gene expression and 
the epigenome of t(8;21) patient cells and t(8;21) cell lines together with the AML1-ETO/RUNX1 
proteome complex.
We revealed in t(8;21) patient blasts AML1-ETO binding to both promoter and distal elements 
and that each type of binding is associated with specific chromatin characteristics. Promoter 
binding sites are high in acetylation and associated with expressed genes whereas distal sites are 
reduced in acetylation and linked with lowly expressed genes. Interestingly despite low levels of 
acetylation, these distal regions are not enriched for other repressive marks, suggesting lower 
expression is mostly related to reduced acetylation. We did not observe differences in the p300/
HDAC balance at promoters and distal regions, although occupancy was generally higher for both 
Figure 7. Double knockdown (KD) of AML1-ETO and ERG or AML1-ETO and RUNX1 rescues cells from 
apoptosis. (A-B) Analysis of double KD of AML1-ETO and RUNX1 by (A) RT-qPCR (***p<0.001) and (B) 
western analysis. (C-D) Double KD of AML1-ETO and ERG is confirmed by (C) RT-qPCR (***p<0.001) and (D) 
western analysis. (E-F) Histograms showing the % of sub-G1 cells after (E) AML1-ETO (AE) and RUNX1 or (F) 
AML1-ETO (AE) and ERG double KD. Data represent the mean ± SD values of four independent experiments.
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p300 and HDACs at promoter regions. These results suggest that additional factors are involved in 
regulating the acetylation output at AML1-ETO binding sites. Using genome-wide binding analysis 
we demonstrate that at AML1-ETO promoter binding sites occupancy of the transcription factors 
LMO2 and LYL1 is low whereas at distal sites increased presence of LMO2 and LYL1 is observed. It is 
tempting to speculate that differential binding of these factors is involved in repressing acetylation 
at AML1-ETO distal regions. This would be supported by the observation that knockdown of AML1-
ETO results in decreased binding of LMO2 and increased the expression of associated myeloid 
lineage differentiation genes (Ptasinska et al., 2014).
Our genome-wide analysis also suggests that AML1-ETO and RUNX1 bind genomic regions 
occupied by both HDACs and p300. However, also mutually exclusive binding of RUNX1/p300 and 
AML1-ETO/HDACs has been reported (Ptasinska et al., 2014). Our re-ChIP experiments could show 
co-occupancy of AML1-ETO/RUNX1 as well as AML1-ETO/p300 and AML1-ETO/HDACs at similar 
genomic locations. Although these findings would be in line with other studies suggesting AML1-
ETO/RUNX1 (Li et al., 2015) and AML1-ETO/p300 co-occupancy at single loci (Wang et al., 2011), 
here, as well as in the other studies, only a limited number of regions were included in the re-ChIP 
experiment and no genome-wide re-ChIP analysis was performed.
To better understand the activating and repressive nature of AML1-ETO at protein-DNA level 
we performed, in addition to ChIP-seq analysis, DNA pull downs using t(8;21) cell lysates and 
RUNX1 motif containing oligos. Apart from previously identified AML1-ETO interactors such as the 
transcription factors LYL1 and LMO2 and the deacetylases HDAC1 and HDAC2 we also identified 
several proteins involved in RNA splicing (for example several RBMs and SRSFs), suggesting that 
the RNA processing machinery is directly linked to the transcription regulation machinery and 
deregulated by AML1-ETO. Interestingly, recent mutational analysis in a large cohort of AMLs 
identified splicing factors as commonly mutated in AMLs (Cancer Genome Atlas Research, 2013), 
suggesting deregulation of this machinery might be a general feature of AMLs and also involved in 
t(8;21) leukemogenesis. 
Motif analysis of the patient blasts’ AML1-ETO binding regions revealed the presence of ETS 
motifs, in line with reports that ETS factors are involved in AML1-ETO leukemogenesis (Martens et 
al., 2012; Trombly et al., 2015). Interestingly, we did not find ETS factors in our RUNX1 motif pull 
down analysis suggesting protein-protein interaction is not sufficient to interact with the RUNX1 
or AML1-ETO complex, but the additional presence of a DNA consensus binding site is required in 
order to stabilize interaction with these complexes. 
Of the ETS factors we got particularly interested in ERG, as it is required for definitive 
hematopoiesis and self-renewal of hematopoietic stem cells (Loughran et al., 2008; Ng et al., 
2011) and showed co-occupancy with AML1-ETO at all binding sites in t(8;21) cell lines and blasts. 
Moreover, so far no mutation is reported for ERG in t(8;21) leukemogenesis, underscoring that its 
activity might be essential for AML1-ETO leukemogenesis. Interestingly, upon knockdown of ERG in 
t(8;21) cells we observed an increase in sub-G1 cells, indicative of apoptosis onset. In addition, we 
could corroborate previous reports that upon RUNX1 knockdown a similar phenotype was observed 
(Ben-Ami et al., 2013) and that a delicate balance of RUNX1 and AML1-ETO is essential for leukemic 
maintenance of Kasumi-1 cells. Perturbation of this equilibrium by depletion of AML1-ETO leads 
to loss of self-renewal, whereas knockdown of RUNX1 results in apoptotic cell death (Ben-Ami et 
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al., 2013; Spirin et al., 2014). Here, our ERG knockdown results suggest that apart from RUNX1 and 
AML1-ETO, t(8;21) cells are also dependent on ERG expression and as such, in addition to RUNX1, 
are also ERG addicted.   
We confirmed the AML1-ETO/RUNX1 balance dependency by generating a stable inducible 
RUNX1 knockdown system in Kasumi-1 cells and suggest that increased expression of the AML1-
ETO gene might be linked to the induced apoptosis program. The present study demonstrates that 
not only knockdown of RUNX1, but also knockdown of ERG upregulates AML-ETO expression and 
thus interferes with the AML-ETO/RUNX1 equilibrium, possibly resulting in more AML-ETO binding 
to RUNX1 target genes or redistribution of AML1-ETO binding as suggested previously (Ptasinska 
et al., 2014). 
Using an novel iPSCs model system, we verified that overexpression of AML-ETO induces cell 
death, suggesting that only a specific dose of AML1-ETO relates to leukemogenesis, corroborating 
previous findings (Pabst et al., 2001; Tonks et al., 2004). In addition, the link between oncogene 
overdose, i.e. higher expression of AML1-ETO, and increased apoptosis, corroborates previous 
studies of inherent pro-apoptotic activities of AML1-ETO (Lu et al., 2006) and an anti-apoptotic 
role for RUNX1 (Ben-Ami et al., 2013). Oncogene overdose is a relatively new concept highlighted 
in particular by recent studies of mutant-BRAF in melanoma and the fusion kinase nucleophosmin-
anaplastic lymphoma kinase (NPM-ALK) in anaplastic large cell lymphoma (Amin et al., 2015). To 
our knowledge this concept, which is based on mutated kinases, has not been reported for AML 
associated oncogenes nor extended to mutated transcription factors.
Importantly, we could show that double knockdown of either RUNX1 and AML1-ETO or ERG 
and AML1-ETO rescues the cells from apoptosis, further illustrating the critical role of increased 
AML1-ETO expression in apoptosis induction and the importance of a fine tuned AML1-ETO/RUNX1 
and AML1-ETO/ERG expression equilibrium. Corroborating these results are previous observations 
in SKNO-1 cells selected for stable continuous ERG knockdown in which reduced AML1-ETO 
expression (as compared to wildtype SKNO-1 cells) was observed (Martens et al., 2012), which 
suggested that only sub-clones that in addition to reduced ERG also harbored low AML1-ETO could 
survive selection. 
Together these results show that a delicate balance of AML-ETO, RUNX1 and ERG expression is 
required for leukemic maintenance. Altering this balance might be used as a therapeutic entry point 
to induce apoptosis in t(8;21) cells.
Experimental procedures
Cell culture 
Kasumi-1 (Asou et al., 1991) was routinely cultured in RPMI 1640 supplemented with 10% FCS 
and 1% pen/strep at 37˚ C. Kasumi-1 shRNA stable cell lines were cultured in tet-free FBS and 
shRNA expression was induced for 72h for RT qPCR and 7 days for cell cycle analysis by adding 
600 ng/ml doxycycline. iPSCs cells were generated from megakaryoblast at the Sanquin Research 
Department of Hematopoiesis, Amsterdam, The Netherlands. AML1-ETO expressing iPSCs cell were 
generated by using a previously described strategy of knock-in using an AAVS1 homology donor 
vector and CRISPR-Cas9 (Mali et al., 2013). Briefly two million iPSCs were nucleofected with donor 
vector containing an inducible promoter for expression of the cloned gene (Qian et al., 2014) and 
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a gene targeting vector for the AAVS1 locus (Mali et al., 2013). Transfected cells were plated in 
one well of a vitronectin (Life technologies) coated 6 well plate in E8 media (Life technologies) 
supplemented with 10 µM of ROCK inhibitor for 24 hr. Cells were dissociated using accutase (Life 
technologies) and seeded at low density on a vitronectin coated dish in E8 media together with 
0.25 µg/ml puromyocin. Cells were selected for puromyocin for 14 days and positive clones were 
selected by PCR. AML1-ETO iPSCs were routinely maintained in E8 media (Life technologies) on 
vitronectin coated plates. 
Granulocytic and monocytic differentiation
For granulocytic and monocytic differentiation AML1-ETO iPSCs were dissociated using accutase 
and resuspended in E8 media supplemented with ROCK inhibitor (10 µg/ml). Cells were seeded at a 
density on Geltrex (Life technologies) coated six well plate, so that only 4-5 colonies emerge in each 
well. Cells were maintained in E8 media until individual colonies grew up to approximately 500 mm 
in diameter. E8 media was then replaced by stemline media supplemented with 1% penstrep, 1:100 
ITS and cytokines (20 ng/ml BMP4, 40 ng/ml VEGF and 5 ng/ml bFGF). This day was considered as 
day 0 of differentiation and the medium was refreshed after 3 days. On day 6, the cytokines were 
again replaced with a specific cytokine cocktail for monocyte ( 50 ng/ml SCF, 50 ng/ml FLT3, 50 ng/
ml IL3, 50 ng/ml M-CSF and 10 ng/ml TPO) (Niwa et al., 2011) or neutrophil differentiation (50 ng/
ml SCF, 50 ng/ml IL3, 50 ng/ml G-CSF and 5 ng/ml TPO ) (Morishima et al., 2014) after medium was 
changed every 3-4 days. The overall scheme of differentiation is outlined in supplementary Figure 
S5D. Dox (14ng) was added on the 6th day of differentiation and cells were kept continuously in dox 
until analyzed by flow analysis.
ChIP and ChIP-Seq
Chromatin from cell lines was harvested as described (Mandoli et al., 2014). ChIPs were performed 
using specific antibodies to AML1-ETO (Diagenode, C15310197), RUNX1 (Abcam; ab23980), ERG 
(Santa Cruz; sc-353), FLI1 (Santa Cruz; sc-356), GATA2 (Santa Cruz; sc-9008), HEB (Santa Cruz; sc-
357), and LYL1 (Santa Cruz; sc-374164) and analyzed by quantitative PCR or sequencing analysis. 
Relative occupancy was calculated as fold over background, for which the second exon of the 
Myoglobin gene or the promoter of the H2B gene was used. Chromatin isolation and ChIP-seq from 
primary t(8;21) AMLs was done according to Blueprint protocols (www.blueprint-epigenome.eu) 
using Diagenode antibodies. 
Illumina high-throughput sequencing
ChIP-seq libraries for transcription factors were prepared from precipitated DNA of 5 million 
cells (4-5 pooled biological replicas) using the Kapa hyperprep kit. For RNA-seq, 250 ng of RNA 
was used for ribozero (Illumina MRZ11124) and subsequent library preparation. Libraries were 
loaded on E-gel and a band corresponding to ~300 bp (DNA + Adaptor) was collected and used 
for cluster generation on the Illumina HiSeq genome analyzer. The 42-50 bp tags were mapped to 
the reference human genome hg19 using the Burrows-Wheeler Alignment Tool (BWA). For each 
base pair in the genome, the number of overlapping sequence reads was determined, averaged 
over a 10 bp window and visualized in the UCSC genome browser (http://genome.ucsc.edu). All 
ChIP-seq and RNA-seq data can be downloaded from the Gene Expression Omnibus (GSE76464 and 
GSE23730), or the Blueprint DCC (http://dcc.blueprint-epigenome.eu/#/files) and the bioinformatic 
analysis of the data is described in the Supplemental Information.
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Pulldown, dimethyl labelling and LC-MS/MS (liquid 
chromatography mass spectrometry) analysis
Nuclear extract preparation and pulldown were performed as described in Supplemental 
experimental procedures. Forward and reverse pull down proteins were labelled by dimethyl 
isotopes (Boersema et al., 2009) mixed and measured by Q Exactive mass spectrometer (Thermo 
Fisher Scientific). Raw data was processed by MaxQuant software and plots were generated using 
Perseus.
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Supplemental Information
Methods
Chromatin immunoprecipitation (ChIP)
Cells were crosslinked with 1% formaldehyde for 20 min at room temperature, quenched with 
0.125 M glycine and washed with three buffers: (i) PBS, (ii) buffer of composition 0.25% Triton X 
100, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6 and (iii) 0.15 M NaCl, 10 mM EDTA, 0.5 mM 
EGTA, 20 mM HEPES pH 7.6. Cells were then suspended in ChIP incubation buffer ( 0.15% SDS, 1% 
Triton X 100, 150 mMNaCl, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6) and sonicated using 
a Bioruptor sonicator (Diagenode) for 20 min at high power, 30 sec ON, 30 seconds OFF. Sonicated 
chromatin was centrifuged at maximum speed for 10 min and then incubated overnight at 4° C in 
incubation buffer supplemented with 0.1% BSA with protein A/G-Sepharose beads (Santa Cruz) and 
1 µg of antibody. Beads were washed sequentially with four different wash buffers at 4˚ C: two times 
with a solution of composition 0.1% SDS, 0.1% DOC, 1% Triton, 150 mM NaCl, TEE (10 mM Tris pH 
8, 0.1 mM EDTA and 0.5 mM EGTA), one time with a similar buffer but now with 500 mM NaCl, one 
time with a solution of composition 0.25 M LiCl, 0.5% DOC, 0.5% NP-40, TEE and two times with 
TEE. Precipitated chromatin was eluted from the beads with 400 μl of elution buffer (1% SDS, 0.1 M 
NaHCO3) at room temperature for 20 minutes. Protein-DNA crosslinks were reversed at 65° C for 4 
hours in the presence of 200 mM NaCl, after which DNA was isolated by Qiagen column. Chromatin 
isolation and ChIP-seq from primary t(8;21) AMLs was done according to Blueprint protocols (www.
blueprint-epigenome.eu/index.cfm?p=7BF8A4B6-F4FE-861A-2AD57A08D63D0B58.) Antibodies 
and primers for qPCR can be found below. For qPCR, relative occupancy was calculated as fold over 
background, for which the second exon of the Myoglobin gene or the promoter of the H2B gene was 
used. 
Re-ChIP
Re-Chip was performed as described (Martens et al., 2012). Briefly chromatin was first incubated 
overnight at 4° C with first antibodies as for regular ChIPs. After standard washing, elution was 
performed with 1% SDS (30 min, 37 °C). Eluates from at least three ChIPs were combined, diluted 
with incubation buffer with protease inhibitors and incubated overnight with secondary antibodies 
and protein A/G beads at 4 °C. The subsequent steps were performed as for regular ChIPs followed 
by qPCR.
RUNX1 and ERG knockdown (KD)
ERG knockdown was performed previously in SKNO-1 cells (Martens et al., 2012). In this experiment 
ERG shRNA constructs and empty control constructs were transduced using viral particles generated 
in HEK293T cells and subsequently selected using puromycin for two weeks after which shRNA 
expression was further induced for 72 hours using doxycyclin. Due to leakage of the ERG knockdown 
construct even before doxycycline induction only empty control transduced cells and shRNA ERG 
transduced cells (each selected for ~3 weeks) could be compared. Given the results reported in the 
current study, these shRNA ERG transduced cells likely represented subclones selected to tolerate 
ERG reduction through simultaneous downregulation of AML1-ETO, as observed in Martens et al. 
(2012).  
Here we generated new stable inducible ERG knock down cell lines using Kasumi-1 cells and 
using an alternative vector system, select for no/minimal leakage and thereby allow immediate 
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comparison of ERG (or other) knockdown effects on gene expression without clonal selection. For 
this the FH1tUTG lentiviral construct for inducible RUNX1 or ERG shRNA expression was prepared 
as described previously (Herold et al., 2008). Lentiviral particles were produced in Cos-7 cells and 
subsequently Kasumi-1 cells were infected with filtered viral supernatant. GFP Positive cells were 
sorted by FACS (GFP acts as selection marker) and induced for shRNA expression using 600 ng/ml 
doxycycline. An shRNA targeting a common region of AML1-ETO and RUNX1 was used for double 
knockdown of RUNX1/AML1-ETO. For ERG/AML1-ETO double KD, AML1-ETO shRNA was cloned in 
the FH1tUT- mcherry vector. The ERG shRNA cell line (GFP positive) was transduced with AML1-ETO 
FH1tUT- mcherry lentivirus and double positive cells (GFP and mcherry) were sorted by FACS. After 
validations of KDs by qPCR and western blot analysis, strand specific RNA-seq was performed.
Strand specific RNA sequencing
Total RNA was extracted with the RNeasy kit with on-column DNase treatment (Qiagen) and the 
concentration was measured with a Qubit fluorometer (Invitrogen). 250 ng of total RNA was treated 
by Ribo-Zero rRNA Removal Kit (epicentre) to remove ribosomal RNAs according to manufacturer 
instructions. 16 µl of purified RNA was fragmented by addition of 4 µl 5x fragmentation buffer 
(200 mMTris acetate pH 8.2, 500 mM potassium acetate and 150 mM magnesium acetate) and 
incubated at 94° C for exactly 90 s. After ethanol precipitation, fragmented RNA was mixed with 5 
μg random hexamers, followed by incubation at 70° C for 10 min and chilling on ice. We synthesized 
first-strand cDNA with this RNA primer mix by adding 4 μl 5× first-strand buffer, 2 μl 100 mM DTT, 1 
μl 10 mM dNTPs, 132 ng of actinomycin D, 200 U SuperScript III, followed by 2 h incubation at 48° 
C. First strand cDNA was purified by Qiagen mini elute column to remove dNTPs and eluted in 34 
μl elution buffer. Second-strand cDNA was synthesized by adding 91.8 μl, 5 μg random hexamers, 4 
μl of 5× first-strand buffer, 2 μl of 100 mM DTT, 4 μl of 10 mM dNTPs with dTTP replaced by dUTP, 
30 μl of 5× second-strand buffer, 40 U of Escherichia coli DNA polymer¬ase, 10 U of E. coli DNA 
ligase and 2 U of E. coli RNase H, and incubated at 16° C for 2 h followed by incubation with 10 U 
T4 polymerase at 16° C for 10 minutes. Double stranded cDNA was purified by Qiagen mini elute 
column and used for library preparation as described in the kapa hyperprep protocol. We incubated 
1 U USER (NEB) with adaptor-ligated cDNA at 37° C for 15 min followed by 5 min at 95° C before PCR. 
DNase1-Seq
DNase I libraries were prepared from the CD34+ or CD33+ cells of t(8:21) blast. Cells were selected, 
nuclei were isolated using Buffer A (15 mMNaCl, 60 mMKCl, 1 mM EDTA, pH 8.0, 0.5 mM EGTA, 
pH 8.0, 15 mMTris-HCl, pH 8.0, 0.5 mM Spermidine) supplemented with 0.015 % IGEPAL CA-630 
detergent. DNaseI treatment was done for 3 minutes and the reaction was stopped with stop buffer 
(50 mMTris-HCl, pH 8, 100 mMNaCl, 0.10 % SDS, 100 mM EDTA, pH 8.0, 1 mM Spermidine, 0.3 mM 
Spermine). The sample was further fractionated on 9% Sucrose gradient for 24 hours at 25000 rpm 
at 16˚ C. Fractions containing fragments smaller than 1kb were purified and processed according to 
the Illumina library preparation protocol.
Cell cycle analysis.
The cell cycle was analyzed using Propidium Iodide (PI). After harvesting, the cells were fixed 
overnight in 75% ethanol. Next, cells were washed twice with PBS supplemented with 0.5% BSA 
and incubated in PI staining solution, containing PI (50µg/mL, Biotium), 0.1% sodium citrate, 0.1% 
NP-40 (Sigma) and RNAse A (0.1mg/mL), overnight at 4° C. Fluorescence was measured using the 
BD FACScan system and subsequent analysis was performed with Flowing software (http://www.
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flowingsoftware.com/). Apoptosis assay was perform using Annexin V staining according to BD 
instructions.
FACS analysis
Suspension cells were collected and washed with PBA buffer (PBS + 1% BSA). Cells were incubated 
with 1% human serum (HS) to inhibit unspecific antibody binding. Cells were stained with CD34 (BD 
biosciences, clone 581) and CD31 (ebiosciences, WM 581) antibodies. Isotype antibodies were used 
as control. The data was collected and analyzed by FlowJo software.
Nuclear extract preparation and Pull down
Nuclear extract was prepared as previously described (Spruijt et al., 2013), snap-frozen in liquid 
nitrogen and stored at -80°C. For pull down, bait (containing the RUNX1 motif) and control 
(containing a scrambled RUNX1 motif) oligonucleotides were generated by annealing 2 nM of sense 
and 4 nM antisense strands in total volume of 80 ul. Sense strand of both bait and control oligos 
were biotinylated at the 5’ end for coupling to streptavidin sepharose beads. 85 ul of streptavidin 
sepharose slurry (GE Healthcare, 17511301) was washed with DB buffer (20 mMTris-HCl, pH 8.0, 
2 M NaCl, 0.5 mM EDTA, 0.03% NP-40) and divided equally in two tubes. 80 ul of annealed bait or 
control was added to each tube in a total volume of 360 ul of DB buffer and incubated for 1h at RT on 
rotation wheel. After coupling, the beads were washed two times with DBB, two times in PB buffer, 
resuspended in 80 ul of PBB and divided in two tubes. 500ug of nuclear lysate was added to beads 
in a total volume of 600 ul PB buffer (150 mM NaCl, 50 mMTris/HCl pH 8.0, 10 mM MgCl2, 0.5% NP-
40, Complete Protease Inhibitor-EDTA [Roche]) supplemented with 10ug of poly dIdC and incubated 
for 90 minutes at 4° C on a rotation wheel. The beads were then washed two times with PBB and 
two times with wash buffer (150 mM NaCl, 50 mM Tris/HCl pH 8.0) to remove the detergent present 
in the PBB. Beads was resuspended in 50ul of urea sol (2M urea, 50 mM HEPES pH 8.0, 10mM DTT) 
and incubated for 30 min at RT with shaking. Subsequently 50mM IAA was added for alkylation and 
incubated in dark for 20 min at RT with shaking. Proteins were digested on-bead by adding 0.4 μg of 
a trypsin/LysC mix (Promega) and incubated for 1 h at 25° C in thermoshaker. Beads were collected 
by centrifugation and supernatant was transferred to collection tube. Beads were washed with 
50ul of 2M urea in HEPES, centrifuged and supernatant was transferred to same collection tube. 
Digestion was continued at 25° C overnight at RT. Next day samples were acidified by adding 10 μL 
of TFA , purified on stage-tips (Rappsilber et al., 2007) and samples were dimethyl labeled.
Dimethyl Labeling and Mass spectrometry
For dimethyl labeling digested samples were eluted in 200 ul of 60% ACN and then reduced in 
volume by speedvac to 50 ul. 50 ul 200mM TEAB was added and dimethyl labeling was performed 
as described in original dimethyl protocol (Boersema et al., 2009). A standard setup in pull down 
with dimethyl labeling consist of two experiments, forward and reverse. In the forward experiment 
pull down proteins from control oligo is incubated with light and bait proteins with heavy isotope. 
In the reverse experiment, pull down proteins from control oligo is incubated with heavy and bait 
proteins with light isotope. Four microliters of 4% CH2O (light) or CD2O (heavy) together with 4 μL 
of 0.6 M NaBH3CN was incubated with the sample for 1 h at room temperature, with shaking. The 
reaction was stopped by adding 16 μL of 1% NH3. Corresponding light and heavy labeled samples 
were merged, acidified with 5 μL of TFA and purified by stage tip. 
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Mass spec run and raw data analysis was performed as described for standard dimethyl pull down 
(Hubner et al., 2015). Protein group files were processed and scatter plot were generated by 
Perseus.
Bioinformatic analyses
Peak calling
Peak calling algorithm MACS1.3.3 (Zhang et al., 2008) was used to detect the binding sites at a 
p-value cut off for peak detection of 10-6. 
Tag counting
Tags within a given region were counted and adjusted to represent the number of tags within a 1 kb 
region. Subsequently the percentage of these tags as a measure of the total number of sequenced 
tags of the sample was calculated and displayed as heat maps or boxplots in Figures 1A, 1B, 1F, 3B, 
4A, 4B, 4F, 5A, 5C and S1. 
Peak distribution analysis
To determine genomic locations of binding sites, the peak file was analyzed using a script that 
annotates binding sites according to all RefSeq genes. With this script every binding site is annotated 
either as promoter (-500 bp to the Transcription Start Site), exon, intron or intergenic (everything 
else). 
Motif analysis
For motif analysis of AML1-ETO binding sites, we used GimmeMotifs (van Heeringen et al., 2011). 
Expression analysis
RNA-seq reads were uniquely mapped to the human reference genome and subsequently used for 
bioinformatic analysis. RPKM (reads per kilobase of gene length per million reads) (Mortazavi et al., 
2008) values for RefSeq genes were computed using tag counting scripts and used to analyze the 
expression level of genes in Kasumi-1 cells. 
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Supplemental Figures
A B
	
Figure S1 (Related to Figure 1). (A) Expression values (FPKM) of RUNX1 and AML1-ETO in the two patients 
for which epigenomic analysis was performed. (B) Intensity plot displaying DNase1 accessibility and 
histone marks at promoter and distal element AML1-ETO binding sites of 2 t(8;21) blasts (#115 and # 12). 
	
Figure S2 (Related 
to Figure 2). Scatter 
plot showing the 
results of a pull-down 
mass spectrometry 
experiment from SKNO-1 
cells. Proteins are plotted 
by their di-methyl ratios 
in the forward (x axis) 
and reverse (y axis) di-
methyl experiment. 
Specific interactors of 
the AML-ETO/RUNX1 
pulldown are identified 
in the lower right 
quadrant. 
	
Figure S3 (Related to Figure 4). Cell cycle analysis of MS275 treated Kasumi-1 cells. (A) Cells were 
treated with MS275 for 24 h and cell cycle analysis was performed on FACS using propidium iodide. 
(B) Bar diagram showing the distribution of analyzed cells. Increases in the sub-G1 fraction are a 
hallmark of increased cell death.
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Figure S4 (Related to Figure 5). Cell viability and cell cycle analysis after RUNX1 or ERG knockdown. (A-B) 
RUNX-1.2 shRNA stable cell lines were induced for expression of shRNA for 7 days and (A) cell viability was 
checked by trypan-blue cell counting and (B) apoptosis by Annexin V staining. Left: Annexin V staining of 
control cells. Right: Annexin V staining of knockdown cells. Shown is the representative result of a duplicate 
experiment. (C) Western blot analysis of ERG knockdown after 72 h of ERG shRNA induction. (D-E) ERG 
shRNA stable cell lines were induced for expression of ERG shRNA for 7 days and cell viability was checked 
by (D) trypan-blue cell counting and (E) cell cycle analysis of control (top) and knockdown ERG cells (bottom) 
using propidium iodide. (F) Control and ERG shRNA induced cells (7 days induction) were analyzed by 
Annexin V staining. (G) Flow analysis of Annexin V stained cells. Left: ERG control. Right: ERG knockdown. 
(H) RT-qPCR showing the expression of CASP8 and BCL2 expression (normalized to GAPDH) before and after 
expression of ERG shRNA for 72h. 
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Figure S5 (Related to Figure 6). Expression and occupancies in AML1-ETO expressing and non expressing 
cells. (A) RNA-seq based RPKM expression of AML1-ETO before and after ERG knockdown in Kasumi-1 cells. 
(B) Western blot displaying less expression of ERG and more expression of AML1-ETO after induction of 
ERG shRNA for 72h. (C) p300 and HDAC1 ChIP-qPCR before and after induction of ERG shRNA for 72h. Two 
primers were used for qPCR designed from the promoter of AML1-ETO and data was normalized with H2B. 
Left: p300 ChIP showing increased occupancy after knockdown. Right: HDAC1 ChIP showing decreased 
occupancy after knockdown. (D) Neutrophil and monocyte differentiation scheme of human iPSCs. iPSCs 
were seeded on Geltrex-coated plates and maintained in E8 media for 2 weeks. E8 Media was then replaced 
with cytokine supplemented stemline media. The indicated cytokines were present in the medium on the 
indicated days. Top: Neutrophil differentiation. Bottom: Monocyte differentiation. (E-F) FACS analysis of 
cells after neutrophil (E) or monocyte differentiation (F) of iPSCs yielding ~74% CD15 and/or CD16 (markers 
for neutrophils) positive cells and ~61% CD14 (marker for monocytes) positive cells, respectively. (G). Effect 
of dox concentration on AML1-ETO expression in iPSCs as compared to expression levels in Kasumi-1 cells. 
AML1-ETO levels were normalized to GAPDH. (H) Left: RPKM expression of a selected number of genes 
before and after knockdown of AML1-ETO in Kasumi-1 cells. Right: Gene expression changes upon AML1-
ETO induction (plus dox) in iPS cells. Gene targets were assessed for expression changes using RT-qPCR after 
induction of AML1-ETO expression. 
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Figure S6 (Related to Figure 7). Double knockdown (KD) of AML1-ETO and ERG or AML1-ETO and RUNX1 
rescues cells from apoptosis. (A-B) RUNX-1.1 shRNA was used for double KD of AML1-ETO and RUNX1 and 
(A) cell viability was checked by trypan-blue cell counting and (B) cell cycle analysis of control and double 
KD Kasumi-1 cells by FACS/propidium iodide. Shown is the representative result of a duplicate experiment. 
(C) Double KD of AML1-ETO and ERG was performed using specific shRNAs for AML1-ETO and ERG, and 
cell cycle analysis was performed on FACS using propidium iodide. Shown is the representative result of a 
duplicate experiment. 
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Supplementary Tables
Table 1: Primers
ChIP FUT7 Forward TGAAACCAACCCTCAAGGTC
Reverse TCACTGGCATGAATGAGAGC
ChIP OGG Forward CCACCCTGATTTCTCATTGG
Reverse CAACCACCGCTCATTTCAC
ChIP NFE2 Forward GGTTAGCAGCATACGTGGAG
Reverse ACGATACGGAGAAAACCACG
ChIP SPI1 Forward GGGTAAGAGCCTGTGTCAGC
Reverse CAGATGCACGTCCTCGATAC
ChIP KREMEN1 Forward CGAGAGTGACATCCAGTTGC
Reverse TTCACAACCGTTCCAGATGA
ChIP MYOG Forward AAGTTTGACAAGTTCAAGCACCTG
Reverse TGGCACCATGCTTCTTTAAGTC
ChIP RUNX1_P1 Forward GAAAACTTCTTTGGGCCTCAT
Reverse CTGTGGGTTGGTGATGCTC
ChIP RUNX1_P2 Forward GGCAACAGTTGGAGCTTTTC
Reverse GTATTTCTCCAGGCGGTTCA
RT-qPCR RUNX1 Forward TCTGCAGAACTTTCCAGTCG
Reverse AAGGCGCCTGGATAGTGCAT
RT-qPCR AML1-ETO Forward CACCTACCACAGAGCCATCAAA
Reverse ATCCACAGGTGAGTCTGGCATT
RT-qPCR ERG Forward GACCCAGCAGCTCATATC
Reverse ATGGCCAGCACTATTAAG
RT-qPCR GAPDH Forward GAAGGTGAAGGTCGGAGTC
Reverse GAAGATGGTGATGGGATTTC
RT-qPCR CASP8 Forward AATGTTGGAGGAAAGCAATC
Reverse CATAGTCGTTGATTATCTTCAGC
RT-qPCR BCL2 Forward TCCGCATCAGGAAGGCTAGA
Reverse AGGACCAGGCCTCCAAGCT
RT-qPCR CD82 Forward CATGAATCGCCCTGAGGTCACCTA
Reverse GCCTGCACCTTCTCCATGCAGCCC
RT-qPCR NKG7 Forward TCCAGACCTTCTTCTCCTGG
Reverse GCCTTCTGCTCACAAGGTTT
RT-qPCR NFE2 Forward CAGAGCAGGAACAGGGTGAT
Reverse TGGAGGTCCAAGGTATGGAG
RT-qPCR IRF8 Forward TCCGGATCCCTTGGAAACAC
Reverse CCTCAGGAACAATTCGGTAA
RT-qPCR PRAM1 Forward CCTCAGTTCAGCAAGCCGCCAGGAG
Reverse CCAGGGGGAGTGGTTGGTTTTCCAG
RT-qPCR ID3 Forward TCATCTCCAACGACAAAAGG
Reverse ACCAGGTTTAGTCTCCAGGAA
RT-qPCR ST18 Forward AGGGTAGAGAAGGCAGGACGG
Reverse AGGTCTCTTCCACATCGCCCC
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Table 2: Antibodies
Antibody Catalogue no Company
AML-ETO1 C15310197 Diagenode
RUNX1 ab23980 Abcam
ERG sc-354 Santa Cruz
FLI1 sc-356 Santa Cruz
GATA2 sc-9008 Santa Cruz
TAL1 sc-12984 Santa Cruz
LYL1 sc-374164 Santa Cruz
p300 sc-585 Santa Cruz
HDAC1 ab7028 Abcam
HDAC2 ab7029 Abcam
H3K9K14ac 044_DA-0010 Diagenode
H3K4me3 C15410003-50 Diagenode
H3K4me1 C15410194 Diagenode
H3K27ac C15410196 Diagenode
H3K36me3 C15410192 Diagenode
H3K27me3 C15410195 Diagenode
H3K9me3 C15410193 Diagenode
Table 3: shRNA sequences used for knock down
AML1-ETO CCTCGAAATCGTACTGAGAAG
ERG CGACATCCTTCTCTCACAT
RUNX-1.1    GAACCACTCCACTGCCTTTAA
RUNX-1.2    GAACCAGGTTGCAAGATTTAA
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Abstract
In 11q23 leukemias the N terminal part of the MLL gene is fused to over 60 different partner genes. 
In order to define a core set of MLLr targets, we investigated the genome wide binding of the 
MLL-AF9 and MLL-AF4 fusion proteins and associated epigenetic signatures in AML cell lines THP-1 
and MV4-11. We uncovered both common as well as specific MLL-AF9 and MLL-AF4 target genes, 
which were all marked by H3K79me2, H3K27ac, and H3K4me3. Apart from promoter binding, we 
also identified MLL-AF9 and MLL-AF4 binding at specific subsets of non-overlapping active distal 
regulatory elements. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct 
a common gene program, which represents part of the RUNX1 gene program and constitutes 
of CD34+ and monocyte specific genes. Comparing these datasets identified several zinc finger 
transcription factors as potential MLL-AF9 co-regulators. Together, these results suggest that MLL-
fusions collaborate with specific subsets of TFs to deregulate the RUNX1 gene program in 11q23 
AMLs. 
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Introduction
Mixed Lineage Leukemia (MLL), encoded by the Lysine (K)-specific Methyl Transferase 2A (KMT2A) 
gene at 11q23, is a H3K4me3 depositing protein active during early development. MLL rearranged 
(MLLr) leukemias are responsible for about 10% of all Acute Lymphoblastic and Myeloid Leukemias 
(ALL/AML)1. The N-terminal CXXC-domain containing DNA binding part of the MLL gene can by 
genomic translocation be fused to over 60 different fusion partners2. The two most common fusion 
partners, AF9 (MLLT3) and AF4 (AFF1), are found in 30% of MLLr AML and 66% of MLLr ALL cases 
respectively3.
The most prevalent fusion partners (including AF9 and AF4) are present in the Super Elongation 
Complex (SEC), therefore leading to a general MLLr mechanism of action despite being composed 
of different proteins4,5. The SEC normally binds to RNA polymerase II and facilitates transcriptional 
elongation. In MLLr leukemias, the SEC is tethered to the DNA binding domain of MLL via the fusion 
partner, leading to aberrant transcription of MLL target genes. Next to that, AF9 as well as other 
fusion partners such as ENL, AF10, and AF17 are present in the DOT1L complex (DOTCOM). This 
deposits H3K79me2 on actively transcribed genes, leading to aberrant H3K79me2 deposition in 
these subsets of MLLr induced leukemias6-8. As such, a promising avenue for treatment of MLLr 
induced leukemia is inhibition of DOT1L9,10. 
Furthermore, AMLs in general and MLLr leukemia in particular have been shown to be sensitive 
to inhibition of BET family proteins such as BRD4 which regulate transcription elongation via P-TEFb 
at promoters and enhancers11-14. MLL fusion proteins have also been shown to interfere with 
RUNX115-17, and modulate PU.1 via its distal regulatory elements18. Moreover, MLLr and other AMLs 
are sensitive to inhibition of mediator kinases19, linking modulation of distal regulatory elements to 
execution of the MLLr leukemic program. 
Thus far, genome-wide maps of MLL binding are only available in mouse models of AML7, human 
ALL20-22, and of MLL-AF6 in the human AML cell line ML-223. No reports to date have described 
genome-wide MLL-AF9 and -AF4 binding in human AML.
Here, we set out to investigate the molecular mechanisms and targets of MLLr induced AML. For 
this, we characterized the genome wide binding, epigenetic signature and gene expression program 
of wildtype (wt) MLL, MLL-AF9 and MLL-AF4 in human AML cells. We show that MLL-fusion proteins 
bind in a ‘broad’ mode elongating over the gene body as well as in a ‘sharp’ mode stalled on the 
TSS, in addition to non-genic elements, such as distal enhancers. We show that MLL-AF9 and MLL-
AF4 share only a subset of target genes, yet show enrichment for the same pathways in both the 
shared as well as the MLL-AF9 and MLL-AF4 specific gene sets. These target genes are marked by 
H3K79me2, H3K4me3, and H3K27ac enrichment as well as by RUNX1 occupancy and constitute a 
mixture of CD34+ and monocyte expressed gene sets. Together these results suggest that in MLLr 
AML the RUNX1 mediated progenitor to monocyte differentiation program is deregulated. 
Results
MLL-fusions and wild type MLL show a broad and sharp binding mode
To investigate the binding sites of MLL-AF9 we used a sub-strain of THP-1 cells that express both wt 
MLL as well as MLL-AF9, but not wt AF9 (Figure 1A-B, S1A). Using antibodies against the N-terminus 
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of MLL-1 (ab1542/ab1547) and the C-terminus of AF9 (ab1327/ab1474) (Figure 1A) in ChIP-qPCR 
showed enrichment for the canonical HOXA MLL-fusion target region in THP-1 cells (Figure 1C), 
while HOXA7 and MEIS1 were, in contrast to expectations24-26 not enriched. Western analysis against 
MLL and AF9 using our antibodies yielded no detectable protein levels in THP-1 cells (Data not 
shown). Subsequently, we performed ChIP-seq experiments using MLL and AF9 antibodies in THP-
1 MLLr cells which confirmed enrichment on the HOXA locus for both antibodies (Figure 1D, top). 
Interestingly, we observed that both MLL and AF9 show not only ‘broad mode’ enriched regions 
elongating over gene bodies (Figure 1D, middle), but also ‘sharp mode’ enriched regions on target 
promoters and enhancers (Figure 1D, bottom).
Using MACS2 for defining sharp peaks and HOMER for defining broad regions (see materials and 
methods), we identified 16,099 unfiltered MLL occupied regions in THP-1 cells (Table S1). Of these, 
8217 were ‘broad mode’ (mean length ~12kb) and 7882 ‘sharp mode’ (mean length ~4.6kb) (Figure 
1E, left). Analysis of the genomic distribution revealed that the ‘broad mode’ peaks cover more TSS 
regions (Figure 1E, right), while the ‘sharp mode’ peaks seem to occur in intergenic regions more 
often. 
Since AF9 was not expressed from its endogenous locus in this sub-strain of THP-1 cells (Figure 
1B, S1A), we defined MLL-AF9 binding peaks as those MLL binding sites which show a high AF9 
signal, and MLL-wt binding events those that show a low AF9 signal (Figure 1F). This distilled our 
list of MLL occupied regions down to 1,613 high confidence MLL-AF9 fusion binding sites, including 
known AML and MLLr targets such as HOXA9, CDK6, MYB, MYC, JMJD1C, FOXP2, FLI1, RUNX1, PBX3, 
BCL2, and BRD4, as well as 439 high confidence MLL-wt binding sites (Table S1). 84% of these MLL-
AF9 binding sites are ‘broad mode’, versus 58% of wild type MLL binding sites (Figure 1G, left), and 
they occupy more TSS regions as compared to wild type MLL (Figure 1G, right).
As MEIS1 occupancy and expression is near universal for all MLL fusion induced AML and ALL27,28, 
we investigated the MEIS1 locus in THP-1 cells using our genome-wide data (Figure S1B). This 
corroborated our ChIP-qPCR finding that MEIS1 is not bound by MLL-AF9 and not expressed in THP-1 
cells, as it is marked only by H3K4me3 at its promoter, but not by MLL, AF9, H3K27ac, or H3K79me2. 
MEIS1 expression in MLL fusion induced AML has been shown to be especially important for the 
initial transformation of the leukemic cells in mouse models29-32. It is therefore conceivable that at 
some point since the original establishment of the THP-1 cell line in 198033, the locus was silenced 
and its role in leukemic maintenance taken over by another TALE class protein such as e.g. PBX3, 
which is expressed and bound by MLL-AF9 in THP-1 cells.
Figure 1. Genome wide binding patterns of MLL and AF9 in THP-1 cells. (A) Schematic representation of MLL, 
AF9 and MLL-AF9. Antibody binding locations are indicated with dotted lines, primer regions used in (B) 
with a filled line. (B) rt-qPCR experiments (n=5) in THP-1 cells with primers against the C and N termini of 
MLL and AF9 normalized to GAPDH. The N-terminus of AF9 is not expressed, indicating that there is no wild 
type expression of AF9 in this cell line. ***p<0.001 (Welch’s t-test). (C) ChIP-qPCR experiments using two 
anti-MLL-1 and two anti-AF9 antibodies in THP-1 cells and primers for HOXA7 -9, -10 and MEIS1. (D) ChIP-
seq overview of MLL and AF9 binding at the HOXA, ZEB2, and CDKN2C loci in THP-1 cells. (E) Classification of 
MLL and AF9 binding events in ‘broad’ and ‘sharp’ modes. Left: boxplot showing dispersion of peak lengths. 
Right: barplot showing genomic distributions. (F) Classification of MLL-AF9 and MLL wild type binding 
events. Average profiles showing ChIP-seq signal intensities for MLL-AF9 and MLL-wt binding events in THP-
1 cells. (G) Left: Distribution of MLL-AF9 and MLL wild type binding events in ‘broad’ and ‘sharp’ mode. 
Right: Genomic distribution of MLL-AF9 and MLL wild type binding events in ‘broad’ and ‘sharp’ modes. (h) 
Venn diagram illustrating the overlap between our human (THP-1) MLL-AF9 AML targets, MLL-AF9 targets in 
a mouse LSC model (Bernt et al.7) and human MLL-AF4 ALL targets (Guenther et al.20).
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In order to further validate our findings, we performed additional ChIP-seq experiments against 
MLL (ab1542) and AF9 (ab1474) in one MLL-AF9 positive AML patient and repeated the MLL ChIP-
seq in THP-1 cells with an antibody targeting a different epitope (ab1547). ChIP-seq signal intensity 
at our designated MLL-AF9 binding regions shows a good enrichment in all three cases (Figure S1C). 
This indicates our selected MLL-AF9 targets are not only bound by the fusion protein in the cell-line 
system, but also in more plastic primary cells.
As MLL-AF9 induced AML has previously been studied in various mouse models, e.g. Bernt 
2011, Zuber 2011, and Guenther 20087,34,35, we set out to compare our MLL-AF9 target genes with 
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Figure 2. Epigenetic signature of MLL target genes. (A) Distribution of expressed genes (RPKM>0.5), silent 
genes, MLL-AF9, and MLL wt target genes. (B) Overview of AF9, MLL, H3K79me2, H3K27ac and H3K4me3 
binding, and transcriptional activity at the ZEB2 locus in THP-1 cells. (C) Average signal of H3K27ac, H3K4me3 
and H3K79me2 at MLL-AF9 (top), and MLL wild type (middle) target genes, as compared to a random set 
of expressed genes (bottom) (D) Expression levels of MLL-AF9 and MLL wild type target genes ***p<0.001 
(Welch’s t-test). (E) Motif families enriched over background in MLL-AF9 target gene promoters (top left), 
MLL wild type target gene promoters (top right), and motif families in MLL-AF9 target gene promoters 
enriched over MLL wild type target gene promoters (bottom).
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target genes identified in mice. We found a relatively minor overlap of 12-23% between our set and 
the various mouse sets (Figure 1H, Table S2), which was about the same range of overlap found 
between the different mouse studies. This indicates that while a core set of targets is present in 
both human and mouse models, mouse models do not fully recapitulate the situation in human 
leukemogenesis. 
Epigenetic signature of MLL-AF9 target genes
As MLLr leukemias have been suggested to alter the epigenetic signature of affected cells, we 
compared the epigenetic state of the MLL-fusion with wt MLL target genes focusing on H3K4me3, 
H3K79me2 and H3K27ac. For this we took the set of high confidence MLL-AF9 and MLL-wt binding 
events overlapping with RefSeq hg19 genes, identifying 962 MLL-AF9 and 76 MLL-wt target 
genes, corresponding to 11% and 1% of all expressed genes (RPKM>0.5, cut off based on RPKM 
distribution) respectively (Figure 2A). Promoters of MLL-AF9 target genes were marked by H3K4me3 
and H3K27ac, while a H3K79me2 signal on gene bodies decreasing in the 5’ to 3’ direction was 
observed (Figures 2B, C top), indicating that these genes are actively transcribed. A similar pattern 
was seen on wild type MLL target genes, and a random pool of expressed genes, albeit with a mildly 
reduced signal strength for H3K79me2 (p=3.79e-10 and p<2.2e-16, respectively) (Figure 2C, middle, 
bottom). The lower occupancy of H3K79me2 was also reflected by a lower level of gene expression 
of wild type MLL targets as opposed to MLL-AF9 target genes, as determined by RNA-seq (Figure 
2D). This suggests fusion target genes are higher expressed, in concordance with the paradigm that 
MLLr activates MLL target genes by aberrant elongation.
Pathway enrichment analysis of MLL-AF9 target genes revealed a significant (Benjamini-
Hochberg adjusted p-value < 1e-6) enrichment of immune system, hemostasis, and adaptive immune 
Figure 3
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Figure 3. Comparison of MLL-AF4 and MLL-AF9 target genes. (A) Overview of AF4, MLL, H3K79me2, H3K27ac 
and H3K4me3 binding, and transcriptional activity at the ZEB2 locus in MV4-11 cells. (B) Genomic distribution 
of MLL-AF4 and MLL wild type binding events in ‘broad’ and ‘sharp’ modes. (C) Expression levels of MLL-AF4 
and MLL wild type target genes. ***p<0.001 (Welch’s t-test) (D) Distribution of MLL-AF9 specific and MLL-
AF9 and MLL-AF4 common target genes (top). Distribution of MLL wild type target genes in THP-1 and MV4-
11 (bottom). (E) Average signal of H3K4me3, H3K27ac and H3K79me2 on MLL-AF4 and MLL-AF9 common 
and specific target genes. (F) Expression level of MLL-AF9 target genes shared (+) or not shared (-) by MLL-
AF4 in THP-1 and MV4-11 cells (left). Expression level of MLL-AF4 target genes shared (+) or not shared (-) by 
MLL-AF9 in THP-1 and MV4-11 cells (right). ***p<0.001 (Welch’s t-test)
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system pathways (Figure S1D, top). MLL-wt target genes, in contrast, only revealed enrichment 
for the PDGFRB pathway (Figure S1D, bottom), often involved in translocation events leading to 
myeloproliferative disorder36. Motif analysis37 of MLL-AF9 targets revealed enrichment of the ETS, 
AP2 and C2H2-Zf family, while the POU family was depleted over background (Figure 2E, top left). 
Wt MLL target genes were enriched for motifs recognized by C2H2-Zf and ETS families, while the NR 
family was depleted over background (Figure 2E, top right). Direct comparison of MLL-AF9 and MLL-
wt targets revealed both gene sets as similar in terms of motif enrichment, except for the NR and 
AP-2 motif families, which were enriched in the MLL-AF9 target gene set (Figure 2E, bottom). This 
suggests MLL-AF9 mediated deregulation of NR and AP-2 signaling might be involved in aberrant 
hematopoietic and immunological processes.
Similarities of MLL-AF9 and MLL-AF4 binding patterns
To identify common MLL-fusion targets we expanded our analysis by including an MLL-AF4 
expressing AML. As both MLL-AF9 and MLL-AF4 are thought to bind to MLL target genes and are 
linked to aberrant elongation and transcription of their targets via the SEC, we set out to assess the 
subset of MLL target genes commonly bound by the fusion proteins. First, we created genome-
wide binding profiles for MLL, AF4, H3K4me3, H3K79me2, and H3K27ac, as well as an RNA-seq 
expression profile in MV4-11 AML cells expressing the MLL-AF4 fusion protein (Figures 3A, S2A-B). 
As before, we divided the unfiltered MLL targets (28656) in ‘broad mode’ (18782) and ‘sharp mode’ 
(9874), and by rate of AF4 occupancy filtered them down to fusion (2560) and wild type (828) 
binding events (Figures 3B, S2C-D, Table S3), showing a similar distribution as in THP-1 cells (Figure 
S2E). Expression of MLL-AF4 target genes (1722, identified by overlapping the high confidence 
fusion binding events with RefSeq hg19 genes) was significantly higher than MLL-wt genes (308) 
(Figure 3C). Epigenetic signatures and pathway enrichments were also comparable to MLL-AF9 
AMLs (Figure S2F-H), suggesting both MLL-AF9 and MLL-AF4 use similar molecular mechanisms 
to induce leukemia. We also found a similar overlap with the various mouse sets as observed for 
MLL-AF9 (Figure S2I, Table S2).
Comparing the MLL-AF9 and MLL-AF4 target gene sets (Table S4) revealed that a significant 
(p=1.98e-11) 29% (277) of MLL-AF9 target genes are also targeted by MLL-AF4 (Figure 3D, top), 
including known MLLr targets such as BCL2, HOXA9, MYB and BRD4. In contrast, only 3% of wild type 
MLL target genes found in THP-1 were targeted by wild type MLL in MV4-11 (Figure 3D, bottom). 
Next, we analyzed the activity of these common MLL-fusion and MLL wild type target genes versus 
MLL-AF9 and –AF4 specific target genes. Common MLL-AF9 and MLL-AF4 target genes, as well as 
those specific for MLL-AF9 and –AF4 show a comparable level of H3K27ac and H3K4me3 (Figure 3E), 
Figure 4. Characterization of MLL-AF9 bound distal regulatory elements. (A) Average signal of RUNX1 and 
CTCF on MLL-AF9 and MLL wild type target genes. (B) Rate of co-occupancy of MLL-AF9 and MLL wild type 
target genes by RUNX1 and CTCF (left). Expression level of MLL-AF9 target genes grouped by RUNX1 co-
occupancy. ***p<0.001 (Welch’s t-test) (right) (C) Average signal on MLL-AF9 (left) and MLL wild type (right) 
bound enhancers for H3K4me3 and H3K27ac (top), MLL and AF9 (middle), and RUNX1, CTCF and H3K79me2 
(bottom). (D) Genomic distribution of MLL-AF9 and MLL wild type enhancers (top left). Co-occupancy of 
MLL-AF9 and MLL wild type bound enhancers by CTCF, H3K79me2 and RUNX1 (top right). Expression levels 
of MLL-AF9 and MLL wild type intergenic enhancers (bottom left). Expression level of MLL-AF9 bound 
enhancers grouped by H3K79me2 co-occupancy. *p<0.05 (Welch’s t-test) (E) Motif family enrichment for 
MLL-AF9 bound enhancers. (F) Overview of HOXA locus in THP-1 cells showing alignment of AF9, MLL, 
H3K79me2, H3K4me3, H3K27ac, RUNX1 and RNA expression signal with the HOXA TAD boundary (grey box). 
(G) Pathway enrichments of active genes nearest to an MLL-AF9 bound enhancer within the same TAD. (H) 
Long range interactions from the BCL2 and PHLPP1 promoters as measured by 4C in THP-1 cells (black bars, 
q<0.01) aligned with MLL, AF9 and H3K27ac ChIP-seq patterns on MLL-AF9 bound enhancers (gray boxes). 
Arrows highlight examples of interactions of the baited promoters with MLL-AF9 bound enhancers.
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while H3K79me2 is slightly lower in MLL-AF9 AMLs. The presence of H3K79me2 signal on MLL-AF4 
target genes confirms the deposition of this histone tail mark also on MLL-AF4 targets in AML22,38.
The gene expression levels as determined by RNA-seq are comparable for shared fusion targets 
in THP-1 and MV4-11, while the MLL-AF9 and –AF4 specific target genes are lower expressed in 
MV4-11 and THP-1 respectively, with median RPKM values of 23 and 17 for the MLL-AF9 specific 
target genes and 25 and 18 for the MLL-AF4 specific target genes respectively (Figure 3F). Together, 
this indicates that the set of shared MLL-fusion target genes might represent a ‘core’ set of targets 
important for driving the leukemic potential of both MLL-AF9 and –AF4.
Interplay of MLLr target genes with RUNX1 and CTCF
As RUNX1 is a known factor in several types of translocated AML and ALL39-42 and has been suggested 
to be involved in MLLr leukemias15,16,43, we investigated RUNX1 DNA-binding in MLL-fusion induced 
AML. Next to that, it was recently shown that MLL translocated leukemias are affected by mediator 
kinase inhibition19. The mediator complex44 is associated with regulation of RNA-polymerase II at 
promoters and distal regulatory elements. Cohesin, important for the establishment of promoter-
enhancer interactions, co-localizes with CTCF45 and mediator46. Cohesin mutations are prevalent in 
non-translocated AMLs47 and CTCF is implicated in T-ALL48. Therefore, we investigated CTCF binding 
at MLL-fusion targets, as a proxy for mediator/cohesin binding. CTCF49 (GSM1335528) and RUNX1 
show enrichment on MLL-AF9 target genes, while the signal on wild type MLL genes is slightly 
lower for RUNX1 and almost absent for CTCF (Figure 4A, S3A). 22% (215) of MLL-AF9 target gene 
promoters are occupied by CTCF, versus 11% for MLL-wt target genes. For RUNX1 this overlap is 
80% (767) and 61% (46), respectively (Figure 4B, left). Moreover, RUNX1 co-occupied MLL-AF9 
target genes are higher expressed than MLL-AF9 target genes without RUNX1 co-occupancy (Figure 
4B, right). As RUNX1 binding to MLL-AF4 target genes in MV4-11 cells follows a similar pattern as 
discussed for MLL-AF9 in THP-1 cells (Figure S3B), together these results suggest that targeting the 
RUNX1 gene program is a common feature of MLLr AMLs.
MLL-fusion binding at distal regulatory regions
MLLr leukemias have largely been described to function via aberrant elongation of MLL target 
genes. However, as we noticed a significant portion (~25%) of MLL-AF9 and MLL-wt peaks occurring 
in distal regions (Figure 1G, right), we next set out to characterize these putative MLL bound 
enhancers. Overlapping distal MLL peaks with H3K27ac peaks yielded 342 MLL-AF9 bound and 75 
MLL-wt bound active enhancers with high H3K27ac and low H3K4me3 signal (Figure 4C, top and 
middle, Table S5). Interestingly, while RUNX1 was detected on both MLL-AF9 and MLL-wt enhancer 
peaks, CTCF and H3K79me2 signals were specific for MLL-AF9 bound enhancers (Figure 4C bottom, 
S4A). 
As MLL-AF9 and MLL-wt enhancers occupy both intergenic as well as intronic regions (Figure 
4D, top left) we further characterized only the set of MLL-bound intergenic enhancers to prevent 
mixing gene body and intronic enhancer chromatin signatures. A higher percentage of MLL-AF9 
bound enhancers (39%) than MLL-wt bound enhancers (12%) was marked by H3K79me2 (Figure 
4D, top right). This might reflect aberrant deposition of the histone mark by DOT1L tethered to 
the MLL-AF9 fusion protein. RUNX1 differences were less striking, while a CTCF peak is present in 
50% of all MLL-AF9 bound intergenic regions, versus 11% for MLL-wt, pointing towards increased 
interaction with mediator for the MLL-fusion bound enhancers. Next to that, MLL-AF9 bound 
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intergenic enhancer regions showed a significantly higher expression of enhancer RNA than MLL-
wt bound regions (Figure 4D, bottom left), with MLL-AF9 bound intergenic regions co-occupied by 
H3K79me2 showing an even higher expression (Figure 4D, bottom right). Taken together, these 
findings indicate that MLL-AF9 bound enhancer regions are epigenetically more activated than their 
wild type counterparts, and might show aberrant H3K79me2 deposition and expression due to the 
binding of the MLL-fusion protein.
Next, we wondered how distal binding sites identified in MV4-11 cells for the MLL-AF4 fusion 
would compare to the MLL-AF9 bound enhancers, as a difference in distal regulatory elements 
could potentially explain the difference in gene expression we found between the MLL-AF9 and 
MLL-AF4 specific target genes (Figure 3F). MLL-AF4 active distal binding regions were similarly 
grouped based on H3K27ac (although average H3K27ac signal was lower as compared to MLL-
AF9 distal regions), MLL and AF4 signal (Figure S4B, Table S5). Unlike the MLL-fusion target genes, 
there was virtually no overlap (2%) between MLL-AF9 and MLL-AF4 enhancers, indicating that the 
core set of common target genes might be regulated by a variable set of regulatory regions in the 
different MLL-fusions. Interestingly, we observed the same decrease in co-occupancy of H3K79me2 
on MLL-AF4 versus MLL-wt intergenic enhancers, while RUNX1 co-occupancy was slightly higher 
in the wild type set, and no significant difference in enhancer RNA expression between MLL-AF4 
and wild type MLL intergenic enhancers was observed (Figure S4C). This could indicate that as the 
epigenetic landscape of MLL-AF9 and MLL-AF4 bound active enhancers is similar except for a lower 
H3K27ac signal, transcriptional activity of these elements might be restricted to MLL-AF9 based 
leukemia, potentially either as a result of differences in complex presence (DOTCOM vs. SEC) or 
H3K27ac occupancy.
Next, we set out to determine the genes these enhancers are potentially interacting with. 
The majority of MLL- fusion bound enhancer regions are located between 5 and 500 kb from the 
nearest TSS (Figure S4D-E). However, as the TSS closest to an enhancer is not necessarily the one it 
acts upon, we refined our list of closest genes by comparison with topologically associating domain 
(TAD) data and by including active genes only. For this, we combined the CTCF binding data in THP-
1 with TADs in human monocytes as determined by HiC (T.K., S.W. and H.S., in preparation) to get 
an approximate distribution of TADs. Subsequently, we linked the MLL-AF9 bound enhancers to 
the closest active (H3K27ac marked) gene within the same TAD, resulting in 247 genes putatively 
regulated by MLL-AF9 bound enhancers, including BCL2, PHLPP1, RUNX1 and SPI1 (Table S6). We 
confirmed that our THP-1 TAD list includes the boundary at the 5’ of the HOXA cluster, as described 
in THP-1 cells49 (Figure 4F) and performed further validation using 4C-seq experiments on the 
promoters of BCL2 and PHLPP1, both MLL-AF9 target genes identified in this study, as bait. This 
allowed to confirm interactions formed by these promoters with MLL-AF9 bound active enhancers 
(Figure 4H). 
Interestingly, of the 247 genes regulated by MLL-AF9 occupied enhancers, 25% (61) are MLL-
AF9 promoter/gene body occupied genes, which is significantly (p<0.0001) more than in a random 
selection of genes. Next to that, GSEA pathway analysis of this set of 247 genes revealed a strong 
enrichment for cancer (q<1e-5), CMYB (q<1e-5), acute myeloid leukemia (q<1e-4), and immune system 
(q<1e-4) pathways (Figure 4G) providing a strong indication that these genes and their putative 
enhancers are indeed implicated in MLL-AF9 mediated leukemogenesis and/or maintenance. 
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Expression of MLL-AF9 targets in primary cells
Finally, we compared gene expression of MLL-fusion cell lines and primary AML blasts to CD34+ 
hematopoietic progenitor cells and primary human monocytes (Table S7). We established that 
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Figure 5. Gene expression levels of MLL-AF9 patient blasts as compared to CD34+ cells, monocytes, and 
AML blasts. (A) Distance based clustering on the expression of all hg19 refSeq genes. (B) PCA analysis on the 
expression of MLL-AF9 target genes. (C) Pathway enrichments for MLL-AF9 target genes in PC1 (top left) and 
PC2 (top right). Expression levels of MLL-AF9 target genes in PC1 (bottom left) and PC2 (bottom right). (D) 
Distribution of differentially expressed AP2, C2H2-Zf, ETS, NR, POU, and T-box TFs. Green dots: Benjamini-
Hochberg adjusted p-value < 0.01 and fold change > 4; Orange dots: Benjamini-Hochberg adjusted p-value 
< 0.05; Red dots: fold change > 1. (E) Euclidean distance clustering of 74 TFs expressed significantly different 
in MLL-AF9 cells versus monocytes, CD34+, and MLL-AF4 cells. (F-G) Mean RPKM of MLL-AF9 AML high (F) 
and low (G) expressed TFs in CD34+ cells (n=3), THP-1 (n=2), MV4-11 (n=1), Monocytes (n=3), MLL-AF9 blasts 
(n=5), AML-ETO blasts (CGA, n=7), CBFß-MYH11 blasts (CGA, n=11), MLLr blasts (CGA, n=11), PML-RARα 
blasts (CGA, n=16), and other AMLs (CGA, n=134).
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patient blasts cluster separately from CD34+ cells and monocytes (Figure 5A), Next, we focused 
on the subset of MLL-fusion target genes and investigated their spread by principle component 
analysis (PCA) (Figure 5B, Table S9). We found that primary MLL-fusion samples and cell lines differ 
from monocytes by one principle component (PC1), and from CD34+ cells by another (PC2), which 
is confirmed by functional analysis of PC1 associated pathways (Figure 5C, top left) and analysis 
of the average RPKM of genes in PC1 in the various cell types, which revealed a higher spread 
of expression levels for this subset in monocytes (Figure 5C, bottom left). Analogous functional 
analysis of PC2 revealed enrichment for pathways more associated with dividing (CD34+) progenitor 
cells (Figure 5C, top right) and an average CD34+ RPKM with a higher spread (Figure 5C, bottom 
right). Together, this suggests that AML associated MLL-fusions impose a block during monocyte 
differentiation.
To identify the TFs that cooperate with MLL-fusion in driving leukemogenesis, we investigated 
whether the expression of 878 TFs associated with the MLL-fusion enriched motif families (Figures 
2E,4E, S2H, S4F) is different between MLL-fusion positive cells, CD34+ cells and monocytes. We 
identified 146 TFs differentially expressed in one or more cell types (Figure 5D, green dots, Table 
S9). Subsequently, we filtered these TFs based on an RPKM cut-off of 5 in at least one sample, 
similarity of the MLL-AF9 samples, and a deviation from the mean in the same direction in at least 
2 samples, and clustered the remaining 74 TFs on expression pattern in monocytes, CD34+ cells, 
and MLL-AF9 and MLL-AF4 expressing cells, revealing 6 TF clusters (Figure 5E), each of which is 
differentially expressed in MLL-AF9 cells as compared to normal cell types or MLL-AF4 expressing 
cells and potentially involved in co-regulating MLL-AF9 binding sites. To confirm this specificity, we 
compared the clustering results to expression in other types of AML (Ley et al.50). This identified 
3 factors, ZNF521, ZNF433 and ZNF532 for which expression (Figure 5F) was increased in MLL-AF9 
positive cells only, suggesting these collaborate with MLL-AF9 in deregulating gene expression and 
driving leukemogenesis, and several tumor suppressing factors, such as ETV3, NR4A1, and EGR2 
whose expression (Figure 5G) is down regulated in MLLr as well as all other types of AML included 
in the analysis. Deregulation of e.g. ZNF521, NR4A1, and EGR2 has indeed previously been implicated 
in AML51-53.
In summary, these results show that MLL-fusion target genes identified in this study can be 
divided in a group behaving more like CD34+ cells and a group behaving more like monocytes. 
Similarly, expression of TF family members whose motifs were enriched under MLL-AF9 and -AF4 
target genes and enhancers can also be classified as CD34+ like, monocyte like, or MLLr specific. 
Disturbance of the normal gene expression patterns of both direct MLLr targets and co-regulating 
TFs potentially produces the leukemogenic phenotype witnessed in MLL translocated AML.
Discussion
In this study, we investigated the genome wide binding and epigenetic signature of MLL-AF9, MLL-
AF4, and wild type MLL in AML derived cell lines carrying the respective MLL-fusions. Enrichment 
of H3K79me2, H3K27ac, and RUNX1 signal was high on both MLL-AF9 and MLL-AF4 target genes. 
Enrichment of H3K79me2 confirms that deposition of this histone modification on aberrantly 
activated MLL-fusion target genes is also a feature of MLL-AF4 induced AML, as was shown for 
MLL-AF4 in murine and human ALL models22,38. Deposition of H3K79me2 is possibly deregulated in 
all MLLr acute leukemias involving a component of the SEC, via indirect association of the SEC with 
DOT1L via AF9 or ENL54,55. However, as H3K79me2 is enriched on all activated genes in general, and 
112
Chapter 4
not just on aberrantly activated MLL-fusion targets, inhibiting DOT1L function to non-specifically 
stop H3K79me2 deposition9,56 may introduce deleterious off-target effects.
Enrichment of H3K27ac on aberrantly activated MLLr target gene promoters -and BRD4 being 
an MLLr target- corroborates the facilitating role of bromodomain proteins in transcription of MLLr 
targets57, as evident from AML susceptibility to BET inhibition58. This suggests a positive feedback 
loop where transcription of MLLr targets is facilitated by BRD4, and BRD4 is transcribed because it 
is an MLLr target.
The large overlap between MLLr and RUNX1 binding sites and the identification of RUNX1 as an 
MLLr target gene suggests that MLLr AML deregulates a (subset of) the RUNX1 program, important 
for hematopoietic development59. This is reminiscent of the way the CBFß-MYH11 oncofusion 
modulates expression of RUNX1 targets39 and AML1-ETO can increase expression of a subset of 
RUNX1 targets60,61. Together with aberrant expression of genes such as MYC in most AML subtypes62,63 
this hints at the existence of a core set of genes, including a subset of the RUNX1 program, that is 
important for leukemic transformation and maintenance in translocation induced AML.
In addition to MLL-fusion binding to promoter regions as expected by the consensus of MLLr 
acting through aberrant activation of MLL target genes, we determined a significant number of 
MLL-fusion binding sites at active distal regulatory elements enriched for H3K27ac, H3K79me2, 
and RUNX1, and in close proximity to genes enriched for pathways related to leukemia. In light of 
this, it seems likely that MLLr does not only act directly on their target genes but can also modulate 
expression of target genes via distal regulatory elements. The MLL-AF4 and MLL-AF9 bound 
enhancers showed almost no overlap, indicating that each MLLr subtype has a distinct enhancer 
repertoire. This is in line with several studies linking differences in acquired and innate resistance 
to BET inhibition in various AML cell lines and different clones to a dynamic or variable enhancer 
landscape12,64. 
Moreover, MLL-AF9 bound enhancers are enriched for CTCF binding, which is in line with MLLr 
AML cells being responsive to treatment with mediator kinase inhibitors19. This suggests an active 
role for MLL-AF9 in modulating the chromatin conformation to facilitate target gene expression 
via interference with the interplay between CTCF, RAD21 (cohesin), and the mediator complex65,66.
We extracted an extended set of core MLLr target genes including known targets such as MYC, 
RUNX1, BCL2, and CDK6, which can potentially be used to develop new strategies for combating 
MLLr leukemias, for instance by fine-tuning the targeting of existing potential treatments such as 
inhibition of DOT1L7,9,56, BLC2i67 or BET11 to MLL-fusion target genes only. Next to that, the uncovered 
sets of MLL-AF9 and MLL-AF4 specific target genes such as ZNF521 and CDKN2A respectively, indicate 
that each specific fusion partner also has its own unique binding signature, which may potentially 
be exploited against MLLr blasts with resistance against a more general treatment such as BET 
inhibition57.
Lastly, we show that gene expression of MLL-AF9 target genes can be divided in CD34+ like 
and monocyte like groups, thereby keeping the MLL-AF9 positive leukemic cells in a state between 
CD34+ progenitor cells and fully differentiated monocytes. Likewise, TFs from families with motifs 
enriched under MLL-fusion targets can be divided in CD34+ like, monocyte like, and MLLr specific 
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groups, uncovering TFs like ZNF521 and ZNF433 that are indirectly involved in expression or 
selection of MLLr target genes, and tumor suppressing TFs like ETV3 and NR4A1 that are down 
regulated in MLLr leukemias. Interestingly, ZNF521 is also an MLL-AF9 target, suggesting a feed-
forward loop of ZNF521 and the MLL-AF9 leukemic program.
Materials and Methods
Cell culture
THP-133 and MV4-1168 cells were routinely cultured in RPMI 1640 supplemented with 10% FCS and 
1% pen/strep at 37° C in a humidified incubator with 5% CO2. Mycoplasm status was determined 
every 6 months.
Patient Samples
Bone marrow samples from MLL-AF9 positive AML patients were collected at diagnosis. The study 
was conducted in accordance with the Declaration of Helsinki and institutional guidelines and 
regulations (CMO 2013/064). Patient data are summarized in Table 1.
ChIP and ChIP-Seq
Chromatin from cell lines was harvested as described69. ChIPs were performed using antibodies 
against MLL-1, AF9, AF4, RUNX1, H3K4me3, H3K27ac, and H3K79me2 and analyzed by quantitative 
PCR or sequencing. Relative occupancy was calculated as fold over background, for which the 
promoter of the Myoglobin gene was used.
rt-qPCR and RNA-seq
Total RNA was extracted with TRIzol (Invitrogen) or RNAsol (GenDepot), treated with DNAse 
on column (Qiagen) and analyzed by reverse transcriptase quantitative PCR or strand specific 
sequencing. 
Illumina high-throughput sequencing
ChIP-seq and RNA-seq libraries were prepared according to manufacturer’s instructions. All data 
can be downloaded from the Gene Expression Omnibus GSE79899, GSM1631708, GSM1704846, 
and GSM1704847, or through the Blueprint DCC (http://dcc.blueprint-epigenome.eu/#/home).
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Supplemental Material
Extended Experimental Procedures
Chromatin immunoprecipitation (ChIP)
Cells were crosslinked with 1% formaldehyde for 20 min at room temperature, quenched with 0.125 
M glycine and washed with three buffers: (i) PBS, (ii) 0.25% Triton X 100, 10 mM EDTA, 0.5 mM EGTA, 
20 mM HEPES pH 7.6 and (iii) 0.15 M NaCl, 10mM EDTA, 0.5 mM EGTA, 20mM HEPES pH 7.6. Cells 
were then suspended in ChIP incubation buffer (0.15% SDS, 1% Triton X 100, 150 mM NaCl, 10 mM 
EDTA, 0.5 mM EGTA, 20mM HEPES pH 7.6) and sonicated using a Bioruptor sonicator (Diagenode) 
for 20 min at high power, 30 s ON, 30 s OFF. Sonicated chromatin was centrifuged at maximum 
speed for 10 min and then incubated overnight at 4° C in incubation buffer supplemented with 0.1% 
BSA with protein A Dynabeads (Thermo Fisher Scientific) and 2 µg of antibody. Beads were washed 
sequentially with four different wash buffers at 4˚ C: two times with a solution of 0.1% SDS, 0.1% 
DOC, 1% Triton, 150 mM NaCl, TEE (10mM Tris pH 8, 0.1mM EDTA and 0.5mM EGTA), one time with 
a similar buffer but now with 500 mM NaCl, one time with a solution of 0.25 M LiCl, 0.5% DOC, 0.5% 
NP-40, TEE and two times with TEE. Precipitated chromatin was eluted from the beads with 400 μl 
of elution buffer (1% SDS, 0.1 M NaHCO
3) at room temperature for 20 min. Protein-DNA crosslinks 
were reversed at 65° C for 4 h in the presence of 200 mM NaCl, after which DNA was isolated by 
Qiagen column. Antibodies and primers for qPCR can be found below. For qPCR, relative occupancy 
was calculated as fold over background, for which the promoter of the Myoglobin gene was used.
rt-qPCR
cDNA was synthesized using iScript (BioRad) and enrichment was calculated as fold over the 1st 
exon of GAPDH.
Strand-specific RNA-seq
Total RNA was extracted by TRIzol (Invitrogen), subjected to on-column DNase treatment (Qiagen) 
and the concentration was measured with a Qubit fluorometer (Invitrogen). 250 ng of total RNA 
was used with the Ribo-Zero rRNA Removal Kit (Illumina) to remove ribosomal RNAs according to 
manufacturer instructions. 16 µl of purified RNA was fragmented by addition of 4 µl 5x fragmentation 
buffer (200 mMTris acetate pH 8.2, 500 mM potassium acetate and 150 mM magnesium acetate) 
and incubated at 94° C for exactly 90 s. After ethanol precipitation, fragmented RNA was mixed 
with 5 μg random hexamers, followed by incubation at 70° C for 10 min and chilling on ice. We 
synthesized first-strand cDNA with this RNA primer mix by adding 4 μl 5× first-strand buffer, 2 μl 
100 mM DTT, 1 μl 10 mM dNTPs, 132 ng of actinomycin D, 200 U SuperScript III, followed by 2 h 
incubation at 48° C. First strand cDNA was purified by Qiagen mini elute column to remove dNTPs 
and eluted in 34 μl elution buffer. Second-strand cDNA was synthesized by adding 91.8 μl, 5 μg 
random hexamers, 4 μl of 5× first-strand buffer, 2 μl of 100 mM DTT, 4 μl of 10 mM dNTPs with dTTP 
replaced by dUTP, 30 μl of 5× second-strand buffer, 40 U of Escherichia coli DNA polymer¬ase, 10 U 
of E. coli DNA ligase and 2 U of E. coli RNase H, and incubated at 16° C for 2 h followed by incubation 
with 10 U T4 polymerase at 16° C for 10 min. Double stranded cDNA was purified by Qiagen mini 
elute column and used for library preparation as described in the KAPA Hyper Prep protocol. We 
incubated 1 U USER (NEB) with adaptor-ligated cDNA at 37° C for 15 min followed by 5 min at 95° C 
before PCR to ensure strand specificity.
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Illumina high-throughput sequencing
ChIP-seq libraries were prepared from precipitated DNA of 5 million cells (5-8 pooled biological 
replicas) for MLL, AF9, AF4, and RUNX1, or from 1 million cells for the histone tail modifications. End 
repair was performed using Klenow and T4 PNK. A 3’ protruding A base was generated using Taq 
polymerase and adaptors were ligated. The DNA was loaded on E-gel and fragments corresponding 
to ~300 bp (ChIP fragment + adaptors) were excised. The DNA was isolated, amplified by PCR 
and used for cluster generation and sequencing on the Genome Analyzer (Illumina) or HiSeq 
2000 (Illumina). For RNA-seq 250 ng of RNA was used for ribosomal RNA depletion with RiboZero 
(Illumina) and subsequent strand specific library preparation. The 42-50 bp tags were mapped to 
the reference human genome hg19 using the Burrows-Wheeler Alignment Tool (BWA) for ChIP-seq 
or TopHat2 (Bowtie2) for RNA-seq. For each base pair in the genome, the number of overlapping 
sequence reads was determined, averaged over a 10 bp window and visualized in the UCSC genome 
browser (http://genome.ucsc.edu).
4C-Seq
4C assays were performed as described previously1 with minor modifications. Briefly, 107 cells were 
cross-linked for 10 minutes with 2% paraformaldehyde, quenched with glycine and lysed in 50 ml 
lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 5mM EDTA, 0,5% NP-40, 1% TX-100, 1X protease 
inhibitors) for 30 min. Nuclei were then digested by DpnII enzyme followed by inactivation of 
restriction enzyme by incubating at 65˚ C for 20 min. The digested chromatin was subsequently 
ligated (circularized) overnight at 16˚ C with 50U T4 ligase. Ligated chromatin was then reverse 
cross-linked by incubating with proteinase K at 65˚ C and subsequently, the RNA was removed by 
additional incubation at 37˚ C with RNase A. The purified DNA was further digested with MseI as 
a second restriction enzyme, followed by circularization of the DNA. 4C product was subsequently 
amplified with bait-specific inverse primers (see Primers – 4C-seq). From each 4C library, about 
3200 ng DNA was amplified in multiple parallel PCR reactions containing 200ng of DNA each, which 
were subsequently pooled and purified. Amplified bait-containing DNA fragments were ligated to 
NextFlex DNA barcoded adaptors (Bioo Scientific). Adaptor ligated DNA was purified by Agencourt 
AMPure XP purification system (Beckman Coulter), PCR amplified (8 cycles) and sequenced paired-
end on the Illumina NextSeq 500 to obtain 50bp long reads. 
Bioinformatic analyses
Alignment
Tags were mapped to the reference human genome hg19 using the Burrows-Wheeler Alignment 
Tool2 (BWA) for ChIP-seq or TopHat23 (Bowtie24) for RNA-seq samples. SamTools5 was used for 
creation and manipulation of BAM files for each experiment. Before down stream use, duplicates 
reads and reads with a MAPQ<15 were discarded for ChIP-seq samples. For RNA-seq, only reads 
with MAPQ<15 were discarded. For ChIP-seq visualization, the number of overlapping sequence 
reads was determined per base pair, averaged over a 10 bp window and visualized in the UCSC 
genome browser (http://genome.ucsc.edu). For strand specific RNA-seq visualization, separate 
tracks were created for both strands, which were displayed in pairs using UCSC trackHubs.
Peak calling
Peak calling software MACS26 was used to detect ‘sharp’ mode binding sites of MLL and all binding 
sites of H3K4me3, H3K27ac, RUNX1, and CTCF with a q-value cut off of 1e-6 or 1e-9. For ‘broad’ mode 
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MLL binding sites and all H3K79me2 binding sites, HOMER2 findPeaks software7 was used with the 
following settings: -fdr 1e-6 -size 5000 -minDist 10000. 
MLL binding site classification
MLL binding sites from MACS2 and HOMER2 were merged with bedTools8, and split again in ‘sharp’ 
and ‘broad’ mode peak lists using a length cut-off of 7500bp, or split into ‘fusion’ and ‘wild type’ 
binding sites by means of fusion partner signal strength. For this, AF9 (or AF4) tags within MLL 
binding regions were counted and adjusted to represent the number of tags within a 1 kb region. 
Subsequently the percentage of these tags as a measure of the total number of sequenced tags 
of the sample was calculated. Finally, the AF9 (or AF4) normalized tag counts per MLL binding site 
obtained in this way were binned, and the MLL binding sites containing the upper quartile of AF9 (or 
AF4) normalized tag counts were identified as MLL-fusion binding sites, while the MLL binding sites 
containing the lower quartile of AF9 (or AF4) normalized tag counts were identified as MLL wild type 
binding sites. Overlaps between gene sets were tested for significance using a hypergeometric test 
with 23503 refseq hg19 genes as total universe.
Tag counting
Tags within a given region were counted and adjusted to represent the number of tags within a 1 kb 
region. Subsequently the percentage of these tags as a measure of the total number of sequenced 
tags of the sample was calculated and displayed as heat maps with the Fluff package9 or as average 
profiles with ngs.plot software10.
Peak distribution analysis
To determine genomic locations of binding sites, corresponding peak files were analyzed using a 
script that annotates binding sites according to all RefSeq hg19 genes. With this script every binding 
site is annotated either as promoter (2000 bp window around the Transcription Start Site), exon, 
intron or intergenic (everything else). MLL binding sites were identified as gene targets or distal 
binding sites based on this classification. Distal MLL binding sites were further characterized as 
active enhancers based on intersection with H3K27ac peaks using BED tools.
Motif analysis
Peaks were culled to 300 bp, and used with Gimme Motifs11 software to determine underlying 
known motifs. Motifs were subsequently grouped into motif families and their relative occurrence 
as opposed to either motifs called from genomic annotation and length matched random regions 
or a second set of called peaks (e.g. fusion versus wild type).
Pathway Enrichment analysis
Specific sets of binding regions / genes were analyzed for molecular pathways enrichments using 
the Gene Set Enrichment Analyses (GSEA)12,13 web tool with the ‘canonical pathways’ (CP) collection.
Expression analysis
Normalized (RPKM) values for all refSeq hg19 genes were calculated using HOMER2 analyzeRepeats 
software. Various subsets of these RPKM tables (e.g. only MLL-fusion bound genes) as well as the set 
of Ley et al. AML patients blast RPKMs14 were loaded into an R 3.2.3 environment15 for visualization 
as box and bar plots. Raw tag count tables were also generated using HOMER2 analyzeRepeats and 
loaded into R for distance and Pearson correlation clustering and PCA analyses using the DESeq2 
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package16. After PCA analysis, the top contributing genes per principal component (PC) were 
extracted by converting the rotation values per PC into z-scores and filtering out only those genes 
with sigma > 1.5.
4C-seq analysis
A reduced genome was generated by extracting the sequences flanking DpnII sites (30bp on each 
strand from the DpnII sites to downstream) based on build version hg19 of the human genome. 
Only uniquely mapped DpnII sites were considered for downstream analysis.
Reads from each library were parsed based on the bait-specific primer sequence and mapped to 
the reduced genome using bwa (version 0.6.2) with the default parameters. 4C signal was calculated 
using a sliding window of 10 Kb (±5 Kb of a given DpnII site) and normalized to the total number 
uniquely mapped reads. Interactions were called using the r3Cseq R package17 using an aggregate 
window of 2 kb and an FDR q-value cut-off of 0.05.
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Antibodies
Primers
ChIP-qPCR
Anti- Epitope Cat. No. Manufacturer
MLL-1 QGQESDSSETSVRGP-C AT71-Ab1542 Diagenode
MLL-1 PIFDNFRPPPLTPED-C AT73-Ab1547 Diagenode
AF9 SSASSPLHHEPPPPL L-C AT22-Ab1327 Diagenode
AF9 FTPSQTRQQGP RSI -C AT23-Ab1474 Diagenode
AF4 - Ab31812 Abcam
H3K4me3 - pAb003-050 Diagenode
H3K27ac - pAb-174-050 Diagenode
H3K79me2 - Ab3594 Abcam
RUNX1 - Ab23980 Abcam
Target Region Forward Reverse
HOXA7 Promoter AGCTGGGAGACGTTGACTTT GACAGGCCGGACTTAGACTC
HOXA9 Promoter GGGAGACGGGAGAGTACAGA GCTCTACGATGGGGTTTGTT
HOXA10 Promoter ACCGCAGGATGAAACTGAAG TTCCCCCAGAAAACAACAAA
MEIS1 Promoter CGGGTTCTAGCATTCTGGTC TCTCCCTCTTTGCAAGTGCT
MB Promoter GGATTGAGTCTGCCCAGG GATGGAAGGGCAGAGGTG
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cDNA
4C-seq
Name Target 
Region
Forward Reverse
MLL-N1 KMT2A
N-terminus
TCAGCTGCAGGGAAGAAAGG CTATAAACCGCCGAGGGGTC
MLL-N2 KMT2A
N-terminus
TGTGAGAATCTTTCAGATGAGATGT CTTTTTCAAGGGCCAGTCGC
MLL-C KMT2A
C-terminus
CCACAGAGTGTGGGAGGAAC AGAGGAACTGGATGCCAAGC
AF9-N MLLT3
N-terminus
TGGCTAGCTCGTGTGCCGTG CCGGACCGCGTACGAACACC
AF9-C MLLT3
C-terminus
GCAGCCGAAGTCGCAGAGTTA AGGGTGGTGGAGGTTCGTGATGT
GAPDH 1st exon GCCTCAAGATCATCAGCAATGC TGGTCATGAGTCCTTCCACGA
Name Reading Non-Reading
PHLPP1 bait 1 GGAAGAGGTAGTCATTTTGGA GGGTCCTGATGAGTCTTTGT
PHLPP1 bait 2 GTGGTTCTCGTAAGGGGATC CTCCCGGCGCATGATTAA
BCL2 bait1 TTTCTCGAGCTCTTGAGATC GGCAGGAATCCTCTTCTGAT
BCL2 bait 2 ATCAGGTCCTTGGAATGATC TGCTAGCTCTCTTCTGAAGC
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Supplemental Figure 1. Genome wide 
binding of MLL and AF9. (A) The expression 
of the C-terminal and N-terminal exons of 
AF9 (MLLT3) in THP-1 cells and monocytes 
(left). UCSC genome browser screenshot 
depicting the expression of the AF9 
(MLLT3) locus in THP-1 cells. Arrows 
indicate the location of primers used for rt-
qPCR and the fusion breakpoint. (B) UCSC 
genome browser screenshot depicting the 
MEIS1 locus in THP-1 and MV4-11 cells. 
(C) Average signal intensity at MLL-AF9 
target genes for MLL (ab1547) ChIP-seq in 
THP-1 cells (left), and MLL (ab1542) and 
AF9 (ab1474) ChIP-seq in patient AML_
MLLAF9_5. (D) Pathway enrichment for 
MLL-AF9 (top) and MLL wild type (bottom) 
target genes.
Supplemental Figure 2. Genome wide 
binding patterns of MLL and AF4 in MV4-
11 cells. (A) Schematic representation of 
MLL, AF4 and MLL-AF4. Antibody binding 
locations are indicated with dotted lines. 
(B) ChIP-qPCR experiments using an anti-
MLL-1 and an anti-AF4 antibody in MV4-
11 cells with primers for HOXA7 -9, -10 
and MEIS1. (C) Classification of MLL and 
AF4 binding events in ‘broad’ and ‘sharp’ 
modes. Left: boxplot showing dispersion 
of peak lengths. Right: barplot showing 
genomic distributions. (D) Classification 
of MLL-AF4 and MLL wild type binding 
events. Average profiles showing ChIP-
seq signal intensities for MLL-AF4 and 
MLL-wt binding events in MV4-11 cells. 
(E) Distribution of MLL-AF4 and MLL wild 
type binding events in ‘broad’ and ‘sharp’ 
mode. (F) Average signal of H3K27ac, 
H3K4me3 and H3K79me2 at MLL-AF4 
(top) and MLL wild type (middle) target 
genes, as compared to a random pool of 
expressed genes (bottom). (G) Pathway 
enrichment for MLL-AF4 (top) and MLL 
wild type (bottom) target genes. (H) 
Motif families on MLL-AF4 target gene 
promoters enriched over MLL wild type 
target gene promoters.
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Supplemental Figure 3: RUNX1 and CTCF binding at MLL-fusion target genes. (A) UCSC genome browser 
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genes in MV4-11 cells.
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Supplemental Figure 4. Characterization of MLL-AF4 bound distal regulator elements. (A) UCSC genome 
browser screenshots depicting binding of AF9, MLL, H3K79me2, H3K4me3, and H3K27ac at MLL-AF9 target 
enhancers. (B) Average signal on MLL-AF4 (left) and MLL wild type (right) bound enhancers for H3K4me3 
and H3K27ac (top), MLL and AF4 (middle), and RUNX1 and H3K79me2 (bottom). (C) Rate of co-occupancy of 
MLL-AF4 and MLL wild type bound enhancers by H3K79me2 and RUNX1 (top). Expression levels of MLL-AF4 
and MLL wild type intergenic enhancers (bottom). (D) Distance to nearest TSS for MLL-AF9 bound enhancers. 
(E) Distance to nearest TSS for MLL-AF4 bound enhancers. (F) Motif family enrichment for MLL-AF4 bound 
enhancers over MLL-wt bound enhancers
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Abstract
Overexpression of the BRE (Brain and Reproductive organ-Expressed) gene defines a distinct pediatric 
and adult acute myeloid leukemia (AML) subgroup. Here we identify a promoter enriched for 
active chromatin marks in BRE intron 4 causing strong bi-allelic expression of a previously unknown 
C-terminal BRE transcript. This transcript starts with BRE intron 4 sequences spliced to exon 5 and 
downstream sequences, and codes for an N-terminally truncated BRE protein. Remarkably, the new 
BRE transcript was highly expressed in over 50% of 11q23/KMT2A-rearranged and t(8;16)/KAT6A-
CREBBP cases, while it was virtually absent from other AML subsets and normal tissues. In gene 
reporter assays, the AML-specific fusion protein KMT2A-MLLT3 transactivated the intragenic BRE 
promoter. Further epigenome analyses revealed 97 additional intragenic promoter marks frequently 
bound by KMT2A in AML with C-terminal BRE expression. The corresponding genes may be part of a 
context-dependent KMT2A-MLLT3-driven oncogenic program, because they were higher expressed 
in this AML subtype compared to other groups. C-terminal BRE might be an important contributor 
to this program because in a case with relapsed AML, we observed an ins(11;2) fusing CHORD1 to 
BRE at the region where intragenic transcription starts in KMT2A-rearranged and KAT6A-CREBBP AML.
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Introduction
Oncogene activation contributes to cancer onset and can be associated with treatment response. 
For instance, in AML, high MECOM (MDS1-EVI1 complex) expression predicts poor outcome1. 
Chromosome 3 rearrangements juxtaposing a GATA2 super-enhancer to the MECOM locus 
cause MECOM overexpression,2,3 but MECOM overexpression also occurs without chromosome 
3 rearrangements. MECOM activation is caused by independent and recurrent chromosomal 
abnormalities, strongly suggesting its contribution to disease pathogenesis. Indeed, inhibition 
of MECOM expression resulted in cellular differentiation and growth inhibition in preclinical AML 
models.2,4-6 MECOM overexpression lacking chromosome 3 abnormalities is recurrently found 
in AML with KMT2A (Lysine methyl transferase 2A, MLL) translocations. MLLT3 (Mixed-Lineage 
Leukemia Translocated To Chromosome 3, AF9) is the most frequent fusion partner of KMT2A7 8 and 
KMT2A-MLLT3 may contribute to MECOM overexpression.9 Since the majority of KMT2A-MLLT3 AML 
lacks MECOM overexpression,10,11 MECOM activation by KMT2A-MLLT3 may be context dependent. 
Earlier we reported that KMT2A-MLLT3 AML is characterized by mutually exclusive MECOM and BRE 
overexpression.10-12 These findings are relevant, because both pediatric and adult KMT2A-MLLT3 
AML with BRE overexpression are associated with a favorable outcome.10-12 BRE is expressed at high 
levels in blood cells in general, suggesting a general function in hematopoiesis. BRE functions in 
BRCA-1 (Breast Cancer 1) mediated DNA damage repair, BRISC (BRCC36 isopeptidase complex) 
mediated de-ubiquitination and in protection from apoptosis and senescence.13-20 Its exact 
function in hematopoiesis remains to be determined. Importantly, it is currently unknown how BRE 
overexpression is caused in KMT2A-MLLT3 AML. Here, we generated RNA-seq and ChIP-seq profiles 
from KMT2A-MLLT3 samples to obtain more insight into the mechanisms causing BRE overexpression.
 
Materials and methods 
Human samples
Bone marrow and peripheral blood samples were collected at diagnosis and relapse. The study was 
performed in accordance with the Code of Conduct for Responsible use of Human Tissue in Medical 
Research and institutional guidelines and regulations. For many samples used in this study, sample 
collection has been described before.11,21-23 Table 1 summarizes characteristics of samples used for 
ChIP-seq and RNA-seq studies.
Cell culture, RNA isolation, cDNA synthesis, RT-(q)PCR, 5’ RACE and luciferase reporter assays
Extensive methods for cell culture, RNA isolation, cDNA synthesis, RT-(q)PCRs, 5’ Rapid Amplification 
of cDNA Ends (RACE) and luciferase reporter assays are described in the supplementary information. 
ChIP, ChIP-Seq, Illumina high-throughput sequencing
Methods for H3K4me1, H3K4me3, H3K27ac and KMT2A ChIP-seq/qPCR, RNA-seq and bio-informatic 
analyses are described in the supplementary information. 
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Results
The epigenome of human KMT2A-MLLT3 AML
To gain more insight into the epigenetic regulation of the MECOM and BRE loci in KMT2A-MLLT3 AML, we 
generated H3K4me1, H3K4me3 and H3K27ac ChIP-seq profiles from two primary KMT2A-MLLT3 AML 
samples (one MECOM- and one BRE overexpression [patients P1a and P2a, Table 1]). This revealed 
~30,000 and ~26,000 active promoters (H3K27ac/H3K4me3) as well as ~40,500 and ~46,000 active 
Sample 
number 
Age Sex Tissue Blast 
percentage
High BRE/
MECOM
ChIP-seq/
RNA-seq 
Study number 
P1a/b* 25 Male BM 96
High 
MECOM
RNA-seq25, 
H3K4me1 
(only P1a), 
H3K4me3, 
H3K27ac 
(only P1a) 
ChIP-seq
AML_MLLAF9_125
P2a/b* 27 Female BM 62 High BRE
RNA-seq25, 
H3K4me1 
(only P2a), 
H3K4me3, 
H3K27ac 
(only P2a) 
ChIP-seq
AML_MLLAF9_425
P3 45 Female BM 45 High 
MECOM
RNA-seq25 AML_MLLAF9_325
P4 40 Female BM 95 High BRE
KMT2A25, 
H3K4me3, 
H3K27ac 
ChIP-seq
535821
P5 1 Male BM 45 High BRE
RNA-seq25, 
H3K4me3 
ChIP-seq
AML_MLLAF9_225
P6 69 Female BM 89 High BRE H3K4me3 
ChIP-seq
11-030076
P7 77 Male BM 76 High BRE H3K4me3 
ChIP-seq
12-040773
Table 1: Patient Details
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enhancers (H2K27ac/H3K4me1) for P1a and P2a, respectively. The relative abundance and genomic 
distribution of active promoters and active enhancers was similar between P1a and P2a (Figures 
1B,S1A). The common promoter and enhancer regions (>65% of active promoters/enhancers) 
showed comparable average ChIP-seq signal intensities (Figure 1B). In contrast, patient specific 
active promoters and enhancers showed markedly higher average signals (Figure S1C). Remarkably, 
for H3K4me3/H3K27ac peaks, only 50% overlapped with annotated (RefSeq hg19) promoters, 
suggesting KMT2A-MLLT3 samples might harbor many alternate transcription start sites. Thus, the 
epigenomes of MECOM and BRE overexpressing KMT2A-MLLT3 AML samples are comparable, but also 
contain unique features. 
Deposition of active histone marks at annotated promoters 
in MECOM overexpressing KMT2A-MLLT3 AML
The sample with MECOM overexpression exhibited higher H3K4me3 signals than the sample with 
BRE overexpression at the two annotated MECOM promoter regions (Figure S1D). Additionally, 
H3K27ac was only detected at the H3K4me3 peaks in P1a while no signal was found in P2a, which 
is in line with the low MECOM expression in P2a. These observations were subsequently confirmed 
in additional primary KMT2A-MLLT3 AML samples: by H3K4me3 ChIP-seq (n=2 MECOM, n=5 BRE 
overexpression), RNA-seq (n=2 MECOM, n=2 BRE overexpression), and a H3K27ac ChIP-seq profile 
(BRE overexpression, P4, Figures S1E,S2C). Together, these results show that MECOM overexpression 
is associated with increased deposition of active promoter marks at its two annotated promoters. 
Intragenic promoter marks in BRE in KMT2A-MLLT3 AML
Subsequently, the BRE locus was examined. No differences were detected in active enhancers 
around the BRE locus between the two initial KMT2A-MLLT3 AML samples (not shown). Interestingly, 
apart from enrichment on the annotated promoter, the sample with BRE overexpression contained 
intragenic active promoter marks (H3K4me3/H3K27ac) in BRE intron 4 that were absent in the 
sample with normal BRE/high MECOM expression (Figure 1C). These data were confirmed using 
ChIP-qPCRs on two KMT2A-MLLT3 cell lines and primary samples (Figures 1D,S2A). Analysis of all 
H3K4me3 ChIP-seq profiles revealed that 5/6 samples with BRE overexpression harbored an 
intragenic H3K4me3 peak in BRE (the peak in P6 was not called, likely due to the higher background 
levels), whereas none of the three samples with MECOM overexpression did (Figures 1E,S2B). A 
second H3K27ac profile generated from a sample with BRE overexpression (P4) also showed a clear 
peak in the same region (not shown). These results show that the BRE intragenic active promoter 
marks were specific to KMT2A-MLLT3 samples with BRE overexpression. 
Intragenic transcription activation causes high downstream BRE expression in KMT2A-MLLT3 AML 
Next, we investigated whether the intragenic BRE promoter was accompanied by transcription of a 
transcript. Indeed, RNA-seq from sample P2a (BRE overexpression) showed expression of intronic 
sequences adjacent to the active promoter marks, ~3 kb upstream of exon 5. Downstream exons 
were expressed at a higher level compared to upstream exons (Figure 1C). RNA-seq and RT-qPCR 
in a larger cohort showed that exons upstream of the intragenic promoter were equally expressed 
in all KMT2A-MLLT3 samples (Figure 1F-G). In contrast, downstream exons were 5 to 9-fold higher 
expressed in samples with BRE versus MECOM overexpression (Figure 1G). The start of the new BRE 
RNA transcript as determined by RNA-seq was confirmed by 5’ RACE (Figure 1H) followed by Sanger 
sequencing. The new transcript contained a ~100 bp region within intron 4 (exon 1b) fused to exon 
5. As several samples harbored a heterozygous SNP within exon 1b, which was expressed, we could 
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determine that alternate BRE expression was biallelic (not shown). Besides exons 1b and 5, the novel 
BRE transcript contained exons 6-12 explaining high expression of these downstream exons (Figures 
1C,1I and not shown). Importantly, the new transcript was not detected by 5’ RACE in three KMT2A-
Figure 1
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MLLT3 samples with MECOM overexpression. Instead, the expected transcript containing BRE exons 
1-7 was amplified (~870 bp, Figure 1H). Exon 5 codes for two methionines that potentially serve as 
translation start sites (Figure 1I), which would result in the formation of a 138 or 154 amino acid 
N-terminally truncated protein. In conclusion, these results show that BRE overexpression in KMT2A-
MLLT3 AML is caused by biallelic intragenic transcription activation from an alternate promoter in 
intron 4.
Novel BRE transcript in KMT2A-rearranged and KAT6A-CREBBP AML
Our next goal was to study whether BRE intragenic transcription activation is unique to KMT2A-MLLT3 
AML. We previously described samples with BRE overexpression without detectable rearrangements 
involving KMT2A.12 To determine whether BRE overexpression in these samples is caused by 
intragenic transcription activation, we performed 5’ RACE on two such samples (patients 2184 and 
6948 from Valk et al.21). Identical fragments were identified in these samples as in KMT2A-MLLT3 
AML with BRE overexpression (Figure 1H), suggesting that expression of the new BRE transcript 
may occur independently of KMT2A rearrangements. We developed an RT-qPCR for detection of 
the new BRE transcript (Figure 1I) to determine its prevalence in AML in general (Figure 1J). The 
new BRE transcript was highly expressed (>500) in approximately half of the adult KMT2A-MLLT3 
(13/24) as well as ~70% and ~50% of pediatric KMT2A-MLLT3 (13/19) and KMT2A-MLLT10 AML (7/15), 
respectively. As most KMT2A-rearranged AML samples have French-American-British M4 or M5 
morphology, additional samples were screened for expression of the novel BRE transcript. 2/36 M4/
M5 samples exhibited high expression of the new BRE transcript. Thus, morphological classification 
per se does not correlate with high expression of the new BRE transcript. The novel BRE transcript 
was only sporadically highly expressed in remaining AML samples (2/65) and was not found in other 
hematological malignancies (n=16, Figure 1J). 
Since BRE overexpression was previously detected in one KAT6A-CREBBP patient,11 additional 
samples were screened for the new BRE transcript. Indeed, 3/7 adult and 10/13 pediatric KAT6A-
CREBBP samples exhibited high new BRE transcript levels (Figure 1J). The new BRE transcript was 
hardly detected in normal primary hematopoietic cells (Figure 1J and 20 other human tissues, not 
Figure 1. Intragenic transcription activation in BRE in primary KMT2A-MLLT3 samples with BRE overexpression. 
(A) Representation of the HOXA locus, a well-known KMT2A-MLLT3 target. H3K4me1, H3K27ac, and 
H3K4me3 ChIP-seq profiles of two primary KMT2A-MLLT3 AML samples: P1a (MECOM overexpression) and 
P2a (BRE overexpression). (B) ChIP-seq signal intensity at active promoter loci (H3K4me3/H3K27ac, left) 
and active enhancer loci (H3K4me1/H3K27ac, right) for samples P1a and P2a. (C) ChIP-seq and RNA-seq 
results at the BRE locus showing an intragenic active promoter (H3K27ac/H3K4me3, grey box) and enhanced 
expression of adjacent and downstream sequences in P2a but not P1a. (D) H3K4me3/H3K27ac ChIP-qPCRs 
at the BRE intragenic active promoter (int AP) over background (Myoglobin) in P2b and P1b. Four different 
qPCRs were used. (E) Normalized H3K4me3 signal at the BRE intragenic active promoter in 9 KMT2A-MLLT3 
profiles (n=6 BRE overexpression, n=3 MECOM overexpression). (F) Expression of BRE downstream and 
upstream exons relative to the intragenic active promoter based on RNA-seq data from three samples with 
BRE overexpression (P2a, P2b and P5) and three samples with MECOM overexpression (P1a, P1b and P3). 
(G) Expression of BRE exons 2-3, 3-4, 5-6 and 10-11 normalized to PBGD expression and a KMT2A-MLLT3 
AML sample with MECOM overexpression (calibrator sample, P3). AML cell lines: NB4, OCI-AML3 and THP-
1. (H) 5’ Rapid Ampliciation of cDNA Ends (5’ RACE) using BRE exon 8 reverse primer for cDNA synthesis 
and BRE exon 7 reverse primer for PCR. Samples 6955, 2184, 7416, 7178 and 6948 are from Valk et al., 
200421. (I) Schematic overview of the most abundant BRE transcript in blood cells (NM_199191) and the 
new BRE transcript. The new BRE transcript contains two potential translation start sites in exon 5 that are 
in-frame with the protein encoded by transcript NM_199191. RT-qPCR primers and probe used in Figure 1J 
are indicated. (J) Expression of the new BRE transcript (RT-qPCR) in indicated samples normalized to PBGD 
expression and a calibrator sample (P3). The novel BRE transcript was higher expressed in “Adult KMT2A-
MLLT3”, “Pediatric KMT2A-MLLT3”, “Pediatric KMT2A-MLLT10”, “FAB M4 AML”, “Adult KAT6A-CREBBP” and 
“Pediatric KAT6A-CREBBP” samples compared to “remaining AML” samples (p<0.004). Mal: malignancies.
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shown). Alternate BRE expression or the intragenic BRE H3K4me3/H3K27ac peak that we identified 
were not found in publically available databases (not shown). We conclude that high expression of 
the new BRE transcript is largely confined to KMT2A-rearranged and KAT6A-CREBBP AML and is not 
present in healthy hematopoietic or non-hematopoietic cells. 
Genome-wide intragenic promoter marks in BRE overexpressing KMT2A-MLLT3 AML
To examine whether intragenic transcription activation is unique for BRE, we performed genome-
wide analyses revealing ~7000 H3K4me3/H3K27ac intragenic peaks that were specific for cases with 
BRE overexpression (Figure 2A). To avoid false positives, we narrowed down the group of specific 
intragenic active promoters amongst others by including only those with a marked difference in the 
average H3K4me3 signal (Figures 2B,S3A-B). This analysis yielded intragenic active promoter marks 
that were unique to samples with BRE overexpression in 98 regions, residing in 90 genes (Figures 
2B,S3B,Supplementary Table 1). For MECOM overexpressing samples, similar filtering revealed eight 
(Figure S3A, Supplementary Table 1) specific intragenic active promoter regions. In conclusion, 
BRE overexpressing KMT2A-MLLT3 AML is characterized by specific genome-wide intragenic active 
promoters.
Genes with intragenic active promoter marks are activated 
in BRE overexpressing KMT2A-MLLT3 AML 
We analyzed the expression levels of the 90 genes with intragenic promotersin a large adult AML 
cohort.24 This showed significantly higher expression of these genes in BRE overexpressing samples 
as opposed to 11q23/KMT2A-rearranged MECOM overexpressing samples (p=0.015) and a trend 
towards higher expression compared to other genetically defined patient subsets (Figure 2C). 
Remarkably, RNA-seq profiles described above indicated that only 5 (BRE, PAN3, SMYD3, MS5A7 and 
TGM5) of the 90 genes with intragenic promoters had ≥2-fold increased expression of downstream 
versus upstream exons relative to their intragenic active promoter mark (not shown). These data 
suggest that intragenic active promoter marks are found in actively transcribed genes but do not 
necessarily cause transcription initiation at that position. 
The high expression of downstream SMYD3, PAN3 and TGM5 sequences in KMT2A-MLLT3 samples 
with versus without BRE overexpression was confirmed by qRT-PCR, but this was not found for 
KAT6A-CREBBP AML samples (Figure S3C). These results could imply that KAT6A-CREBBP and KMT2A-
MLLT3 AML do not harbor a similar genome-wide intragenic active promoter signature.
Figure 2. Genome-wide intragenic active promoter marks in BRE overexpressing primary KMT2A-
MLLT3 samples. (A) Overlap of intragenic active promoter peaks in KMT2A-MLLT3 patients with MECOM 
overexpression (P1a) and BRE overexpression (P2a, left). Overlap of intragenic H3K4me3 peaks including 
an additional five samples with high BRE expression and two samples with high MECOM expression (right). 
(B) Average H3K4me3 signal at 98 intragenic active promoter sites for nine KMT2A-MLLT3 AML samples 
(BRE overexpression n=6, MECOM overexpression n=3). (C) Expression of 90 genes containing 98 intragenic 
active promoter marks, in various subtypes of AML. (D) Average KMT2A signal at 98 intragenic promoter 
mark regions (Figures 2B,S3A) in a KMT2A-MLLT3 sample with BRE overexpression (P4). (E) Reporter assays 
showing Renilla normalized Firefly luciferase signal from a control vector (pGL3 basic), from the Hoxa7 
promoter and from three fragments of the new BRE promoter upon increasing concentrations of KMT2A-
MLLT3. Mean ± standard deviation. (F) Transcription factor family motifs enriched under 98 intragenic active 
promoter marks. (G) Differential expression of transcription factors belonging to enriched motif families 
(AP-2, C2H2 and ETS, panel F) in BRE overexpressing versus MECOM overexpressing samples. Red dots: 
(n=168) fold change>2; Orange dots: (n=23) fold change>2, Bonferonni adjusted p-value<0.05; Green dots: 
(n=35) fold change>4, Bonferonni adjusted p-value<0.01. Sig.: significant.
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KMT2A-MLLT3 transactivates the intragenic BRE promoter
To determine whether KMT2A-MLLT3 contributes to intragenic BRE transcription, gene reporter 
assays were performed. Both the Hoxa7 promoter (positive control), as well as BRE fragments 
containing sequences from +17 through +410 bp relative to the novel transcription start site were 
transactivated in a dose-dependent manner by KMT2A-MLLT3 whereas a fragment lacking region 
-133 through +17 bp was not transactivated (Figure 2D). To determine whether KMT2A or KMT2A-Figure 2
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fusion proteins regulate the 98 intragenic active promoter marks, we analyzed three KMT2A ChIP-
seq profiles,25 one from a primary KMT2A-MLLT3 sample with BRE overexpression and two from 
the KMT2A-rearranged cell lines THP-1 and MV4-11 (Figure S4A). KMT2A signals were enriched at 
the 98 intragenic active promoter marks in all three samples (Figures 2E,S4B). The level of KMT2A 
enrichment at the 98 intragenic promoter marks was similar to KMT2A enrichment in previously 
defined25 KMT2A-fusion binding sites in THP-1 and MV4-11 cells (Figure S4C-D). These data suggest 
that KMT2A/KMT2A-fusion proteins bind to the intragenic active promoter marks to contribute to 
high expression of the respective genes.
AP-2, C2H2-Znf, and ETS transcription factor motif enrichment at intragenic promoter marks
Since only part of the KMT2A-MLLT3 AML samples have BRE overexpression, other factors besides 
KMT2A-MLLT3 might be involved in expression of the new BRE transcript. To identify candidates that 
may bind intragenic active promoter marks, we performed transcription factor (TF) motif analysis. 
This showed enrichment of motifs for AP-2, C2H2-Znf, and ETS TF families (Figure 2F). RNA-seq data 
from two BRE and two MECOM overexpressing samples revealed significant differential expression of 
58 TFs belonging to these families (Figure 2G). Only two TFs were higher expressed in BRE compared 
to MECOM overexpressing samples (PLAG1 and ZNF595). Possibly, PLAG1 and ZNF595 are involved in 
enhancing transcription of the 90 genes with intragenic promoters.
A novel ins(11;2) fuses CHORDC1 to BRE exon 5
As described above, the BRE gene is actively transcribed from an intragenic promoter preceding exon 
5. To find other changes in BRE in AML, we screened an RNA-seq AML library (32 paired diagnosis-
relapse samples) for alterations in the BRE gene. Interestingly, an in-frame fusion transcript between 
CHORDC1 exon 5 (chromosome 11) and BRE exon 5 (chromosome 2) was found in a relapsed AML 
case. This fusion was confirmed by RT-PCR followed by Sanger sequencing and an insertion of 
chromosome 2 into 11 was confirmed by karyotyping (Figure 3A-B). The fusion of CHORDC1 to 
exon 5 of the BRE gene is remarkable, because protein translation of the new BRE transcript in 
cases with BRE overexpression may also start in exon 5. Thus, the predicted protein derived from 
both the fusion as well as the new BRE transcript may contain a similar C-terminal part of the BRE 
protein (Figure 3C). BRE and CHORDC1 were equally expressed in the diagnosis and relapse samples 
(stranded RNA-seq data, not shown). The CHORDC1-BRE fusion was not detected at diagnosis nor 
in 200 randomly selected de novo AML cases (not shown), indicating that this fusion is rare in de 
novo AML and may be associated with relapsed AML. Thus, leukemia-specific expression of the 
C-terminus of BRE may be caused by intragenic transcription activation or chromosomal insertions.
Discussion
Here, we report abnormal expression of C-terminal BRE sequences specific for AML, caused by 
distinct, non-random events; by a chromosomal insertion and by intragenic transcription initiation in 
11q23/KMT2A-rearranged and t(8;16)/KAT6A-CREBBP AML. The intragenic transcriptional activation 
cannot be explained by recurrent chromosomal abnormalities affecting the BRE locus itself, because 
the alternate transcript was expressed from both alleles. Instead, the oncofusion protein KMT2A-
MLLT3 could be involved in intragenic BRE activation. In KMT2A-MLLT3 AML harboring the intragenic 
BRE promoter, we observed active intragenic promoter marks in 89 additional genes. KMT2A/
KMT2A-fusion protein enrichment was observed at these promoter marks and the corresponding 
genes were overexpressed in KMT2A-rearranged AML. Moreover, KMT2A-MLLT3 activated the 
intragenic BRE promoter in reporter assays. These findings suggest that KMT2A-MLLT3 contributes 
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Figure 3. A novel t(11;2) translocation fuses CHORDC1 exon 5 to BRE exon 5. (A) Sanger sequencing of the 
CHORDC1-BRE fusion transcript. (B) Karyotype of AML at time of relapse: 46,XY,ins(11;2)(q14;p13p23)
[10] (C) Schematic representation of the full-length and predicted new BRE proteins, CHORDC1 and the 
CHORDC1-BRE fusion protein (UEV:Ubiquitin E2 variant, CHORD:Cysteine- and histidine-rich, CS:interaction 
module named after CHORD-containing proteins and SGT1). Amino acid numbers refer to proteins encoded 
by BRE transcript 3 (NM_199191) and CHORDC1 transcript 1 (NM_012124).
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to alternate transcription initiation in BRE. It should, however, be noted that especially in adult AML 
a significant number of patients with these two fusion oncoproteins lacks high expression of the 
new BRE transcript. Thus, intragenic BRE activation may be dependent on additional factors. Motif 
analyses of KMT2A-MLLT3 AML showed an overrepresentation of AP-2, C2H2-Znf, and ETS TF binding 
sites at intragenic promoter marks with C2H2-Znf TFs PLAG1 and ZNF595 being highly expressed in 
cases with BRE overexpression. It would be interesting to test the contribution of especially PLAG1 to 
alternate BRE expression, as PLAG1 has been implicated in AML development.26, 27
Earlier we reported that patients with BRE overexpression have a superior outcome compared 
to MECOM overexpressing patients. The unique 5’ end of the novel BRE transcript allows for reliable 
detection by RT-qPCR enabling an optimal recognition of both subtypes. Importantly, the association 
of alternate BRE expression with good clinical outcome appears to be restricted to KMT2A-rearranged 
AML, as patients with t(8;16)/KAT6A-CREBBP have a very dismal outcome in general.
KMT2A-MLLT3 and KAT6A-CREBBP may contribute to AML pathogenesis through altering gene 
expression.28-33 We observed that the genes with active intragenic promoter marks were bound 
by KMT2A/KMT2A-fusion proteins and indeed, the respective genes showed highest expression 
compared to other AML subtypes. These genes might represent a newly identified oncogenic 
program. It is tempting to speculate that alternate BRE contributes to this oncogenic program for 
various reasons. Abnormal BRE expression is exclusively observed in AML and caused by distinct 
mechanisms. The novel BRE transcript contains two translation start sites in exon 5 that could 
lead to N-terminally truncated BRE isoforms. The in-frame CHORDC1-BRE fusion includes a similar 
C-terminal part of BRE. BRE is required for proper function of the BRCA1-A and BRISC complexes, 
which are involved in DNA repair and cell cycle regulation.14,17-20,34,35 Another important constituent 
of these complexes is BRCC3. Mutations in BRCC3 and other components of these two complexes 
have recently been observed in myeloid malignancies, including AML.36 BRE overexpression is also 
found in other malignancies and correlates with higher grade tumors.37,38 In addition to AML, BRE 
has prognostic impact in breast cancer and a translocation including downstream BRE sequences 
has been observed in adrenocortical carcinoma.39,40 We conclude that it will be interesting to 
determine whether leukemia-specific alternate BRE transcripts contribute to disease pathogenesis.
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Supplementary Material
Supplementary Materials and methods
Cell culture
The AML cell lines HL-60, THP-1, NB4 and NOMO-1 were maintained in Rosswell Memorial Park 
Institute (RPMI) 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 
10% heat-inactivated fetal calf serum (FCS) at a density between 100’000 and 1’000’000 cells/ml 
(HL-60), 200’000 and 1’000’000 cells/ml (THP-1 and NB-4), or 400’000 and 1’5000’000 cells/ml 
(NOMO-1). OCI-AML3 cells were cultured in alpha-Minimal Essential Medium (alpha-MEM, Gibco) 
supplemented with 20% heat-inactivated FCS at a density between 500’000 and 1’500’000 cells/
ml. SKOV3 cells were maintained in McCoy’s 5a Medium (Gibco) supplemented with 10% heat-
inactivated FCS. 293FT cells (ThermoFisher) were cultured in Dulbecco’s Modified Eagles Medium 
(DMEM, Gibco) supplemented with 10% non-heat-inactivated FCS, 1% non-essential amino acids 
(Gibco), 1% L-glutamine (Gibco), 500 µg/ml geneticin (Gibco) and 1% penicillin-streptomycin 
(Gibco). All cell lines were maintained in a humidified incubator at 37˚ C in 5% CO
2.
RNA isolation, cDNA synthesis and RT-qPCR
Total RNA was extracted with TRIzol (Ambion, Thermo Fisher Scientific, Waltham, MA, USA), RNAsol 
(GenDepot, Gentaur, Kampenhout, Belgium) or the RNeasy mini kit (Qiagen, Hilden, Germany) 
according to standard procedures. Total RNA from 20 tissues was bought from Clontech (Saint-
Germain-en-Laye, France, liver, heart, fetal liver, stomach, adrenal gland, salivary gland, trachea, brain, 
uterus, thyroid, lung, skeletal, fetal brain, placenta, small intestine, spleen, thymus, kidney, prostate, 
and brain cerebellum). RNA was treated with DNAse (on Qiagen columns) and analyzed by strand 
specific sequencing, or RNA was reverse-transcribed using Superscript II or Moloney Murine Leukemia 
Virus (M-MLV) Reverse Transcriptase (RT) according to manufacturer’s instructions (Invitrogen). For 
quantitative Real Time Polymerase Chain Reaction (RT-qPCR), BRE, β-Actin, and PBGD cDNA was 
amplified using Taqman 2x Universal PCR Master Mix (Applied biosystems, Warrington, UK), SMYD3, 
TGM5, and PAN3 cDNA using SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) as 
recommended by the manufacturer, and MECOM cDNA using 1X buffer A (Thermo Fisher Scientific, 
Waltham, MA, USA), 4 mM MgCl
2, 0.125 mM dNTPs (GE Healthcare Life Sciences, Buckinghamshire, 
UK), and 1.25 U AmpliTaq Gold per reaction (ThermoFisher Scientific). BRE cDNA of exons 2-3, 
3-4, 5-6 and 10-11 as well as β-Actin cDNA was amplified using predeveloped primer/probe sets 
Hs00610425_m1, Hs01046287_m1, Hs01046288_m1, Hs01046283_m1 (all FAM-MGB) and 
4310881E (VIC-TAMRA), respectively (Life Technologies, Thermo Fisher Scientific). MECOM and PBGD 
cDNA was amplified using MECOM forward primer 5’-GGTCAACAAACCAATTTAGACAGACA, reverse 
primer 5’- TTCAGAATGAGGCGACGATGT and probe 5’-VIC- ATGGGAACATGTCCGGTAC-MGB and 
PBGD forward primer 5’-GCGGAGCCATGTCTGGTAA, reverse primer 5’-GGGTACCCACGCGAATCAC 
and probe 5’-VIC-CTCATCTTTGGGCTGTTTTCTTCC-TAMRA. cDNA of the new BRE transcript 
was amplified using forward primer 5’-GGATTGGTTGGGCTTGTTCA, reverse primer 
5’-CAAGTTCCTTCACCACAAGTAAGAGA and probe 5’-FAM-CACATAGAATCTTGCCTCC-MGB. The 
SMYD3 forward primer (5’-CCTTTTGCCCTGGTGGGATT) was located within the intragenic H3K4me3 
peak, in an intron ~257 kb upstream of the next annotated exon indicated by UCSC (RefSeq Genes), 
where the reverse primer (5’-CCTGCATCTCCGCATTACAGA) was located. TGM5 and PAN3 primers 
were located in previously defined exons downstream of the intragenic H3K4me3 peak - forward 
primer 5’-ATGGATAGTTTGGGCAGCGT and reverse primer 5’-CTTGGGGGAATGAAGAGGGG (PAN3) 
and gene expression assay Hs00909973_m1, FAM-MGB (TGM5, Life Technologies). RT-qPCR was 
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performed in the 7500 Real Time PCR System (Applied Biosystems). The amplification efficiency 
(E) of BRE and PBGD RT-qPCRs was determined using the slope of a standard curve, E=10(-1/slope). 
Expression levels were calculated with the delta delta CT method, for BRE quantification taking 
these efficiencies into account. A standardized SKOV3/HL60 cDNA series was taken along in each RT-
qPCR to determine which samples had high MECOM expression. Data were analyzed using 7500 Fast 
System Software v1.3.1 (Applied Biosystems).
Publically available databases
Alternate BRE expression, CAGE signal or the intragenic BRE H3K4me3/H3K27ac peak that we 
identified were not found in primary hematopoietic cells in publically available databases BLUEPRINT, 
Roadmap, Expressed Sequence Tags, ENCODE, CODEX, Fantom.
RT-PCR CHORDC1-BRE
The CHORDC1-BRE fusion was confirmed by cDNA amplification using the primers: forward 
5’-TGCCTCCCTAAAACAAGCAC (CHORDC1 exon 5) and reverse 5’- GCGGCTACATTGGAATTGGT-3’ 
(BRE exon 5) in 0.4mM dNTP, 15 pmol primers, 2mM MgCl2, Taq polymerase and 1x buffer (Thermo 
Fisher, Walthan, MA). Cycling conditions: 1 cycle 5’ 94˚C, 35 cycles 1’ 94˚C, 1’ 58˚C/1’ 60˚C/1’ 62˚C, 
1’ 72˚C, and 1 cycle 7’ 72˚C. The PCR products were purified using MultiScreen plates (Merck 
Millipore, Amsterdam, the Netherlands) and sequenced on the ABI PRISM 3100 genetic analyzer 
(Thermo Fisher). 
5’ Rapid Amplification of cDNA Ends (5’ RACE)
5’ RACE was performed as recommended by the manufacturer (Thermo Fisher). In brief, 1.4 µg of 
RNA was reverse transcribed using a reverse primer in BRE exon 8 5’-CTCCTCCTGGAAAAGCTGGG. 
For one of the samples with BRE overexpression, a control was taken along where the Superscript 
II reverse transcriptase was replaced by water. After cDNA synthesis, RNA was digested using 
RNAse mix (RNase H and RNase T1) and the sample was purified by S.N.A.P. column isolation. A 
poly-C tail was added to the 3’ end of the single stranded BRE cDNA using TdT and dCTPs. Finally, 
the 3’ end of the cDNA (originating from the 5’ end of the transcript) was amplified by Taq DNA 
polymerase using a deoxyinosine-containing anchor primer and the BRE exon 7 reverse primer 
5’-GCCACATCTTCTCCAGGGTC. Amplification was as follows: (1) preincubation at 94˚ C for 2 
minutes, (2) 35 cycles of denaturation at 94˚ C for 1 minute, primer annealing at 55˚ C for 1 minute 
and elongation at 72˚ C for 2 minutes, (3) final extension at 72˚ C for 7 minutes. 5’ RACE PCR 
products were ligated into a linear pDrive plasmid (Qiagen PCR Cloning kit). Various PCR product-
to-vector ratios were used to allow efficient ligation of PCR products with different sizes (10, 15 
and 20 times molar excess based on 450 bp PCR product) overnight at 16˚ C. Blue-white selection 
of colonies using 0.8 mg X-gal (Applichem, Boom B.V., Meppel, the Netherlands) and 2 mmol 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, Life Technologies) per ampicillin (Sigma Aldrich) Luria-
Bertani-agar plate (BD Biosciences) allowed for selecting colonies with insert. White colonies were 
inoculated in 3 ml Luria-Bertani medium (BD Biosciences) containing 50 µg/ml ampicillin sodium 
salt (Sigma-Aldrich). DNA was extracted using the Nucleospin Gel and PCR clean-up kit (Machery-
Nagel, Bioké, Leiden, the Netherlands) and the insert was Sanger sequenced using primers 
5’-CAGGAAACAGCTATGAC and 5’-GTAAAACGACGGCCAGT.
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Luciferase reporter assays
293FT cells (ThermoFisher) were cultured in Dulbecco’s Modified Eagles Medium (DMEM, Gibco) 
supplemented with 10% non-heat-inactivated FCS, 1% non-essential amino acids (Gibco), 1% 
L-glutamine (Gibco), 500 µg/ml geneticin (Gibco) and 1% penicillin-streptomycin (Gibco). Dual 
luciferase reporter assays were performed similarly as described before.1 In brief, 293FT cells 
were seeded into 24 wells plates at 30% confluency. 24 hours later, cells were transfected using 
lipofectamine (Invitrogen) and 0.8 µg pGL3-basic Luciferase Firefly vector (pGL3-basic, pGL3-Hoxa7 
promoter2 or pGL3-new BRE promoter -633 through 410 bp / -133 through 410 bp / -133 through 
17 bp relative to the transcription start site of the novel BRE transcript) and 0.4 µg pGL3-basic 
Renilla Firefly vector. A total of 0.8 µg pcDNA vector (empty vector and/or KMT2A-MLLT3-FLAG) was 
transfected. pcDNA KMT2A-MLLT3-FLAG was added in increasing concentrations: 0, 0.1, 0.25, 0.5 
and 0.75 µg DNA. 48 hours after transfection, medium was aspirated, cells were washed with PBS 
and lysed using 100 µl passive lysis buffer provided by the manufacturer (Dual-Luciferase Reporter 
Assay System, Promega, Madison, WI, USA). Luciferase signal from 1 µl lysate was detected 
using 10 µl LAR II and 10 µl Stop&Glo (Dual-Luciferase Reporter Assay System, Promega) on the 
Fluostar Optima. Experiments were perfomed six times, in duplicate. A two-sided paired t-test 
was performed to determine statically different normalized Firefly luciferase signal between the 
experimental promoter and pGL3 basic empty vector (GraphPad Prism 5).
ChIP and ChIP-seq
Chromatin from cell lines was harvested as described.3 ChIPs were performed using antibodies 
against KMT2A, H3K4me1, H3K4me3 and H3K27ac and analyzed by quantitative PCR or sequencing. 
Primer sequences used for ChIP-qPCR are provided in Supplementary Table 2. Relative occupancy 
was calculated as fold over background, for which the promoter of the Myoglobin gene was used.
Cells were crosslinked with 1% formaldehyde for 20 min at room temperature, quenched with 
0.125 M glycine and washed with three buffers: (i) PBS, (ii) 0.25% Triton X 100, 10 mM EDTA, 0.5 
mM EGTA, 20 mM HEPES pH 7.6 and (iii) 0.15 M NaCl, 10mM EDTA, 0.5 mM EGTA, 20mM HEPES 
pH 7.6. Cells were then suspended in ChIP incubation buffer (0.15% SDS, 1% Triton X 100, 150 mM 
NaCl, 10 mM EDTA, 0.5 mM EGTA, 20mM HEPES pH 7.6) and sonicated using a Bioruptor sonicator 
(Diagenode) for 20 min at high power, 30 s ON, 30 s OFF. Sonicated chromatin was centrifuged at 
maximum speed for 10 min and then incubated overnight at 4° C in incubation buffer supplemented 
with 0.1% BSA with protein A Dynabeads (Thermo Fisher Scientific) and 2 µg of antibody. Beads 
were washed sequentially with four different wash buffers at 4˚ C: two times with a solution of 0.1% 
SDS, 0.1% DOC, 1% Triton, 150 mM NaCl, TEE (10mM Tris pH 8, 0.1mM EDTA and 0.5mM EGTA), one 
time with a similar buffer but now with 500 mM NaCl, one time with a solution of 0.25 M LiCl, 0.5% 
DOC, 0.5% NP-40, TEE and two times with TEE. Precipitated chromatin was eluted from the beads 
with 400 μl of elution buffer (1% SDS, 0.1 M NaHCO
3) at room temperature for 20 min. Protein-DNA 
crosslinks were reversed at 65° C for 4 h in the presence of 200 mM NaCl, after which DNA was 
isolated by Qiagen column. For qPCR, relative occupancy was calculated as fold over background, 
for which the promoter of the Myoglobin gene was used.
Illumina high-throughput sequencing
ChIP-seq libraries were prepared from precipitated DNA of 5 million cells (5-8 pooled biological 
replicas) for KMT2A, or from 1 million cells for the histone tail modifications. End repair was 
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performed using Klenow and T4 PNK. A 3’ protruding A base was generated using Taq polymerase 
and adaptors were ligated. The DNA was loaded on E-gel and fragments corresponding to ~300 bp 
(ChIP fragment adaptors) were excised. The DNA was isolated, amplified by PCR and used for cluster 
generation and sequencing on the Genome Analyzer (Illumina) or HiSeq 2000 (Illumina). 
For RNA-seq, total RNA was extracted by TRIzol (Invitrogen), subjected to on-column DNase 
treatment (Qiagen) and the concentration was measured with a Qubit fluorometer (Invitrogen). 
250 ng of total RNA was used with the Ribo-Zero rRNA Removal Kit (Illumina) to remove ribosomal 
RNAs according to manufacturer instructions. 16 µl of purified RNA was fragmented by addition of 
4 µl 5x fragmentation buffer (200 mMTris acetate pH 8.2, 500 mM potassium acetate and 150 mM 
magnesium acetate) and incubated at 94° C for exactly 90 s. After ethanol precipitation, fragmented 
RNA was mixed with 5 μg random hexamers, followed by incubation at 70° C for 10 min and chilling 
on ice. We synthesized first-strand cDNA with this RNA primer mix by adding 4 μl 5X first-strand 
buffer, 2 μl 100 mM DTT, 1 μl 10 mM dNTPs, 132 ng of actinomycin D, 200 U SuperScript III, followed 
by 2 h incubation at 48° C. First strand cDNA was purified by Qiagen mini elute column to remove 
dNTPs and eluted in 34 μl elution buffer. Second-strand cDNA was synthesized by adding 91.8 μl, 5 
μg random hexamers, 4 μl of 5X first-strand buffer, 2 μl of 100 mM DTT, 4 μl of 10 mM dNTPs with 
dTTP replaced by dUTP, 30 μl of 5X second-strand buffer, 40 U of Escherichia coli DNA polymer¬ase, 
10 U of E. coli DNA ligase and 2 U of E. coli RNase H, and incubated at 16° C for 2 h followed by 
incubation with 10 U T4 polymerase at 16° C for 10 min. Double stranded cDNA was purified by 
Qiagen mini elute column and used for library preparation as described in the KAPA Hyper Prep 
protocol. We incubated 1 U USER (NEB) with adaptor-ligated cDNA at 37° C for 15 min followed by 
5 min at 95° C before PCR to ensure strand specificity.
All data can be downloaded from the Gene Expression Omnibus GSE89336, GSE798994 or through 
the BLUEPRINT DCC (http://dcc.blueprint-epigenome.eu/#/home).
Stranded RNA sequencing of a diagnosis and relapse AML sample pair
Mononuclear cells were isolated by ficoll separation of a diagnostic and relapse bone marrow 
sample of a single AML patient. At diagnosis the male 53 year old patient had an AML FAB-M1 (83% 
blasts) with a normal karyotype (46,XY[23]) and a homozygous RUNX1 mutation (R174Q) and a 
FLT3 internal tandem duplication (ITD). The patient relapsed after 344 days with a AML FAB-M0 (5% 
blasts) with karyotype 46,XY,ins(11;2)(q14;p13p23)[10] and the same RUNX1 mutation and FLT3 ITD, 
both homozygous at relapse. Total RNA was extracted using RNAbee reagent (BioConnect, Huissen, 
NL). RNA concentration was measured using the NanoDrop (OD260/280 1.8-2.0). 
The RNA sample was diluted to concentration of 0.1 – 1µg. Ribosomal RNA was depleted according 
to manufacturer’s protocol (TruSeq Stranded Total RNA, Illumina Inc.). The purified RNA was then 
sheared into small fragments (app. 200 bp) and these fragments were then reverse-transcribed into 
first strand cDNA using Super script II and random primers (Thermo Fisher, Waltham, MA). Second 
strand cDNA synthesis was carried out using DNA polymerase and RNaseH. Subsequently, adaptors 
were ligated, the library was amplified by PCR, normalized, pooled and run on Illumina HiSeq2000, 
according to manufacturer’s recommendation (Illumina, San Diego, CA).
Quality control of the sequencing run was assessed by using ShortRead. The alignment to the 
reference genome was accomplished using Bowtie2 with TopHat2. The Human Genome version 19 
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(hg19) (Santa Cruz (UCSC), CA) was used as the reference genome. SAMtools was used to index the 
compressed binary format (BAM) files outputted by TopHat2 and the Integrative Genomics Viewer 
(IGV) was used for visualization of the aligned paired-end reads and assessment of possible novel 
fusions. Read counts per gene were retrieved using HTSeq-count, removing counts below 10, using 
the default mode union. Defuse was used to detect fusion genes. 
Bioinformatic analyses
Alignment
Tags were mapped to the reference human genome hg19 using the Burrows-Wheeler Alignment 
Tool (BWA) for ChIP-seq or TopHat2 (Bowtie2) for RNA-seq samples. SAMtools was used for creation 
and manipulation of BAM files for each experiment. Before downstream use, duplicates reads 
and reads with a MAPQ<15 were discarded for ChIP-seq samples. For RNA-seq, only reads with 
MAPQ<15 were discarded. For ChIP-seq visualization, the number of overlapping sequence reads 
was determined per base pair, averaged over a 10 bp window and visualized in the UCSC genome 
browser (http://genome.ucsc.edu). For strand specific RNA-seq visualization, separate tracks were 
created for both strands, which were displayed in pairs using UCSC trackHubs.
Peak calling
Peak calling software MACS2 was used to detect binding sites with a q-value cut off of 1e-6 or 1e-9.
Tag counting
Tags within a given region were counted and adjusted to represent the number of tags within a 1 kb 
region. Subsequently the percentage of these tags as a measure of the total number of sequenced 
tags of the sample was calculated and displayed as heat maps with the Fluff package or as average 
profiles with ngs.plot software.
Peak distribution analysis
To determine genomic locations of binding sites, corresponding peak files were analyzed using a 
script that annotates binding sites according to all RefSeq hg19 genes. With this script every binding 
site is annotated either as promoter (2000 bp window around the Transcription Start Site), exon, 
intron or intergenic (everything else).
Expression analysis
Normalized (RPKM) values for all refSeq hg19 genes were calculated using HOMER2 analyzeRepeats 
software.
Motif analysis 
Peaks were culled to 300 bp, and used with Gimme Motifs5 software to determine underlying 
known transcription factor motifs. Motifs were subsequently grouped into motif families and their 
relative occurrence as opposed to motifs called from genomic annotation and length matched 
random regions.
Statistical analyses of micro-array and RT-qPCR data
The expression of several genes was studied in a Affymetrix HG-U133 plus 2.0 microarray dataset 
containing 525 AML samples, 11 CD34 donor and 5 normal bone marrow (BM) control samples that 
we published before.6 A two-sided Mann-Whitney U test was performed to determine statically 
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different median expression (micro-array or RT-qPCR data) between sample groups (GraphPad 
Prism 5 and R v3.2).
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Supplemental Figures
Figure S1. Validation of ChIP-seq profiles and visualization of the MECOM locus. (A) Genomic distribution 
of active promoter (left) and active enhancer peaks (right) in KMT2A-MLLT3 AML samples from P1a 
(MECOM overexpression) and P2a (BRE overexpression). Random: genomic distribution of length matched 
random regions. (B) Overlap of active promoter (left) and active enhancer peaks (right) in KMT2A-MLLT3 
AML samples from P1a and P2a. (C) Average signal of H3K4me3, H3K27ac, and H3K4me1 at common and 
unique active promoter (AP, left) and active enhancer peaks (AE, right) in samples P1a and P2a. P1a specific 
enhancers are characterized by increased H3K27ac as compared to P2a, while P2a specific enhancers are 
characterized by increased H3K4me1. (D) ChIP-seq results of P1a and P2a on the MECOM locus showing 
more pronounced active promoter and active enhancer marks on annotated promoters in the sample with 
MECOM overexpression (P1a), but not in the sample with BRE overexpression (P2a). (E) H3K4me3, H3K27ac 
ChIP-seq and RNA-seq results from nine, one and four primary KMT2A-MLLT3 AML samples on the MECOM 
locus, respectively. Samples P1a, P1b and P3 have MECOM overexpression, samples P2a, P2b, P4-7 have BRE 
overexpression.
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Figure S2. H3K4me3 ChIP-qPCR and ChIP-seq results on the BRE and HOXA loci. (A) H3K4me3 ChIP-qPCR 
occupancies at the BRE intragenic promoter in BRE overexpressing NOMO-1 and normal BRE THP-1 cells. 
Four different qPCRs were used that were within the BRE intragenic active promoter (int AP) as identified 
by ChIP-seq.  RT-qPCR showed that NOMO-1 had high expression and THP-1 had low expression of the new 
BRE transcript (656 and 2, respectively, compared to calibrator sample as in Figure 1J, data not shown). (B) 
H3K4me3 ChIP-seq results from nine KMT2A-MLLT3 AML samples on the BRE locus. Samples P1a, P1b and 
P3 have MECOM overexpression, samples P2a, P2b, P4-7 have BRE overexpression. (C) H3K4me3 ChIP-seq 
results from nine KMT2A-MLLT3 AML samples (P1a-P7) on the HOXA locus.
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Figure S3. Genome-wide detection of BRE overexpression specific intragenic promoter marks and qRT-PCR 
on genes with intragenic transcription initiation. (A) This figure was based on all intragenic active promoter 
marks (H3K4me3 and H3K27ac peaks) in P1a and P2a. To determine subgroup specific intragenic active 
promoter marks, the other seven H3K4me3 profiles were added to the analysis. Green bars show all 
intragenic (active) promoter marks overlapping in at least 4/6 BRE overexpressing samples or 2/3 MECOM 
overexpressing samples. Orange bars show the number of overlapping intragenic active promoter marks 
with a higher normalized H3K4me3 signal in MECOM overexpressing versus BRE overexpressing samples 
or vice versa. Purple bars show the number of overlapping intragenic active promoter sites with a >8-
fold higher normalized H3K4me3 signal in samples with MECOM overexpression versus samples with BRE 
overexpression or vice versa. (B) Left: Average H3K27ac signal at 98 regions with BRE overexpression specific 
intragenic active promoter marks. Middle and right: Average H3K4me3 (middle) and H3K27ac (right) signal 
at 68 intragenic active promoter sites with a higher H3K4me3 signal in MECOM overexpressing samples than 
BRE overexpressing samples (log2(signal ratio)>0 as depicted in (A)) showing that these intragenic active 
promoter marks are not specific for MECOM overexpressing samples. Thus, the log2(signal ratio)>3 (more 
than 8-fold higher H3K4me3 signal) filtering step is required to determine subgroup specific active promoter 
regions. (C) SMYD3 (left), TGM5 (middle) and PAN3 (right) RT-qPCR results of KMT2A-MLLT3 and KAT6A-
CREBBP samples with high (>500 versus calibrator sample in Figure 1J) versus low (<500 versus calibrator 
sample in Figure 1J) expression of the new BRE transcript.
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Figure S4. KMT2A occupancy at previously identified KMT2A-MLLT3 targets and at genome-wide intragenic 
active promoter marks specific for samples with BRE overexpression. (A) KMT2A ChIP-seq signal at the HOXA 
locus in BRE overexpressing patient P4. (B) Average KMT2A signal at 98 intragenic active promoter marks 
specific for BRE overexpressing samples in KMT2A-MLLT3 cell line THP-1 and KMT2A-AFF1 cell line MV4-11, 
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General objectives
In this thesis, we set out to characterize the genome-wide binding patterns of various onco-fusion 
proteins, in order to assess their impact on the hematopoietic gene expression program. This 
program can be affected by an onco-fusion protein either directly or via manipulation of epigenetic 
patterns such as histone modifications. Furthermore, we aim to distill from the data gathered for 
the individual onco-fusions a more general mechanism of leukemogenesis, and to identify common 
factors and/or pathways affected in a plurality of genomic translocation induced AMLs.
Aims of this thesis
As we discuss in chapter 1, acute myeloid leukemia is a heterogonous disease which in many 
cases is not caused by a single point mutation but rather by a chromosomal aberration such as 
translocations, inversions or deletions. Expression of fused or truncated oncogenic proteins from 
these aberrant loci can lead to a disruption of several pathways within the hematopoietic gene 
program, leading to leukemic transformation. Often, the genes involved in these chromosomal 
aberrations are epigenetic modifiers or transcription factors active during normal hematopoietic 
development. Therefore, we discuss in chapter 1 the importance of using genome-wide techniques 
to evaluate the differences in the epigenetic landscape and transcription factor binding between 
various types of leukemia and normal hematopoietic cells, in order to elucidate the mechanisms 
and pathways responsible for leukemic development. In subsequent chapters, we utilize these 
techniques to obtain individual oncogene characteristics. Here, we specifically look at the FUS-ERG 
(chapter 2), AML-ETO (chapter 3), and MLL (chapters 4 and 5) onco-fusion proteins. 
We will discuss these oncogenes first individually followed by their common features to 
understand the general mechanisms associated with leukemic transformation. Lastly, we will 
discuss the pitfalls of current and the possibilities for future research in this field.
Functional analysis of individual oncogenes
The ETS family of transcription factors, including such proteins as ERG and RUNX1, is implicated 
in various subtypes of acute myeloid leukemia. Expression of the FUS-ERG fusion protein arising 
from t(16;21)p(11;q22) in normal human myeloid progenitors has been shown to result in a block 
of development at the promyelocytic stage1, an arrest in erythroid and myeloid differentiation and 
an increase in proliferation and self-renewal capacity of human myeloid progenitors1. However, 
these transduction experiments can only partially recapitulate the disease state2. In chapter 2, we 
therefore describe for the first time the molecular mechanisms underlying the actions of the FUS-
ERG onco-fusion in AML at a genome-wide level in patient derived cell line models. We found that 
this onco-fusion is expressed at similar levels as wt ERG, and might interfere with normal ETS factor 
regulation. We discovered that the onco-fusion protein occupies genomic regions bound by ERG, 
RUNX1, FLI1, GATA2, LMO2, LYL1, TAL1/SCL, which together form a heptad of transcription factors 
associated with stem cell programs and clinical outcome in acute myeloid leukemia, suggesting the 
expression of FUS-ERG might interfere with the activity but not the assembly of this heptad.
In addition, we identified binding of the nuclear receptor heterodimer RARα-RXR to FUS-ERG 
occupied genomic regions, suggesting the onco-fusion protein might be involved in modulating 
the retinoic acid response. Treatment of t(16;21) cells with All-Trans Retinoic Acid resulted in cell 
differentiation as exemplified by increased expression of the myeloid differentiation markers CD11b 
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and CD383,4. Prolonged treatment with ATRA resulted in apoptosis consistent with the onset of 
post-differentiation cell death. Together these results suggest that ATRA triggers differentiation and 
thereby stops self-renewal in t(16;21) AML cells. Thus far only APLs are unique among leukemias 
due to their sensitivity to ATRA5. However, our results would suggest that also for t(16;21) AMLs 
ATRA treatment might provide an entry point for eradicating the leukemic cells.    
Our genome-wide profiling revealed that upon ATRA treatment FUS-ERG binding is lost at 
enhancers and promoters, correlating with increased ERG binding at enhancers and loss of RNAPII 
binding at promoters. RNAPII loss at promoters likely reflects transcriptional initiation corroborating 
the RNA-seq analysis that revealed increased transcription of a majority of FUS-ERG target genes. 
Together, these results suggest FUS-ERG might act as a transcriptional repressor. 
To further test this we performed knock down of FUS-ERG in t(16;21) cells and could show that 
loss of the onco-fusion protein results in higher expression of a subset of 138 genes that are also 
higher expressed after ATRA treatment. Interestingly, functional analysis of this gene set revealed 
enrichment for myeloid differentiation programs, corroborating at the gene level the FUS-ERG 
imposed block of retinoic acid induced differentiation. 
The repressive activities of FUS-ERG towards myeloid differentiation genes, including master 
regulators of hematopoiesis such as SPI1, GATA2, GFI1, JUNB or JUNC mimics the molecular effects 
previously reported for other onco-fusion proteins such as AML1-ETO6 and PML-RARα7,8, which 
target many of the same genes as FUS-ERG. Both AML1-ETO and PML-RARα have been shown 
to multimerize and recruit histone deacetylase (HDAC) activities in order to repress target gene 
transcription9-13. As FUS-ERG binding sites harbor multiple ETS consensus sequences and the onco-
fusion protein through its FUS domain might also have oligomerization capacity14, it is tempting to 
speculate FUS-ERG might use a similar mechanism to inhibit transcription. 
Together our results from chapter 2 reveal that FUS-ERG has a key role in t(16;21) AMLs through 
aberrant regulation of the ATRA response and inhibiting differentiation along the myeloid lineage.
To further elucidate the role of the RUNX1 program in the development of acute myeloid 
leukemia, we next investigated the molecular mechanism(s) of AML1-ETO (RUNX1-RUNX1T1) in 
leukemogenesis. Therefore, we analyzed gene expression and the epigenome of t(8;21) patient 
cells and t(8;21) cell lines together with the AML1-ETO/RUNX1 proteome in chapter 3.
We revealed in t(8;21) patient blasts AML1-ETO binding to both promoter and distal elements 
and that each type of binding is associated with specific chromatin characteristics. Promoter 
binding sites are high in acetylation and associated with expressed genes whereas distal sites are 
reduced in acetylation and linked with lowly expressed genes. Interestingly, despite low levels 
of acetylation these distal regions are not enriched for other repressive marks, suggesting lower 
expression is mostly related to reduced acetylation. We did not observe differences in the p300/
HDAC balance at promoters and distal regions, although occupancy was generally higher for both 
p300 and HDACs at promoter regions. These results suggest that additional factors are involved in 
regulating the acetylation output at AML1-ETO binding sites. Using genome-wide binding analysis 
we demonstrate that at AML1-ETO promoter binding sites occupancy of the transcription factors 
LMO2 and LYL1 is low whereas at distal sites increased presence of LMO2 and LYL1 is observed. It is 
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tempting to speculate that differential binding of these factors is involved in repressing acetylation 
at AML1-ETO distal regions. This would be supported by the observation that knock down of AML1-
ETO results in decreased binding of LMO2 and increased the expression of associated myeloid 
lineage differentiation genes15.
Our genome-wide analysis also suggests that AML1-ETO and RUNX1 bind genomic regions 
occupied by both HDACs and p300. However, also mutually exclusive binding of RUNX1/p300 and 
AML1-ETO/HDACs has been reported15. Our re-ChIP experiments could show co-occupancy of 
AML1-ETO/RUNX1 as well as AML1-ETO/p300 and AML1-ETO/HDACs at similar genomic locations. 
Although these findings would be in line with other studies suggesting AML1-ETO/RUNX116 and 
AML1-ETO/p300 co-occupancy at single loci17, here, as well as in the other studies, only a limited 
number of regions were included in the re-ChIP experiments and no genome-wide re-ChIP analysis 
was performed.
To better understand the activating and repressive nature of AML1-ETO at protein-DNA level we 
performed, in addition to ChIP-seq analysis, DNA pull downs using t(8;21) cell lysates and RUNX1 motif 
containing oligos. Apart from previously identified AML1-ETO interactors such as the transcription 
factors LYL1 and LMO2 and the deacetylases HDAC1 and HDAC2 we also identified several proteins 
involved in RNA splicing (for example several RBMs and SRSFs), suggesting that the RNA processing 
machinery is directly linked to the transcription regulation machinery and deregulated by AML1-
ETO. Interestingly, recent mutational analysis in a large cohort of AMLs identified splicing factors as 
commonly mutated in AMLs18, suggesting deregulation of this machinery might be a general feature 
of AMLs and also involved in t(8;21) leukemogenesis. 
Motif analysis of the patient blasts’ AML1-ETO binding regions revealed the presence of 
ETS motifs, in line with reports that ETS factors are involved in AML1-ETO leukemogenesis6,19. 
Interestingly, we did not find ETS factors in our RUNX1 motif pull down analysis suggesting protein-
protein interaction is not sufficient to interact with the RUNX1 or AML1-ETO complex, but the 
additional presence of a DNA consensus binding site is required in order to stabilize interaction with 
these complexes. 
An ETS factor of particular interest is ERG, as it is part of the FUS-ERG onco-fusion as discussed in 
chapter 2, is required for definitive hematopoiesis and self-renewal of hematopoietic stem cells20,21, 
and showed co-occupancy with AML1-ETO at all binding sites in t(8;21) cell lines and blasts. 
Moreover, so far no mutation has been reported for ERG in t(8;21) leukemogenesis, underscoring 
that its activity might be essential for AML1-ETO leukemogenesis. Interestingly, upon knockdown 
of ERG in t(8;21) cells we observed an increase in sub-G1 cells, indicative of apoptosis onset. In 
addition, we could corroborate previous reports that upon RUNX1 knockdown a similar phenotype 
was observed22, and that a delicate balance of RUNX1 and AML1-ETO is essential for leukemic 
maintenance of Kasumi-1 cells. Perturbation of this equilibrium by depletion of AML1-ETO leads to 
loss of self-renewal, whereas knockdown of RUNX1 results in apoptotic cell death22,23. Here, our ERG 
knockdown results suggest that apart from RUNX1 and AML1-ETO, t(8;21) cells are also dependent 
on ERG expression and as such, in addition to RUNX1, are also ERG addicted.   
We confirmed the dependency on AML1-ETO/RUNX1 balance by generating a stable inducible 
RUNX1 knockdown system in Kasumi-1 cells, and suggest that increased expression of AML1-ETO 
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might be linked to the induced apoptosis program. The present study demonstrates that not only 
knockdown of RUNX1, but also knockdown of ERG upregulates AML-ETO expression and thus 
interferes with the AML-ETO/RUNX1 equilibrium, possibly resulting in more AML-ETO binding to 
RUNX1 target genes or redistribution of AML1-ETO binding, as suggested previously15. 
Using a novel iPSC model system, we verified that overexpression of AML-ETO induces cell 
death, suggesting that only a specific dose of AML1-ETO relates to leukemogenesis, corroborating 
previous findings24,25. In addition, the link between oncogene overdose, i.e. higher expression of 
AML1-ETO, and increased apoptosis, corroborates previous studies of inherent pro-apoptotic 
activities of AML1-ETO26 and an anti-apoptotic role for RUNX122. Oncogene overdose is a relatively 
new concept highlighted in particular by recent studies of mutant-BRAF in melanoma and the fusion 
kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) in anaplastic large cell lymphoma27. 
To our knowledge this concept, which is based on mutated kinases, has not been reported for AML 
associated oncogenes nor extended to mutated transcription factors.
Importantly, we could show that double knockdown of either RUNX1 and AML1-ETO or ERG and 
AML1-ETO rescues the cells from apoptosis, further illustrating the critical role of increased AML1-
ETO expression in apoptosis induction and the importance of a finely tuned AML1-ETO/RUNX1 and 
AML1-ETO/ERG expression equilibrium. Corroborating these results are previous observations in 
SKNO-1 cells selected for stable continuous ERG knockdown in which reduced AML1-ETO expression 
(as compared to wildtype SKNO-1 cells) was observed6, which suggested that only sub clones that in 
addition to reduced ERG also harbored low AML1-ETO could survive selection. 
Together our results from chapter 3 show that a delicate balance of AML-ETO, RUNX1 and 
ERG expression is required for leukemic maintenance. Altering this balance might be used as a 
therapeutic entry point to induce apoptosis in t(8;21) cells.
In chapter 4, we moved on to investigate the genome wide binding and epigenetic signature of 
MLL-AF9, MLL-AF4, and wild type MLL in AML derived cell lines carrying the respective MLL-fusions. 
Enrichment of H3K79me2, H3K27ac, and RUNX1 signal was high on both MLL-AF9 and MLL-AF4 
target genes. Enrichment of H3K79me2 confirms that deposition of this histone modification on 
aberrantly activated MLL-fusion target genes is also a feature of MLL-AF4 induced AML, as was 
shown for MLL-AF4 in murine and human ALL models28,29. Deposition of H3K79me2 is possibly 
deregulated in all MLLr acute leukemias involving a component of the SEC, via indirect association 
of the SEC with DOT1L via AF9 or ENL30,31. However, as H3K79me2 is enriched on all activated genes 
in general, and not just on aberrantly activated MLL-fusion targets, inhibiting DOT1L function to 
non-specifically stop H3K79me2 deposition32,33 may introduce deleterious off-target effects.
Enrichment of H3K27ac on aberrantly activated MLLr target gene promoters -and BRD4 being 
an MLLr target- corroborates the facilitating role of bromodomain proteins in transcription of MLLr 
targets34, as evident from AML susceptibility to BET inhibition35. This suggests a positive feedback 
loop where transcription of MLLr targets is facilitated by BRD4, and BRD4 is transcribed because it 
is an MLLr target.
The large overlap between MLLr and RUNX1 binding sites and the identification of RUNX1 as an 
MLLr target gene suggests that MLLr AML deregulates a (subset of) the RUNX1 program, important 
163
Discussion
 
for hematopoietic development36. This is reminiscent of the way the CBFβ-MYH11 oncofusion 
modulates expression of RUNX1 targets37 and AML1-ETO can increase expression of a subset of 
RUNX1 targets38,39. Together with aberrant expression of genes such as MYC in most AML subtypes40,41 
this hints at the existence of a core set of genes, including a subset of the RUNX1 program, that is 
important for leukemic transformation and maintenance in translocation induced AML.
In addition to MLL-fusion binding to promoter regions as expected by the consensus of MLLr 
acting through aberrant activation of MLL target genes, we determined a significant number of 
MLL-fusion binding sites at active distal regulatory elements enriched for H3K27ac, H3K79me2, 
and RUNX1, and in close proximity to genes enriched for pathways related to leukemia. In light of 
this, it seems likely that MLLr does not only act directly on their target genes but can also modulate 
expression of target genes via distal regulatory elements. The MLL-AF4 and MLL-AF9 bound 
enhancers showed almost no overlap, indicating that each MLLr subtype has a distinct enhancer 
repertoire. This is in line with several studies linking differences in acquired and innate resistance 
to BET inhibition in various AML cell lines and different clones to a dynamic or variable enhancer 
landscape42,43. 
Moreover, MLL-AF9 bound enhancers are enriched for CTCF binding, which is in line with MLLr 
AML cells being responsive to treatment with mediator kinase inhibitors44. This suggests an active 
role for MLL-AF9 in modulating the chromatin conformation to facilitate target gene expression 
via interference with the interplay between CTCF, RAD21 (cohesin), and the mediator complex45,46.
We extracted an extended set of core MLLr target genes including known targets such as MYC, 
RUNX1, BCL2, and CDK6, which can potentially be used to develop new strategies for combating MLLr 
leukemias, for instance by fine-tuning the targeting of existing potential treatments such as inhibition 
of DOT1L32,33,47, BLC2i48 or BET49 to MLL-fusion target genes only. Next to that, the uncovered sets 
of MLL-AF9 and MLL-AF4 specific target genes such as ZNF521 and CDKN2A respectively, indicate 
that each specific fusion partner also has its own unique binding signature, which may potentially 
be exploited against MLLr blasts with resistance against a more general treatment such as BET 
inhibition34.
Lastly, we show that gene expression of MLL-AF9 target genes can be divided in CD34+ like 
and monocyte like groups, thereby keeping the MLL-AF9 positive leukemic cells in a state between 
CD34+ progenitor cells and fully differentiated monocytes. Likewise, TFs from families with motifs 
enriched under MLL-fusion targets can be divided in CD34+ like, monocyte like, and MLLr specific 
groups, uncovering TFs like ZNF521 and ZNF433 that are indirectly involved in expression or 
selection of MLLr target genes, and tumor suppressing TFs like ETV3 and NR4A1 that are down 
regulated in MLLr leukemias. Interestingly, ZNF521 is also an MLL-AF9 target, suggesting a feed-
forward loop of ZNF521 and the MLL-AF9 leukemic program.
Taken together, our results from chapter 4 define a core group of MLL-fusion target genes, an 
MLL-AF9 and -AF4 specific enhancer repertoire, and a key set of transcription factors specifically 
deregulated in MLL-AF9 induced AML.
In chapter 5, we set out to chart the epigenomic landscape of two subsets of MLL-AF9+ AML 
patients, based on MECOM and BRE expression levels. We generated epigenetic and expression 
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profiles of MLL-AF9+ AML patients to examine if outlier high BRE expression could be explained 
by the epigenome of corresponding samples. Remarkably, we found that samples with high BRE 
expression had intronic active promoter marks in BRE, which were absent from samples with high 
MECOM expression. These promoter marks were accompanied by expression starting exactly at that 
site followed by common downstream BRE exons. Intragenic transcription activation marks were 
found in another 97 regions in 89 genes in these samples, but were hardly detected in MLL-AF9+ 
samples with high MECOM expression. 
MLL ChIP-seq and luciferase reporter experiments revealed occupancy of MLL (fusion) 
proteins at these 98 regions and transactivation of the intragenic BRE promoter by MLL-AF9. We 
hypothesize that transcription promoting complexes binding to MLL-AF9 (and possibly MOZ-CBP) 
enhance expression from or around these intragenic promoters. MLL-AF9 translocations also occur 
in acute lymphoblastic leukemia (ALL). Additional experiments should reveal whether genome-
wide intragenic active promoter marks occur in those samples as well. It would also be interesting 
to study whether a common mechanism causes expression of the novel BRE transcript in MOZ-
CBP+ and MLL-AF9+ AML samples. If so, MOZ-CBP+ samples may harbor more intragenic active 
promoter marks. We speculate that altered expression or mutated transcription factors might be 
involved in determining the specific locations of the active promoter marks. AP-2, C2H2-Znf and 
ETS transcription factor motifs were enriched at the 98 intragenic active promoter marks. Further 
research is required to pinpoint specific transcription factors from these families or epigenetic 
modifiers contributing to the appearance of active promoter marks at these regions. 
We previously reported that MLL-AF9+ samples with outlier high BRE expression harbor a distinct 
gene expression profile (GEP). We compared the 22 genes encompassing the GEP50 with those 
containing intragenic active promoter marks. Three out of the twenty-two GEP associated genes 
had intragenic active promoter marks (BRE, ADCY5 and TGM5). This suggests that the genome-wide 
active promoter marks contribute to the unique GEP of patients with outlier high BRE expression. 
It is conceivable that up- or downstream factors and differentiation stage related factors are also 
represented in the GEP.
Like described for humans, murine models of MLL-AF9+ AML have suggested that two types of 
AML may arise. Murine models suggest that when a hematopoietic stem cell is transformed with 
MLL-AF9, it leads to AML with high MECOM expression. However, when a murine common myeloid 
progenitor is transformed, it leads to an AML with normal MECOM expression. Our RNA-seq data 
are in line with this, showing clustering of samples harboring high MECOM expression with CD34+ 
progenitor cells and clustering of samples harboring high BRE expression with CD14+ cells, a more 
mature myeloid cell type. However, outlier high BRE expression has not been described in murine 
models of MLL-AF9+ AML. One explanation for this may be that the intronic region harboring the 
active promoter is only partly conserved between mice and man. This underlines the importance 
of using human, primary samples to study GEPs and epigenomes associated with MLL-AF9+ AML. 
Whether intragenic active promoters also occur in murine models of MLL-AF9+ AML, is currently 
unknown. 
The BRE gene showed high upregulation of downstream versus upstream exons relative to the 
intragenic promoter. Interestingly, the novel BRE transcript contains a translation start site in exon 
5 that could lead to an N terminally truncated isoform of BRE. The in frame CHORDC1-BRE fusion 
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that we found in a relapsed AML case also incorporated the BRE transcript starting from exon 5. 
The C terminus of the BRE protein binds MERIT40, while its N terminus is required for binding to 
other members of the BRCA1A, BRCA1-BARD1 and BRISC complexes. The interaction of BRE and 
MERIT40 has been shown to be crucial for the function of the BRCA1A complex. We speculate that 
the truncated BRE isoform cannot mediate full complex formation, thereby decreasing the amount 
of functional BRCA1A, BRCA1-BARD1 and BRISC complexes. Future experimentation should reveal 
whether a truncated BRE protein isoform is formed. 
AML samples with aberrant BRE expression harbor well-known disease-causing mutations (e.g. 
MLL-AF9, MOZ-CBP, RUNX1 mutation and FLT3 internal tandem duplication). However, based on AML 
models using endogenous MLL-AF9 expression, it has been suggested that additional events are 
required to cause AML. In this light and since intragenic transcriptional activation has recently been 
shown to cause another type of cancer51, it would be interesting to study whether the new BRE 
transcript and CHORDC1-BRE fusion contribute to AML pathogenesis. In summary, our results from 
chapter 5 indicate that the subset of AML-AF9+ AML patients distinguished by high BRE expression 
actually produce a novel BRE isoform. Next to that, about 90 more genes seem to harbor a novel 
intragenic active promoter. Strikingly, we also detected expression of the novel CHRDC1-BRE fusion 
protein which BRE part only includes the exons from the novel BRE isoform.
Common characteristics of fusion proteins
Deregulation of gene expression
Onco-fusion proteins tend to deregulate their targets by aberrant activation, repression, or both. In 
recent years, genome-wide studies have unveiled the mechanism of deregulation beyond what was 
theorized for several onco-fusions. The AML-ETO fusion we discuss in chapter 3, for instance, was 
long thought to operate solely via the repression of RUNX1 targets52-55. However, several studies have 
since shown that next to this aberrant repression of RUNX1 targets, a sizeable proportion of targets 
is in fact activated by the fusion protein16,56-58. As we show in chapter 2, the FUS moiety of the FUS-
ERG onco-fusion guides the protein to RARα target sites, leading to repression of the retinoic acid 
(RA) pathway and a block of myeloid differentiation, which could be relieved by ATRA treatment, a 
feature previously thought to be confined to PML-RARα induced promyelocytic leukemia7. The MLL-
fusions discussed in chapters 4 and 5, on the other hand, act mostly as transcriptional activators of 
their target genes, as their DNA binding MLL moiety guides the effector moiety to the promoters 
of genes marked with H3K4me3 by the wild type MLL, which are subsequently transcribed and 
marked with the H3K79me2 open chromatin mark47,59-62.
Transcription Factor complexes
The aberrant transcription and H3K79me2 deposition by MLL-fusions described above and in 
chapters 4 and 5 is a good example of the influence of transcription factor containing protein 
complexes on the outcome of transcriptional deregulation by onco-fusion proteins. In the case of 
the MLL-fusion onco-proteins, most of the major translocation partners of MLL are -directly or via 
co-factors- part of the Super Elongation Complex (SEC), which associates with RNA-polymerase II 
and facilities gene transcription, and/or the DOT1L complex, which deposits the H3K79me2 histone 
mark associated with an open and active chromatin state47,53,59,61-63. In this way, the MLL-fusion 
onco-proteins instigate aberrant gene expression programs solely via interplay with TF complexes. 
Likewise, as described in chapter 2, the FUS-ERG onco-fusion protein exerts its repressive effects 
on the RA pathway by co-binding in a complex consisting of a heptad of E-twenty-six specific (ETS) 
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TFs, namely: GATA2, LMO2, LYL1, RUNX1, TAL1 and RNAPII, and including the ERG moiety of the 
onco-fusion protein. Lastly, the AML-ETO onco-fusion as described in chapter 3 is also dependent 
on complex formation for its function. The AML1, a.k.a. RUNX1, a.k.a. CBFα2 moiety of the onco-
fusion protein binds the DNA as part of a complex consisting of a subset of the heptad of ETS factors 
described for the FUS-ERG fusion, wild type RUNX122, and the DNA binding stabilizer CBFβ, which is 
also part of the CBFβ-MYH onco-fusion protein in inv(16) AMLs64.
Epigenetics and Transcription Factors
Deregulation of the expression of target genes is not always confined to a direct effect on 
transcription via e.g. facilitating/blocking of RNA-pol II binding. Often times, the onco-fusion proteins 
exert their effects via altering of the chromatin state by changing the histone (tail) modifications. 
In chapter 5 we show that subgroups of varying severity can be distinguished even within patients 
harboring the same onco-fusion, i.e. MLL-AF9, based on differential histone modifications revealing 
promoters for alternate isoforms of expressed genes. Next to that, in chapter 4, we describe how 
the MLL-AF9 onco-fusion protein, in conjunction with the DOT1L complex, can deposit the open/
active chromatin histone modification H3K79me2 not only on its target genes, but also on targeted 
enhancer elements. Moreover, it has also been shown that the MLL-fusion target genes have to 
be marked by both the promoter marking H3K4me3 histone tail modification, deposited by the 
wild type MLL, and the activating H3K27ac histone tail modification. The latter was shown to be 
crucial for a variety of AML subtypes by experiments with BET inhibitors, which block H3K27ac 
deposition34,44,65. The importance of H3K27 acetylation was also evident in chapter 3, where we 
found that the AML1-ETO onco-fusion protein can potentially affect the histone acetylation level of 
RUNX1 targets via recruitment of HDACs, as we found AML1-ETO, RUNX1, HDAC and p300 binding 
at similar genomic regions, which could be confirmed by re-ChIP for a selection of loci. We next 
showed AML1-ETO induced gene repression to indeed be the outcome of a fine balance of ERG, 
wild type AML1 (RUNX1), AML-ETO, HDAC, and p300 binding, keeping the leukemic cells addicted 
to the right dose of the onco-fusion protein. By altering this balance the leukemic cells will go 
into apoptosis and/or differentiation. Altogether this shows manipulation of H3K27ac levels to be a 
potentially powerful tool to combat a wide variety of AML inducing onco-fusion proteins, including 
the ones discussed here in this thesis.
Challenges and limitations
A major point of contention in cancer research is the use of cell lines versus primary material and 
model organisms. While cell lines harboring e.g. a specific translocation are easy to use in large 
quantities and can be manipulated with e.g. drugs or genetic knock-out. However, they represent 
a population that, often for decades, has been evolved to survive in a cell-culture environment, i.e. 
growing in a petri dish in a synthetic medium. This invariably leads to the acquisition of additional 
mutations and chromosomal re-arrangements not present in the original cancer cells. Next to that, 
as the cells are typically growing in a mono culture, effects of the original in vivo niche are lost.
Model organisms, such as mice carrying a knocked-in copy of an oncogene, or reconstituted 
with human immune cells, on the other hand, do provide this niche and can provide a more 
complete picture of disease progression. However, next to the ethical concerns and slower pace of 
working with animal models, these models do not fully recapitulate the human situation, as shown 
in chapters 4 and 5.
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It is therefore important to validate and supplement results obtained in cell lines and model 
organisms in primary patient material, which by definition reflects the disease state in vivo. Patient 
blasts, however, are available in limited quantity per patient, thus limiting the assays that can be 
performed. Moreover, it is not possible to manipulate patient blasts genetically and there is a 
wide variability between patients or even between different blasts from the same patient, as not 
only confounders such as disease progression, age, and cell-of-origin, but also different secondary 
mutations can influence the etiology of the leukemia drastically, as we saw in chapter 5. For these 
reasons, it can be difficult to extract general principles, or pathways common to the disease solely 
form primary material. It therefore seems optimal to use cell lines and/or model organisms in 
conjunction with primary patient material in order to distill a robust model that closely reflects the 
mechanisms of action behind the various subtypes of AML.
In this light, a relatively novel system that overcomes some of the various drawbacks of the 
other systems is the use of human induced pluripotent stem cells (iPSC). These can be transduced 
with a specific oncogene and subsequently differentiated towards e.g. the myeloid lineage. As 
the transduced oncogene can then be activated at any arbitrary time during differentiation, we 
therefore gain the ability to look at cells with the exact same genetic background carrying only the 
desired mutation(s), induced at the same stage of differentiation. This can be used to elucidate 
the true direct effects of the various onco-genes. Next to that, this system could also be used to 
build a leukemia from scratch, by combining mutations in known common targets in AML, e.g. 
RUNX1, ERG, BRD4, in order to establish the truly essential pathways in AML development and 
establishment, regardless of the specific translocation.
Lastly, as indicated above, AML can be a very heterogeneous disease varying even between 
different blasts (sub clones) from the same patient. Indeed, a major problem with the treatment 
of AML is the occurrence of a relapse. Often, as in most cancers, the relapsed clone is far more 
aggressive than the original clone and not susceptible to the original treatment. It is therefore 
important to pairwise study blasts from patients at original presentation of the disease and relapse. 
Commonalities and differences between the two can potentially be used to e.g. block the most 
common (epi-genetic) ‘escape routes’ leading to resistance to treatment and establishment of 
the relapse clone at presentation. For this, the recent development of singe cell RNA-seq, which 
enables us to look at the expression profiles of all individual cells within a population, now makes it 
possible to identify and characterize most sub clones at the original presentation of the disease, as 
well as at the relapse stage. Differential analyses of the make-up of the populations at presentation 
and relapse may provide insight in the mechanisms operational in clones that make it to relapse, 
and provide a prediction of clinical outcome, and (additional) treatment to be given to improve that 
outcome on a per patient basis.
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Outlook
Taken together, the results presented in this thesis show that while various subtypes of AML can be 
caused by a wide variety of genomic aberrations, the underlying affected pathways, such as those 
defined by (e.g. acetylation of) RUNX1, RAR, and ERG, are often shared between subtypes, and 
are part of the normal hematopoietic program. Therefore, a promising avenue of future research 
would be an effort to further pin down a point of convergence where multiple AML variants are 
deregulating the same targets, which might lead to the development of more ‘broad-spectrum’ AML 
therapies that do not need to be tailor made against the multitude of chromosomal aberrations and 
mutations. 
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Acute myeloïde leukemie is een heterogene ziekte, veroorzaakt door een grote verscheidenheid 
aan mutaties en chromosomale aberraties. In ongeveer 40% van de gevallen zorgt een genomische 
translocatie –waarin het functionele en DNA-bindings deel van twee verschillende genen gefuseerd 
raken– voor een deregulatie van het hematopoëtische genexpressie programma. Deze deregulatie 
kan direct of indirect, via een verstoring van het epigenetische landschap, tot stand komen.
Het doel van deze thesis was het onderzoeken van de genoomwijde binding, het bijbehorende 
epigenetische landschap, en de transcriptionele opbrengst van een aantal verschillende onco-fusie 
eiwitten. Op deze manier hopen we ons begrip van de moleculaire mechanismen achter, en de 
overeenkomsten en verschillen tussen de etiologie van verschillende subtypen acute myeloïde 
leukemie te vergroten.
In hoofdstuk 1 bediscussiëren we de transcriptie factoren die de expressie reguleren van genen die 
essentieel zijn voor het functioneren van het hematopoëtische systeem en die de ontwikkeling van 
verschillende typen bloedcel reguleren. Tijdens leukemogenese staat mis-regulatie van transcriptie 
factoren zoals RUNX1, CBFß MLL, C/EBPα, SPI1, GATA en TAL1 centraal. Hier bediscussiëren we 
de mechanismen van transcriptie factor deregulatie in leukemie en hoe in de laatste jaren ‘next 
generation sequencing’ (de laatste generatie DNA-lezende machines) strategieën hebben geholpen 
om de moleculaire rol van veel van deze verkeerd tot expressie komende transcriptie factoren 
te begrijpen. We spitsen ons toe op de eiwitcomplexen waar deze transcriptie factoren in thuis 
horen, de post translationele modificaties van deze factoren, hun rol in de totstandkoming van de 
hogere orde chromatine structuur, en hun invloed op de lokale epigenetische omgeving. We stellen 
dat alleen een uitgebreide kennis van al deze aspecten ons begrip van afwijkende genexpressie 
in leukemie kan vergroten en zo kan bijdragen aan het vinden van nieuwe toegangswegen voor 
therapeutische interventie.
In hoofdstuk 2 gaan we verder met het ontrafelen van de mechanismen achter de ETS 
transcriptiefactor ERG, die geïmpliceerd is als belangrijke regulator van zowel normale als afwijkende 
hematopoëse. In acute myeloïde leukemie met t(16;21) is ERG functie gedereguleerd door een 
fusie met FUS/TLS, wat resulteert in de expressie van een FUS-ERG onco-fusie eiwit. Hoe dit onco-
fusie eiwit het normale ERG-transcriptieprogramma ontregelt is niet duidelijk. Hier laten we zien 
dat FUS-ERG optreedt in de context van een zevental (heptad) van eiwitten (ERG, FLI1, GATA2, 
LYL1, LMO2, RUNX1, en TAL1) die belangrijk zijn voor de juiste expressie van genen die betrokken 
zijn bij het onderhouden van een hematopoëtische stamcel fenotype. Daarnaast bezet FUS-ERG in 
t(16;21) cellen genomische regio’s waar ook de nucleaire receptor heterodimeer RXR-RARα bindt 
en remt daar genexpressie en interfereert met de hematopoëtische differentiatie. Zowel ATRA 
(‘All Trans Retinoic Acid’, volkomen trans retinoïde zuur) als FUS-ERG ‘knock-down’ (uitschakeling) 
behandeling van t(16;21) cellen leidt tot een vermindering van de myeloïde differentiatie blokkade. 
Samen suggereren deze resultaten dat FUS-ERG werkt als een transcriptionele onderdrukker van 
het retinoïde zuur signaal pad.
Daarna, in hoofdstuk 3, kijken we naar de rol van ERG en RUNX1 in een type leukemie veroorzaakt 
door de t(8;21) fusie. Het met t(8;21) acute myeloïde leukemie geassocieerde eiwit AML-ETO 
zorgt voor een afwijkende regulatie van de signaal paden die leiden tot myeloïde differentiatie en 
apoptose. Hier onderzoeken we de effecten van AML-ETO op het transcriptoom en epigenoom van 
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t(8;21) patiënten cellen. We identificeren twee modules. Eén waarin AML-ETO aan promotor regio’s 
van actieve genen bindt, en één waar het bindt aan toegankelijke, lage acetylatie hebbende distale 
elementen die kunnen worden geactiveerd door HDAC-remming. We vinden ERG, FLI1, TAL1 en 
RUNX1 op alle AML-ETO bindingsplaatsen, terwijl LYL1 en LMO2 preferentieel binden aan distale 
elementen. Verhoogde AML-ETO expressie is geassocieerd met de activering van een apoptose 
programma, en expressie van de wild-type transcriptie factoren RUNX1 en ERG is noodzakelijk 
om deze oncogen overdosis tegen te gaan. Samen genomen laten onze resultaten zien dat de 
wisselwerking van het epigenoom met transcriptie factoren een anti-apoptotisch fenotype in stand 
houdt in t(8;21) leukemische cellen.
In hoofdstuk 4 onderzoeken we acute myeloïde leukemieën met een onderliggende 11q23 
translocatie. In 11q23 leukemieën is het N-terminale deel van het MLL (KMT2A) gen gefuseerd met 
een van meer dan zestig verschillende fusie partner genen. Om een kern-set van MLLr doelwit 
genen te bepalen onderzochten we de genoomwijde binding van de MLL-AF9 en MLL-AF4 fusie 
eiwitten en hun bijbehorende epigenetische landschappen in AML. We vonden zowel gedeelde als 
unieke MLL-AF9 en MLL-AF4 doelwit genen, die gemarkeerd waren met H3K79me2, H3K27ac en 
H3K4me3. Naast deze promotor binding vinden we ook MLL-AF9 en MLL-AF4 bindingsplaatsen op 
specifieke subgroepen actieve distale regulatoire elementen. Ondanks deze verschillen in ‘enhancer’ 
(versterkende distale elementen) binding dirigeren MLL-AF9 en ML-AF4 een overeenkomend gen 
programma, bestaande uit een deel van het RUNX1 programma en verschillende CD34+ en monocyt 
specifieke genen. Het vergelijken van deze data sets identificeerde verscheidene zink vinger 
transcriptie factoren als potentiële MLL-AF9 co-regulators. Samen suggereren deze resultaten in 
11q23 AMLs MLL-fusies samenwerken met specifieke subsets van transcriptie factoren om het 
RUNX1 gen programma te dereguleren.
Daarna bediscussiëren we een subset van 11q23 patiënten met hoge expressie van het BRE 
gen in hoofdstuk 5. Hoge BRE expressie in MLL-AF9+ acute myeloïde leukemie is geassocieerd met 
een gunstige prognose, terwijl hoge MECOM expressie samen gaat met een zeer slechte prognose. 
Genoomwijde analyse van hoge BRE en hoge MECOM patiënten laat abnormale intragene H3K4ME3 
markeringen in 90 zien, exclusief in hoge BRE patiënten, ook in het BRE gen zelf. 5’ RACE en RNA-seq 
laten bi-allelische transcriptie van een nieuw BRE transcript zien, startend direct naast de intragene 
promotor markering en gevolgd door ‘downstream’ (in de richting van transcriptie) exonen. 
Luciferase reporter proeven met de intragene BRE promotor lieten zien dat deze wordt geactiveerd 
door MLL-AF9. Het nieuwe BRE transcript leidt mogelijk tot een BRE isovorm die een deel van de 
N-terminus van het gen mist. We ontdekten ook een nieuwe CHORD1-BRE fusie in een patiënt met 
een terugkerende leukemie. Deze BRE fusie ontstond in dezelfde regio waar intragene transcriptie 
activatie start in MLL-AF9+ AML. Dit onderzoek identificeert sterke abnormale intragene transcriptie 
activatie in BRE in MLL-AF9+ AML. Toekomstige studies moeten nog onderzoeken of en hoe deze 
verkorte BRE bijdraagt aan AML pathogenese.
Ten slotte bespreken we in hoofdstuk 6 het werk dat in deze thesis wordt gepresenteerd. 
Globaal gezien gebruiken we genoomwijde gereedschappen om het epigenetische landschap en 
transcriptie factor binding te onderzoeken in leukemische cellen met verschillende genomische 
translocaties. We onderzoeken hoe het hematopoëtische programma in deze cellen is ontregeld, 
en al doende ontrafelen we enkele mechanismen achter acute myeloïde leukemie en openen de 
deur naar toekomstige therapeutische mogelijkheden.
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Acute myeloid leukemia (AML) is a heterogeneous disease, caused by a wide variety of mutations 
and chromosomal aberrations. In about 40% of cases, a genomic translocation -fusing together 
the effector and DNA-binding parts of two distinct genes- can deregulate the hematopoietic gene 
expression program directly or via epigenetic alterations of key pathways. 
In this thesis we aimed to investigate the genome wide binding, the associated epigenetic 
landscape, and the transcriptional output of a number of different onco-fusion proteins, in order 
to further elucidate the molecular mechanisms behind, and the commonalities and differences 
between, the etiology of various subtypes of acute myeloid leukemia.
In chapter 1 we discuss the transcription factors that control expression of genes essential for 
the normal functioning of the hematopoietic system and regulate development of distinct blood 
cell types. During leukemogenesis, aberrant regulation of transcription factors such as RUNX1, CBFß 
MLL, C/EBPα, SPI1, GATA and TAL1 is central to the disease. Here, we will discuss the mechanisms of 
transcription factor deregulation in leukemia and how in recent years next generation sequencing 
approaches have helped to elucidate the molecular role of many of these aberrantly expressed 
transcription factors. We will focus on the complexes in which these factors reside, the role of post 
translational modification of these factors, their involvement in setting up higher order chromatin 
structures as well as their influence on the local epigenetic environment. We suggest that only 
comprehensive knowledge on all these aspects will increase our understanding of aberrant gene 
expression in leukemia as well as open new entry points for therapeutic intervention.
In chapter 2 we move on to unravel the mechanisms behind the ETS transcription factor ERG, 
which has been implicated as a major regulator of both normal and aberrant hematopoiesis. In 
acute myeloid leukemias harboring t(16;21), ERG function is deregulated due to a fusion with 
FUS/TLS resulting in the expression of a FUS-ERG oncofusion protein. How this oncofusion protein 
deregulates the normal ERG transcription program is unclear. Here, we show that FUS-ERG acts 
in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) central to 
proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. Moreover, 
in t(16;21) FUS-ERG co-occupies genomic regions bound by the nuclear receptor heterodimer RXR-
RARα inhibiting target gene expression and interfering with hematopoietic differentiation. All-Trans 
Retinoic Acid treatment of t(16;21) cells as well as FUS-ERG knock down alleviate the myeloid 
differentiation block. Together, the results suggest that FUS-ERG acts as a transcriptional repressor 
of the retinoic acid signaling pathway.
Subsequently, in chapter 3, we look at the role of ERG and RUNX1 in a type of leukemia caused by 
the t(8;21) fusion. The t(8;21) acute myeloid leukemia associated oncoprotein AML1-ETO aberrantly 
regulates the pathways that lead to myeloid differentiation and cell apoptosis. Here, we investigated 
its effects on the transcriptome and epigenome in t(8,21) patient cells. We identify two modules, 
one in which AML1-ETO binds promoter regions of active genes and one represented by distal 
element binding to accessible, low acetylation regions that can be activated by HDAC inhibition. 
We identify ERG, FLI1, TAL1 and RUNX1 at all AML1-ETO occupied genomic regions, while LYL1 
and LMO2 preferentially bind in the context of distal regions. Increased AML1-ETO expression is 
associated with the onset of an apoptosis program, and expression of wild type transcription factors 
RUNX1 and ERG is required to prevent this oncogene overdose. Together our results show that 
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the interplay of the epigenome and transcription factors maintains an anti-apoptotic phenotype in 
t(8;21) AML cells.
In chapter 4 we investigate acute myeloid leukemias with an underlying 11q23 translocation. In 
11q23 leukemias the N terminal part of the MLL gene is fused to over 60 different partner genes. 
In order to define a core set of MLLr targets, we investigated the genome wide binding of the 
MLL-AF9 and MLL-AF4 fusion proteins and associated epigenetic signatures in AML. We uncovered 
both common as well as specific MLL-AF9 and MLL-AF4 target genes, which were all marked by 
H3K79me2, H3K27ac, and H3K4me3. Apart from promoter binding, we also identified MLL-AF9 and 
MLL-AF4 binding at specific subsets of non-overlapping active distal regulatory elements. Despite 
this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, 
which represents part of the RUNX1 gene program and constitutes of CD34+ and monocyte specific 
genes. Comparing these datasets identified several zinc finger transcription factors as potential 
MLL-AF9 co-regulators. Together, these results suggest that MLL-fusions collaborate with specific 
subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs. 
After that, we discuss a subset of 11q23 patients with abnormally high expression of the BRE gene 
in chapter 5. High BRE gene expression in MLL-AF9+ acute myeloid leukemia (AML) is associated 
with a favorable prognosis, while high MECOM expression confers a very poor prognosis. Genome-
wide analyses of high BRE and high MECOM patients showed abnormal intragenic H3K4me3 marks 
in 90 genes exclusively in high BRE samples, including in the BRE gene itself. 5' RACE and RNA-seq 
showed biallelic transcription of a novel BRE transcript starting adjacent to the active promoter 
marks followed by downstream exons. Luciferase reporter assays using the intragenic BRE promoter 
showed that it was transactivated by MLL-AF9. The new BRE transcript may encode a BRE isoform 
that lacks part of the N-terminus. Importantly, we detected a new in frame CHORD1-BRE fusion in 
a case with relapsed AML. The BRE fusion occurred in the same region as intragenic transcription 
activation in BRE in MLL-AF9+ AML. This work identifies strong abnormal intragenic transcription 
activation resulting in the formation of a new BRE transcript in MLL-AF9+ AML. Future studies 
should reveal whether alternate BRE contributes to AML pathogenesis.
Finally, in chapter 6, we discuss the work presented in this thesis. Overall, we use genome wide 
tools to explore the epigenetic landscape and transcription factor binding of leukemic cells harboring 
various genomic translocations. We investigate how the hematopoietic program is deregulated in 
these cells, and by doing so elucidate some of the mechanisms behind acute myeloid leukemia and 
open the door to future therapeutic avenues. 
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Daar zijn we dan, aan het einde van de rit. De blok remmen trekken aan, we schieten vooruit in onze 
stoelen. De karretjes komen knarsend en piepend tot stilstand en de beugels springen open. Met 
weke knieën en de wind nog in ons haar stappen we uit. Het hart bonkt nog na in de keel. Wat een 
ritje... Zullen we nog eens?
Daar zijn we dan, aan het begin van een nieuw hoofdstuk. Het vorige is nu echt voorbij. Zou ik het 
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maar ook een geduld en een volharding. Dus ja, niet waarschijnlijk. Zeker wel.
Het is bitterzoet hier aan het einde, zoals zo vaak met eindes het geval is. Aan de ene kant mis ik 
ons leven in Nijmegen, het lab, de groep, het werk. Aan de andere kant is het fantastisch om er mee 
klaar te zijn, om een nieuwe stap te zetten en in Amsterdam (nou ja vooruit, Zaandam) onze draai te 
vinden. Gericht naar de toekomst, nieuw werk, een nieuwe uitdaging in een ontzettend fijn nieuw 
lab... Dus ja, hoe je het ook wendt of keert, bitterzoet is het goede woord. Cliché of niet. 
Maar goed, genoeg wezenloos gemekker. Laat ik verder gaan met de reden waarom de meeste 
mensen dit boekje lezen: de bedankjes!
Allereerst wil ik natuurlijk mijn begeleider bedanken: 
Joost, bedankt hè!
Zo, en dan nu verder met... Nee, grapje: Joost, vanaf het begin in 2011 voelde ik me meteen al 
op mijn gemak bij jou en met je rustige stijl van leiding geven. Met eeuwig geduld legde je uit wat 
jouw ideeën en hypotheses waren en hoe we het een en ander konden testen. Het was heel fijn dat 
ik altijd bij je naar binnen kon lopen om wat te vragen, te vertellen, of te bediscussiëren. Werken 
met jou gaf me een goed idee van het type groep leider dat ik zelf wel zou willen zijn, mocht ik het 
zover schoppen. Bedankt voor je luisterend oor, je suggesties, en je rots vaste vertrouwen!
Next, I would like to thank the members of our (Joost’s) ‘Mini Leukemia Group’, as next to Joost 
relaxed leadership, the members of this group are what made our ‘U’s (for outsiders: think lab 
cubicles) feel like home! 
First up, Sadia: thank you so much for helping me find my way when I first joined the lab, and for 
your always jolly personality. It was a pleasure having you around. I think your laugh will still ring in 
my ears years from now :-)
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Amit, my friend from Dehradun, thanks to your relentless expertise in everything wet lab related 
my experiments were up and running in no time! Be it western blotting, chip, or RNA-seq, you 
always knew what to do, thanks for that. But more importantly, thank you for your friendship, and 
for some great fun over dinner! I’m still using your curry and dry chicken recipes to great success!
Ana Cantante: thank you (and Nardy!!!) for your great friendship. You were there for us 
regardless of what stupid little crisis we found ourselves in. No matter if we needed a cat or a cat 
sitter, Ana to the rescue! 
Abhishek, thanks for being a solid friend, always there in need, and never too far outside of your 
bio-informatics hideout. We started more or less at the same time, and I’m glad to see we both 
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Guoqiang, Esther, Cheng: thank you so much for all your help, and great talks in and out of the 
lab!
Also, many thanks to the never-ending flow of students that graced our little group from time 
to time, for shorter or longer periods. In particular: Nico, Marjolein, Willemijn, Human, Aline en 
Marije, thank you for your hard work and enthusiasm!
Buiten onze groep zijn er natuurlijk nog veel meer mensen in het lab aan wie ik mijn succes te 
danken heb. Allereerst: de grote baas van de afdeling, de vers geridderde heer professor doctor 
Stunnenberg. Ook bekend als: Henk! 
Henk, harstikke bedankt voor het gunnen van deze kans om in jouw lab te mogen werken. Jouw 
kritische vragen en inzichten hebben mij altijd verder geholpen, zowel als het ging over mijn eigen 
onderzoek, of, op borrels, als het ging om mijn visie op de wetenschap in het algemeen.
Verder wil ik zeer bedanken: Maria, Josephine en Anita! Door jullie inspanning draait het lab als 
een tierelier! Bedankt voor alle hulp en fijne gesprekjes over de jaren!
Ook zeer veel dank aan het analisten team: Eva, Bowon, Kim, Martijn, Yan, Nilofar, bedankt 
voor alle hulp bij het maken van de NGS libraries, het meten en het laden op de machines, en 
jullie engelengeduld bij alle vervolgvragen (Is mijn sample al gesequenced? Nee. Is mijn sample al 
gesequenced? Nee. Is mijn sample al gesequenced? Nee. Is mijn sample al gesequenced? Nee. Is 
mijn sample al gesequenced? Ja! Echt? Nee, grapje...) 
Bilge, thank you for your friendship and support! It has been great spending time with you at 
work, on borrels, and after work! I will never forget how we talked Tanya into coming along on that 
huge, fast, and spinning carnival ride :-D I already miss our little ’coffee breaks’ at work each day, and 
I know Tanya does too. Luckily Utrecht is not that far from AmsterZaandam. 
Next, I would like to give many thanks to near-U neighbours and ex-neighbours Boris and 
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